Altria (MO) 10-K 25 Feb 20 2019 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2019	Feb. 14, 2020	Jun. 30, 2019
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2019
Document Transition Report	false
Entity File Number	1-08940
Entity Registrant Name	ALTRIA GROUP, INC.
Entity Incorporation, State or Country Code	VA
Entity Tax Identification Number	13-3260245
Entity Address, Address Line One	6601 West Broad Street,
Entity Address, City or Town	Richmond,
Entity Address, State or Province	VA
Entity Address, Postal Zip Code	23230
City Area Code	804
Local Phone Number	274-2200
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 88
Entity Common Stock, Shares Outstanding (in shares)		1,858,366,804
Documents Incorporated by Reference	Portions of the registrant’s definitive proxy statement for use in connection with its annual meeting of shareholders to be held on May 14, 2020, to be filed with the Securities and Exchange Commission on or about April 2, 2020, are incorporated by reference into Part III hereof.
Amendment Tag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity Central Index Key	0000764180
Current Fiscal Year End Date	--12-31
Common Stock, $0.33 1/3 par value
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $0.33  1/3 par value
Trading Symbol	MO
Security Exchange Name	NYSE
1.000% Notes due 2023
Entity Information [Line Items]
Title of 12(b) Security	1.000% Notes due 2023
Trading Symbol	MO23A
Security Exchange Name	NYSE
1.700% Notes due 2025
Entity Information [Line Items]
Title of 12(b) Security	1.700% Notes due 2025
Trading Symbol	MO25
Security Exchange Name	NYSE
2.200% Notes due 2027
Entity Information [Line Items]
Title of 12(b) Security	2.200% Notes due 2027
Trading Symbol	MO27
Security Exchange Name	NYSE
3.125% Notes due 2031
Entity Information [Line Items]
Title of 12(b) Security	3.125% Notes due 2031
Trading Symbol	MO31
Security Exchange Name	NYSE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	$ 2,117,000,000	$ 1,333,000,000
Receivables	152,000,000	142,000,000
Inventories:
Leaf tobacco	874,000,000	940,000,000
Other raw materials	192,000,000	186,000,000
Work in process	696,000,000	647,000,000
Finished product	531,000,000	558,000,000
Inventory, net	2,293,000,000	2,331,000,000
Income taxes	116,000,000	167,000,000
Other current assets	146,000,000	326,000,000
Total current assets	4,824,000,000	4,299,000,000
Property, plant and equipment, at cost:
Land and land improvements	353,000,000	309,000,000
Buildings and building equipment	1,461,000,000	1,442,000,000
Machinery and equipment	2,998,000,000	2,981,000,000
Construction in progress	262,000,000	218,000,000
Property, plant and equipment, at cost	5,074,000,000	4,950,000,000
Less accumulated depreciation	3,075,000,000	3,012,000,000
Property, plant and equipment, net	1,999,000,000	1,938,000,000
Goodwill	5,177,000,000	5,196,000,000
Other intangible assets, net	12,687,000,000	12,279,000,000
Investments in equity securities	23,581,000,000	30,496,000,000
Other assets	1,003,000,000	1,251,000,000
Total Assets	49,271,000,000	55,459,000,000
Liabilities
Short-term borrowings	0	12,704,000,000
Current portion of long-term debt	1,000,000,000	1,144,000,000
Accounts payable	325,000,000	399,000,000
Accrued liabilities:
Marketing	393,000,000	586,000,000
Settlement charges	3,346,000,000	3,454,000,000
Other	1,545,000,000	1,403,000,000
Dividends payable	1,565,000,000	1,503,000,000
Total current liabilities	8,174,000,000	21,193,000,000
Long-term debt	27,042,000,000	11,898,000,000
Deferred income taxes	5,083,000,000	4,993,000,000
Accrued pension costs	473,000,000	544,000,000
Accrued postretirement health care costs	1,797,000,000	1,749,000,000
Other liabilities	345,000,000	254,000,000
Total liabilities	42,914,000,000	40,631,000,000
Contingencies (Note 19)
Redeemable noncontrolling interest	38,000,000	39,000,000
Stockholders' Equity
Common stock, par value $0.33 1/3 per share (2,805,961,317 shares issued)	935,000,000	935,000,000
Additional paid-in capital	5,970,000,000	5,961,000,000
Earnings reinvested in the business	36,539,000,000	43,962,000,000
Accumulated other comprehensive losses	(2,864,000,000)	(2,547,000,000)
Cost of repurchased stock (947,979,763 shares at December 31, 2019 and 931,903,722 shares at December 31, 2018)	(34,358,000,000)	(33,524,000,000)
Total stockholders’ equity attributable to Altria	6,222,000,000	14,787,000,000
Noncontrolling interests	97,000,000	2,000,000
Total stockholders’ equity	6,319,000,000	14,789,000,000
Total Liabilities and Stockholders’ Equity	$ 49,271,000,000	$ 55,459,000,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value (usd per share)	$ 0.3333	$ 0.3333
Common stock, shares issued (in shares)	2,805,961,317	2,805,961,317
Cost of repurchased stock, shares (in shares)	947,979,763	931,903,722

Consolidated Statements of Earn

Consolidated Statements of Earnings (Losses) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Net revenues	$ 6,007	$ 6,856	$ 6,619	$ 5,628	$ 6,114	$ 6,837	$ 6,305	$ 6,108	$ 25,110	$ 25,364	$ 25,576
Cost of sales									7,085	7,373	7,531
Excise taxes on products									5,314	5,737	6,082
Gross profit	3,084	3,497	3,319	2,811	2,922	3,255	3,141	2,936	12,711	12,254	11,963
Marketing, administration and research costs									2,226	2,756	2,338
Asset Impairment and Exit Costs									159	383	32
Operating (expense) income									10,326	9,115	9,593
Interest and other debt expense, net									1,280	665	705
Net periodic benefit (income) cost, excluding service cost									(37)	(34)	37
Earnings from equity investments									(1,725)	(890)	(532)
Impairment of JUUL equity securities	4,100	4,500	0	0					8,600	0	0
Loss on Cronos-related financial instruments									1,442	0	0
(Gain) loss on ABI/SABMiller business combination					0	0	0	33	0	33	(445)
Earnings (losses) before income taxes									766	9,341	9,828
Provision (benefit) for income taxes									2,064	2,374	(399)
Net earnings (losses)	(1,814)	(2,602)	1,997	1,121	1,251	1,944	1,877	1,895	(1,298)	6,967	10,227
Net (earnings) losses attributable to noncontrolling interests									5	(4)	(5)
Net earnings (losses) attributable to Altria	$ (1,809)	$ (2,600)	$ 1,996	$ 1,120	$ 1,250	$ 1,943	$ 1,876	$ 1,894	$ (1,293)	$ 6,963	$ 10,222
Per share data:
Basic earnings (losses) per share attributable to Altria (in usd per share)	$ (0.97)	$ (1.39)	$ 1.07	$ 0.60	$ 0.67	$ 1.03	$ 0.99	$ 1	$ (0.70)	$ 3.69	$ 5.31
Diluted earnings (losses) per share attributable to Altria (in usd per share)	$ (1)	$ (1.39)	$ 1.07	$ 0.60	$ 0.66	$ 1.03	$ 0.99	$ 1	$ (0.70)	$ 3.68	$ 5.31

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Earnings (Losses) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Net earnings (losses)	$ (1,298)	$ 6,967	$ 10,227
Other comprehensive earnings (losses), net of deferred income taxes:
Benefit plans	(24)	68	209
ABI	(319)	(309)	(54)
Currency translation adjustments and other	26	(1)	0
Other comprehensive earnings (losses), net of deferred income taxes	(317)	(242)	155
Comprehensive earnings (losses)	(1,615)	6,725	10,382
Comprehensive (earnings) losses attributable to noncontrolling interests	5	(4)	(5)
Comprehensive earnings (losses) attributable to Altria	$ (1,610)	$ 6,721	$ 10,377

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash Provided by (Used in) Operating Activities
Net earnings (losses)	$ (1,298)	$ 6,967	$ 10,227
Adjustments to reconcile net earnings (losses) to operating cash flows:
Depreciation and amortization	226	227	209
Deferred income tax provision (benefit)	(95)	(57)	(3,126)
Earnings from equity investments	(1,725)	(890)	(532)
(Gain) loss on ABI/SABMiller business combination	0	33	(445)
Dividends from ABI	396	657	806
Loss on Cronos-related financial instruments	1,442	0	0
Impairment of JUUL equity securities	8,600	0	0
Asset impairment and exit costs, net of cash paid	41	354	(38)
Cash effects of changes:
Receivables	(8)	0	10
Inventories	42	(129)	(171)
Accounts payable	(79)	27	(55)
Income taxes	89	218	(294)
Accrued liabilities and other current assets	11	(21)	(85)
Accrued settlement charges	(108)	980	(1,259)
Pension and postretirement plans contributions	(56)	(41)	(294)
Pension provisions and postretirement, net	(52)	(13)	(11)
Other, net	411	79	(41)
Net cash provided by (used in) operating activities	7,837	8,391	4,901
Cash Provided by (Used in) Investing Activities
Capital expenditures	(246)	(238)	(199)
Acquisitions of businesses and assets	(421)	(15)	(415)
Investment in JUUL	(5)	(12,800)	0
Investment in Cronos	(1,899)	0	0
Other, net	173	65	147
Net cash (used in) provided by investing activities	(2,398)	(12,988)	(467)
Cash Provided by (Used in) Financing Activities
Proceeds from short-term borrowings	0	12,800	0
Repayment of short-term borrowings	(12,800)	0	0
Long-term debt issued	16,265	0	0
Long-term debt repaid	(1,144)	(864)	0
Repurchases of common stock	(845)	(1,673)	(2,917)
Dividends paid on common stock	(6,069)	(5,415)	(4,807)
Other, net	(119)	(132)	(47)
Net cash used in financing activities	(4,712)	4,716	(7,771)
Cash, cash equivalents and restricted cash:
Increase (decrease)	727	119	(3,337)
Balance at beginning of year	1,433	1,314	4,651
Balance at end of year	2,160	1,433	1,314
Cash paid: Interest	1,102	704	696
Cash Paid: Income taxes	1,977	2,307	3,036
Cash, cash equivalents and restricted cash	$ 2,160	$ 1,314	$ 1,314

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions		Total		Common Stock [Member]	Additional Paid-in Capital [Member]	Earnings Reinvested in the Business [Member]		Accumulated Other Comprehensive Losses [Member]	Cost of Repurchased Stock [Member]	Non-Controlling Interests [Member]
Beginning balance at Dec. 31, 2016		$ 12,773		$ 935	$ 5,893	$ 36,906		$ (2,052)	$ (28,912)	$ 3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (losses)	[1]	10,222				10,222
Other comprehensive earnings (losses), net of deferred income taxes		155						155
Stock award activity		24			59				(35)
Cash dividends declared		(4,877)				(4,877)
Repurchases of common stock		(2,917)							(2,917)
Ending balances at Dec. 31, 2017		15,380		935	5,952	42,251		(1,897)	(31,864)	3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Reclassification due to adoption of ASU 2018-02	[2]	0				408		(408)
Net earnings (losses)		6,963	[1]			6,963	[3]
Other comprehensive earnings (losses), net of deferred income taxes		(242)						(242)
Stock award activity		22			9				13
Cash dividends declared		(5,660)				(5,660)
Repurchases of common stock		(1,673)							(1,673)
Other		(1)								(1)
Ending balances at Dec. 31, 2018		14,789		935	5,961	43,962		(2,547)	(33,524)	2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (losses)	[1]	(1,300)				(1,293)				(7)
Other comprehensive earnings (losses), net of deferred income taxes		(317)						(317)
Stock award activity		20			9				11
Cash dividends declared		(6,130)				(6,130)
Repurchases of common stock		(845)							(845)
Issuance of noncontrolling interest in Helix		88								88
Other		14								14
Ending balances at Dec. 31, 2019		$ 6,319		$ 935	$ 5,970	$ 36,539		$ (2,864)	$ (34,358)	$ 97
[1]	Amounts attributable to noncontrolling interests for each of the years ended December 31, 2019 , 2018 and 2017 exclude net earnings of $2 million , $4 million and $5 million , respectively, due to the redeemable noncontrolling interest related to Stag’s Leap Wine Cellars, which is reported in the mezzanine equity section on the consolidated balance sheets at December 31, 2019 , 2018 and 2017 .
[2]	In 2018, Altria adopted Accounting Standards Update (“ASU”) 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (“ASU 2018-02”), and reclassified the stranded income tax effects of the 2017 Tax Cuts and Jobs Act (the “Tax Reform Act”) on items with accumulated other comprehensive losses to earnings reinvested in the business.
[3]	Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 19 . Contingencies .

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Stockholders' Equity [Abstract]
Net income (loss) attributable to redeemable noncontrolling interest	$ 2	$ 4	$ 5
Cash dividends declared (USD per share)	$ 3.28	$ 3	$ 2.54

Background and Basis of Present

Background and Basis of Presentation	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and Basis of Presentation	Background and Basis of Presentation ▪ Background: At December 31, 2019 , Altria Group, Inc.’s (“Altria”) wholly-owned subsidiaries included Philip Morris USA Inc. (“PM USA”), which is engaged in the manufacture and sale of cigarettes in the United States; John Middleton Co. (“Middleton”), which is engaged in the manufacture and sale of machine-made large cigars and pipe tobacco and is a wholly-owned subsidiary of PM USA; Sherman Group Holdings, LLC and its subsidiaries (“Nat Sherman”), which are engaged in the manufacture and sale of super premium cigarettes and the sale of premium cigars; UST LLC (“UST”), which through its wholly-owned subsidiaries, including U.S. Smokeless Tobacco Company LLC (“USSTC”) and Ste. Michelle Wine Estates Ltd. (“Ste. Michelle”), is engaged in the manufacture and sale of smokeless tobacco products and wine; and Philip Morris Capital Corporation (“PMCC”), which maintains a portfolio of finance assets, substantially all of which are leveraged leases. In addition, Altria owns an 80% interest in Helix Innovations LLC (“Helix”), which is engaged in the manufacture and sale of on! oral nicotine pouches. In December 2018, Altria refocused its innovative product efforts, which included the discontinuation of production and distribution of all e-vapor products by Nu Mark LLC (“Nu Mark”). Prior to that time, Nu Mark was engaged in the manufacture and sale of innovative tobacco products. Other Altria wholly-owned subsidiaries included Altria Group Distribution Company, which provides sales and distribution services to certain Altria operating subsidiaries, and Altria Client Services LLC, which provides various support services in areas such as legal, regulatory, consumer engagement, finance, human resources and external affairs to Altria and its subsidiaries. Altria’s access to the operating cash flows of its wholly-owned subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans by its subsidiaries. At December 31, 2019 , Altria’s significant wholly-owned subsidiaries were not limited by long-term debt or other agreements in their ability to pay cash dividends or make other distributions with respect to their equity interests. At December 31, 2019, Altria had a 10.1% ownership in Anheuser-Busch InBev SA/NV (“ABI”), which Altria accounts for under the equity method of accounting using a one-quarter lag. Altria receives cash dividends on its interest in ABI and will continue to do so as long as ABI pays dividends. During the third quarter of 2019, Helix acquired Burger Söhne Holding and its subsidiaries as well as certain affiliated companies (the “Burger Group”) that are engaged in the manufacture and sale of on! oral nicotine pouches. At closing, Altria indirectly owned an 80% interest in Helix, for which Altria paid $353 million in the third quarter of 2019. The financial results of Helix are included in Altria’s consolidated financial statements as part of its smokeless products segment, with the 20% minority ownership interest in Helix (held by the former shareholders of the Burger Group) included as a noncontrolling interest. The final purchase price allocation, which is subject to post-closing adjustments, will be completed by the third quarter of 2020. In December 2018, Altria, through a wholly-owned subsidiary, purchased shares of non-voting convertible common stock of JUUL Labs, Inc. (“JUUL”), representing a 35% economic interest. JUUL is engaged in the manufacture and sale of e-vapor products globally and is the U.S. leader in e-vapor. At December 31, 2019, Altria had a 35% economic interest in JUUL, which Altria accounts for as an investment in an equity security. In March 2019, Altria, through a subsidiary, completed its acquisition of a 45% economic and voting interest in Cronos Group Inc. (“Cronos”), a global cannabinoid company headquartered in Toronto, Canada. At December 31, 2019, Altria had a 45% economic and voting interest in Cronos, which Altria accounts for under the equity method of accounting using a one-quarter lag. For further discussion of Altria’s investments in equity securities, see Note 7 . Investments in Equity Securities . ▪ Basis of Presentation: The consolidated financial statements include Altria, as well as its wholly-owned and majority-owned subsidiaries. Investments in which Altria has the ability to exercise significant influence over the operating and financial policies of the investee are accounted for under the equity method of accounting. Equity investments in which Altria does not have the ability to exercise significant influence over the operating and financial policies of the investee are accounted for as an investment in an equity security. All intercompany transactions and balances have been eliminated. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of net revenues and expenses during the reporting periods. Significant estimates and assumptions include, among other things, pension and benefit plan assumptions, lives and valuation assumptions for goodwill and other intangible assets, impairment evaluations for equity investments, marketing programs, income taxes, and the estimated residual values of finance leases. Actual results could differ from those estimates. On January 1, 2019, Altria adopted ASU No. 2016-02, Leases (Topic 842) and all related ASU amendments (collectively “ASU No. 2016-02”), which requires entities to recognize lease assets and lease liabilities on the balance sheet and disclose key information about leasing arrangements. Altria has elected to apply the guidance retrospectively at the beginning of the period of adoption. As a result, comparative periods prior to adoption will continue to be presented in accordance with prior lease guidance, including disclosures. The impact of the adoption was not material to Altria’s consolidated financial statements. As a result of the adoption, Altria and its subsidiaries, as lessees, recorded right-of-use assets and lease liabilities of $179 million at January 1, 2019 for its leases, which were all operating leases. There was no cumulative effect adjustment to the opening balance of earnings reinvested in the business. Right-of-use assets and lease liabilities on Altria’s consolidated balance sheet at December 31, 2019 were not materially different than the amounts recorded upon adoption of ASU No. 2016-02. Additionally, in accordance with ASU No. 2016-02, lessor accounting for leveraged leases that commenced before the January 1, 2019 adoption date of ASU No. 2016-02 is unchanged unless there is a change in the scope of, or the consideration for, such leases. As a result, adoption of ASU No. 2016-02 as it relates to PMCC’s leveraged leases had no impact on Altria’s consolidated financial statements at the adoption date. During 2019, PMCC had no new leases nor any changes in the scope of or the consideration for its existing leveraged leases. During the fourth quarter of 2019, in conjunction with its annual impairment testing, Altria adopted ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350) : Simplifying the Test for Goodwill Impairment (“ASU 2017-04”), which simplifies how an entity is required to test goodwill for impairment. For further discussion, see Note 4 . Goodwill and Other Intangible Assets, net . On December 31, 2019, Altria adopted ASU No. 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20) : Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans (“ASU No. 2018-14”), which amends certain defined benefit plan disclosures. The adoption of ASU No. 2018-14 had no impact on the amount of defined benefit plan assets, obligations or expenses recognized by Altria’s businesses. For further discussion, see Note 17 . Benefit Plans . Certain immaterial prior year amounts have been adjusted to conform with the current year’s presentation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies ▪ Cash and Cash Equivalents: Cash equivalents include demand deposits with banks and all highly liquid investments with original maturities of three months or less. Cash equivalents are stated at cost plus accrued interest, which approximates fair value. ▪ Depreciation, Amortization, Impairment Testing and Asset Valuation: Property, plant and equipment are stated at historical costs and depreciated by the straight-line method over the estimated useful lives of the assets. Machinery and equipment are depreciated over periods up to 25 years, and buildings and building improvements over periods up to 50 years. Definite-lived intangible assets are amortized over their estimated useful lives up to 25 years. Altria reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in business circumstances indicate that the carrying value of the assets may not be fully recoverable. Altria performs undiscounted operating cash flow analyses to determine if an impairment exists. For purposes of recognition and measurement of an impairment for assets held for use, Altria groups assets and liabilities at the lowest level for which cash flows are separately identifiable. If Altria determines that an impairment exists, any related impairment loss is calculated based on fair value. Impairment losses on assets to be disposed of, if any, are based on the estimated proceeds to be received, less costs of disposal. Altria also reviews the estimated remaining useful lives of long-lived assets whenever events or changes in business circumstances indicate the lives may have changed. Altria conducts a required annual review of goodwill and indefinite-lived intangible assets for potential impairment, and more frequently if an event occurs or circumstances change that would require Altria to perform an interim review. If the carrying value of a reporting unit that includes goodwill exceeds its fair value, which is determined using discounted cash flows, goodwill is considered impaired. The amount of impairment loss is measured as the difference between the carrying value and the fair value of a reporting unit, but is limited to the total amount of goodwill allocated to a reporting unit. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, which is determined using discounted cash flows, the intangible asset is considered impaired and is reduced to fair value in the period identified. Altria reviews its equity investments accounted for under the equity method of accounting (ABI and Cronos) for impairment by comparing the fair value of each of its investments to their carrying value. If the carrying value of an investment exceeds its fair value and the loss in value is other than temporary, the investment is considered impaired and reduced to fair value, and the impairment is recognized in the period identified. The factors used to make this determination include the duration and magnitude of the fair value decline, the financial condition and near-term prospects of the investee, and Altria’s intent and ability to hold its investment until recovery. Altria reviews its equity investment in JUUL (which is accounted for as an equity security without a readily determinable fair value) for impairment by performing a qualitative assessment of impairment indicators. If a qualitative assessment indicates that Altria’s investment in JUUL is impaired, a quantitative assessment is performed. If the quantitative assessment indicates the fair value of the investment is less than its carrying value, the investment is written down to its fair value in the period identified. ▪ Derivative Financial Instruments: Altria enters into derivatives to mitigate the potential impact of certain market risks, including foreign currency exchange rate risk. Altria uses various types of derivative financial instruments, including forward contracts, options and swaps. Derivative financial instruments are recorded at fair value on the consolidated balance sheets as either assets or liabilities. Derivative financial instruments that qualify for hedge accounting are designated as either fair value hedges, cash flow hedges or net investment hedges at the inception of the contracts. For fair value hedges, changes in the fair value of the derivative, as well as the offsetting changes in the fair value of the hedged item, are recorded in the consolidated statements of earnings (losses) each period. For cash flow hedges, changes in the fair value of the derivative are recorded each period in accumulated other comprehensive earnings (losses) and are reclassified to the consolidated statements of earnings (losses) in the same periods in which operating results are affected by the respective hedged item. For net investment hedges, changes in the fair value of the derivative or foreign currency transaction gains or losses on a nonderivative hedging instrument are recorded in accumulated other comprehensive earnings (losses) to offset the change in the value of the net investment being hedged. Such amounts remain in accumulated other comprehensive earnings (losses) until the complete or substantially complete liquidation of the underlying foreign operations occurs or, for investments in foreign entities accounted for under the equity method of accounting, Altria’s economic interest in the underlying foreign entity decreases. Cash flows from hedging instruments are classified in the same manner as the respective hedged item in the consolidated statements of cash flows. To qualify for hedge accounting, the hedging relationship, both at inception of the hedge and on an ongoing basis, is expected to be highly effective at offsetting changes in the fair value of the hedged risk during the period that the hedge is designated. Altria formally designates and documents, at inception, the financial instrument as a hedge of a specific underlying exposure, the risk management objective, the strategy for undertaking the hedge transaction and method for assessing hedge effectiveness. Additionally, for qualified hedges of forecasted transactions, if it becomes probable that a forecasted transaction will not occur, the hedge would no longer be considered effective and all of the derivative gains and losses would be recorded in the consolidated statement of earnings (losses) in the current period. For financial instruments that are not designated as hedging instruments or do not qualify for hedge accounting, changes in fair value are recorded in the consolidated statements of earnings (losses) each period. Altria does not enter into or hold derivative financial instruments for trading or speculative purposes. ▪ Employee Benefit Plans: Altria provides a range of benefits to certain employees and retired employees, including pension, postretirement health care and postemployment benefits. Altria records annual amounts relating to these plans based on calculations specified by U.S. GAAP, which include various actuarial assumptions as to discount rates, assumed rates of return on plan assets, mortality, compensation increases, turnover rates and health care cost trend rates. Altria recognizes the funded status of its defined benefit pension and other postretirement plans on the consolidated balance sheet and records as a component of other comprehensive earnings (losses), net of deferred income taxes, the gains or losses and prior service costs or credits that have not been recognized as components of net periodic benefit cost. The gains or losses and prior service costs or credits recorded as components of other comprehensive earnings (losses) are subsequently amortized into net periodic benefit cost in future years. ▪ Environmental Costs: Altria is subject to laws and regulations relating to the protection of the environment. Altria provides for expenses associated with environmental remediation obligations on an undiscounted basis when such amounts are probable and can be reasonably estimated. Such accruals are adjusted as new information develops or circumstances change. Compliance with environmental laws and regulations, including the payment of any remediation and compliance costs or damages and the making of related expenditures, has not had, and is not expected to have, a material adverse effect on Altria’s consolidated results of operations, capital expenditures, financial position or cash flows. See Note 19 . Contingencies - Environmental Regulation . ▪ Fair Value Measurements: Altria measures certain assets and liabilities at fair value. Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Altria uses a fair value hierarchy, which gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of inputs used to measure fair value are: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. ▪ Guarantees: Altria recognizes a liability for the fair value of the obligation of qualifying guarantee activities. See Note 19 . Contingencies for a further discussion of guarantees. ▪ Income Taxes: Significant judgment is required in determining income tax provisions and in evaluating tax positions. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse. Altria records a valuation allowance when it is more-likely-than-not that some portion or all of a deferred tax asset will not be realized. Altria recognizes a benefit for uncertain tax positions when a tax position taken or expected to be taken in a tax return is more-likely-than-not to be sustained upon examination by taxing authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Altria recognizes accrued interest and penalties associated with uncertain tax positions as part of the provision for income taxes in its consolidated statements of earnings (losses). ▪ Inventories: The last-in, first-out (“LIFO”) method is used to determine the cost of substantially all tobacco inventories. The cost of the remaining inventories is determined using the first-in, first-out (“FIFO”) and average cost methods. Inventories that are measured using the LIFO method are stated at the lower of cost or market. Inventories that are measured using the FIFO and average cost methods are stated at the lower of cost and net realizable value. It is a generally recognized industry practice to classify leaf tobacco and wine inventories as current assets although part of such inventory, because of the duration of the curing and aging process, ordinarily would not be used within one year . ▪ Litigation Contingencies and Costs: Altria and its subsidiaries record provisions in the consolidated financial statements for pending litigation when it is determined that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. Litigation defense costs are expensed as incurred and included in marketing, administration and research costs in the consolidated statements of earnings (losses). See Note 19 . Contingencies . ▪ Marketing Costs: Altria’s businesses promote their products with consumer incentives, trade promotions and consumer engagement programs. These consumer incentive and trade promotion activities, which include discounts, coupons, rebates, in-store display incentives and volume-based incentives, do not create a distinct deliverable and are, therefore, recorded as a reduction of revenues. Consumer engagement program payments are made to third parties. Altria’s businesses expense these consumer engagement programs, which include event marketing, as incurred and such expenses are included in marketing, administration and research costs in Altria’s consolidated statements of earnings (losses). For interim reporting purposes, Altria’s businesses charge consumer engagement programs and certain consumer incentive expenses to operations as a percentage of sales, based on estimated sales and related expenses for the full year. ▪ Revenue Recognition: Altria’s businesses generate substantially all of their revenue from sales contracts with customers. While Altria’s businesses enter into separate sales contracts with each customer for each product type, all sales contracts are similarly structured. These contracts create an obligation to transfer product to the customer. All performance obligations are satisfied within one year ; therefore, costs to obtain contracts are expensed as incurred and unsatisfied performance obligations are not disclosed. There is no financing component because Altria expects, at contract inception, that the period between when Altria’s businesses transfer product to the customer and when the customer pays for that product will be one year or less. Altria’s businesses define net revenues as revenues, which include excise taxes and shipping and handling charges billed to customers, net of cash discounts for prompt payment, sales returns (also referred to as returned goods) and sales incentives. Altria’s businesses exclude from the transaction price sales taxes and value-added taxes imposed at the time of sale (which do not include excise taxes on cigarettes, cigars, smokeless tobacco or wine billed to customers). Altria’s businesses recognize revenues from sales contracts with customers upon shipment of goods when control of such products is obtained by the customer. Altria’s businesses determine that a customer obtains control of the product upon shipment when title of such product and risk of loss transfers to the customer. Altria’s businesses account for shipping and handling costs as fulfillment costs and such amounts are classified as part of cost of sales in Altria’s consolidated statements of earnings (losses). Altria’s businesses record an allowance for returned goods, based principally on historical volume and return rates, which is included in other accrued liabilities on Altria’s consolidated balance sheets. Altria’s businesses record sales incentives, which consist of consumer incentives and trade promotion activities, as a reduction to revenues (a portion of which is based on amounts estimated as being due to wholesalers, retailers and consumers at the end of a period) based principally on historical volume, utilization and redemption rates. Expected payments for sales incentives are included in accrued marketing liabilities on Altria’s consolidated balance sheets. Payment terms vary depending on product type. Altria’s businesses consider payments received in advance of product shipment as deferred revenue, which is included in other accrued liabilities on Altria’s consolidated balance sheets until revenue is recognized. PM USA receives payment in advance of a customer obtaining control of the product. USSTC receives substantially all payments within one business day of the customer obtaining control of the product. Ste. Michelle receives substantially all payments from customers within 45 days of the customer obtaining control of the product. Amounts due from customers are included in receivables on Altria’s consolidated balance sheets. ▪ New Accounting Guidance Not Yet Adopted: The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, Altria: Standards Description Effective Date for Public Entity Effect on Financial Statements ASU Nos. 2016-13; 2018-19; 2019-04; 2019-05; 2019-10; 2019-11 Measurement of Credit Losses on Financial Instruments (Topic 326) The guidance replaces the current incurred loss impairment methodology for recognizing credit losses for financial assets with a methodology that reflects the entity’s current estimate of all expected credit losses and requires consideration of a broader range of reasonable and supportable information for estimating credit losses. The guidance is effective for annual reporting periods beginning after December 15, 2019, including interim periods within that reporting period. Altria’s adoption of this guidance is not expected to have a material impact on its consolidated financial statements. ASU No. 2018-15 Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (Subtopic 350-40) The guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The guidance is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Altria’s adoption of this guidance is not expected to have a material impact on its consolidated financial statements. ASU 2019-12 Simplifying the Accounting for Income Taxes (Topic 740) The guidance removes certain exceptions for investments, intraperiod allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is permitted, including adoption in any interim period. Altria is in the process of evaluating the impact of this guidance on its consolidated financial statements and related disclosures. ASU 2020-01 Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is permitted, including adoption in any interim period. Altria is in the process of evaluating the impact of this guidance on its consolidated financial statements and related disclosures.

Revenues from Contracts with Cu

Revenues from Contracts with Customers	12 Months Ended
	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	Revenues from Contracts with Customers Altria disaggregates net revenues based on product type. For further discussion, see Note 16 . Segment Reporting . Altria’s businesses offer cash discounts to customers for prompt payment and calculate cash discounts as a percentage of the list price based on historical experience and agreed-upon payment terms. Altria’s businesses record an allowance for cash discounts, which is included as a contra-asset against receivables on Altria’s consolidated balance sheets. There was no allowance for cash discounts at December 31, 2019 and 2018, and there were no differences between amounts recorded as an allowance for cash discounts and cash discounts subsequently given to customers. Altria’s businesses that receive payments in advance of product shipment record such payments as deferred revenue. These payments are included in other accrued liabilities on Altria’s consolidated balance sheets until control of such products is obtained by the customer. Deferred revenue was $362 million and $288 million at December 31, 2019 and 2018, respectively. When cash is received in advance of product shipment, Altria’s businesses satisfy their performance obligations within three days of receiving payment. At December 31, 2019 and 2018, there were no differences between amounts recorded as deferred revenue and amounts subsequently recognized as revenue. Receivables, which primarily reflect sales of wine produced and/or distributed by Ste. Michelle, were $152 million and $142 million at December 31, 2019 and 2018, respectively. At December 31, 2019 and 2018, there were no expected differences between amounts recorded and subsequently received, and Altria’s businesses did not record an allowance for doubtful accounts against these receivables. Altria’s businesses record an allowance for returned goods, which is included in other accrued liabilities on Altria’s consolidated balance sheets. While all of Altria’s tobacco operating companies sell tobacco products with dates relative to freshness as printed on product packaging, it is USSTC’s policy to accept authorized sales returns from its customers for products that have passed such dates due to the limited shelf life of USSTC’s smokeless tobacco products. Altria’s businesses record estimated sales returns, which are based principally on historical volume and return rates, as a reduction to revenues. Actual sales returns will differ from estimated sales returns to the extent actual results differ from estimated assumptions. Altria’s businesses reflect differences between actual and estimated sales returns in the period in which the actual amounts become known. These differences, if any, have not had a material impact on Altria’s consolidated financial statements. All returned goods are destroyed upon return and not included in inventory. Consequently, Altria’s businesses do not record an asset for their right to recover goods from customers upon return. Sales incentives include variable payments related to goods sold by Altria’s businesses. Altria’s businesses include estimates of variable consideration as a reduction to revenues upon shipment of goods to customers. The sales incentives that require significant estimates and judgments are as follows: ▪ Price promotion payments- Altria’s businesses make price promotion payments, substantially all of which are made to their retail partners to incent the promotion of certain product offerings in select geographic areas. ▪ Wholesale and retail participation payments- Altria’s businesses make payments to their wholesale and retail partners to incent merchandising and sharing of sales data in accordance with each business’s trade agreements. These estimates primarily include estimated wholesale to retail sales volume and historical acceptance rates. Actual payments will differ from estimated payments to the extent actual results differ from estimated assumptions. Differences between actual and estimated payments are reflected in the period such information becomes available. These differences, if any, have not had a material impact on Altria’s consolidated financial statements.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets, net	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets, net	Goodwill and Other Intangible Assets, net Goodwill and other intangible assets, net, by segment were as follows: Goodwill Other Intangible Assets, net (in millions) December 31, 2019 December 31, 2018 December 31, 2019 December 31, 2018 Smokeable products $ 99 $ 99 $ 3,071 $ 3,037 Smokeless products 5,078 5,023 9,196 8,825 Wine — 74 238 239 Other — — 182 178 Total $ 5,177 $ 5,196 $ 12,687 $ 12,279 At December 31, 2019 and 2018, the accumulated impairment losses related to goodwill were $185 million and $111 million , respectively. Other intangible assets consisted of the following: December 31, 2019 December 31, 2018 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Indefinite-lived intangible assets $ 11,676 $ — $ 11,846 $ — Definite-lived intangible assets 1,275 264 654 221 Total other intangible assets $ 12,951 $ 264 $ 12,500 $ 221 At December 31, 2019 , indefinite-lived intangible assets consist substantially of trademarks from Altria’s 2009 acquisition of UST ( $9.0 billion ) and 2007 acquisition of Middleton ( $2.6 billion ). Definite-lived intangible assets, which consist primarily of intellectual property, customer relationships and certain cigarette trademarks, are amortized over a weighted-average period of 20 years . Pre-tax amortization expense for definite-lived intangible assets during the years ended December 31, 2019 , 2018 and 2017 , was $44 million , $38 million and $21 million , respectively. In the fourth quarter of 2019, due to a change in estimated useful life, $170 million for an indefinite-lived intangible asset in the smokeable products segment was reclassified to a definite-lived intangible asset, due to an anticipated change in the way the asset will be utilized in the future. Annual amortization expense for each of the next five years is estimated to be approximately $70 million , assuming no additional transactions occur that require the amortization of intangible assets. The changes in goodwill and net carrying amount of intangible assets were as follows: 2019 2018 (in millions) Goodwill Other Intangible Assets, net Goodwill Other Intangible Assets, net Balance at January 1 $ 5,196 $ 12,279 $ 5,307 $ 12,400 Changes due to: Acquisitions (1) 55 451 — 15 Asset impairment (74 ) — (111 ) (98 ) Amortization — (43 ) — (38 ) Balance at December 31 $ 5,177 $ 12,687 $ 5,196 $ 12,279 (1) Substantially all of the 2019 changes reflect Helix’s acquisition of the Burger Group, which held assets consisting primarily of intellectual property. For further discussion, see Note 1 . Background and Basis of Presentation . During the fourth quarter of 2019, in conjunction with its annual impairment testing, Altria adopted ASU 2017-04, which simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. Under ASU 2017-04, an impairment charge is recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value; however, the loss recognized will not exceed the total amount of goodwill allocated to that reporting unit. During 2019, upon completion of Altria’s annual impairment testing of goodwill and other indefinite-lived intangible assets, Altria concluded that goodwill of $74 million in the wine segment was fully impaired as the wine reporting unit was impacted by a slowing growth rate in the premium wine category and higher inventories. During 2018, Altria recorded goodwill and other intangible asset impairment charges of $111 million and $44 million , respectively, related to Altria’s decision in the fourth quarter of 2018 to refocus its innovative product efforts, which included Nu Mark’s discontinuation of production and distribution of all e-vapor products. In addition, during 2018, upon completion of Altria’s annual impairment testing, Altria concluded that the $54 million carrying value of the Columbia Crest trademark in the wine segment was fully impaired as Columbia Crest has been negatively impacted by an accelerated decline in the $7 to $10 premium wine segment, increased competition and reduction in trade support. During 2017, Altria’s quantitative annual impairment test of goodwill and indefinite-lived intangible assets resulted in no

Asset Impairment, Exit and Impl

Asset Impairment, Exit and Implementation Costs	12 Months Ended
	Dec. 31, 2019
Restructuring and Related Activities [Abstract]
Asset Impairment, Exit, and Implementation Costs	Asset Impairment, Exit and Implementation Costs Pre-tax asset impairment, exit and implementation costs consisted of the following: (in millions) Asset Impairment and Exit Costs Implementation Costs Total For the year ended December 31, 2019 2018 2017 2019 (1) 2018 (2) 2017 (2) 2019 2018 2017 Smokeable products $ 59 $ 79 $ 4 $ 33 $ 1 $ 17 $ 92 $ 80 $ 21 Smokeless products 9 20 28 5 3 28 14 23 56 Wine (3) 76 54 — — — — 76 54 — All other 14 227 — (10 ) 63 — 4 290 — General corporate 1 3 — — — — 1 3 — Total 159 383 32 28 67 45 187 450 77 Plus amounts included in net periodic benefit (income) cost, excluding service cost (4) 29 3 1 — — — 29 3 1 Total $ 188 $ 386 $ 33 $ 28 $ 67 $ 45 $ 216 $ 453 $ 78 (1) Included in cost of sales ( $2 million ) and marketing, administration and research costs ( $26 million ) in Altria’s consolidated statement of earnings (losses). (2) Included in cost of sales in Altria’s consolidated statements of earnings (losses). (3) Includes impairment of goodwill for the wine reporting unit in 2019 and impairment of the Columbia Crest trademark in 2018. See Note 4 . Goodwill and Other Intangible Assets, net . (4) Represents settlement and curtailment costs. See Note 17 . Benefit Plans . The 2019 pre-tax asset impairment, exit and implementation costs were related to the cost reduction program and the refocus of innovative product efforts discussed below, and the goodwill impairment for the wine reporting unit. Substantially all of the 2018 pre-tax asset impairment, exit and implementation costs were related to the refocus of innovative product efforts and the cost reduction program discussed below, and the impairment of the Columbia Crest trademark. The pre-tax asset impairment, exit and implementation costs for 2017 were related to the facilities consolidation discussed below. The movement in the restructuring liabilities, substantially all of which were severance liabilities, for the years ended December 31, 2019 and 2018 was as follows: (in millions) Balances at December 31, 2017 $ 33 Charges 154 Cash spent (32 ) Balances at December 31, 2018 155 Charges 59 Cash spent (147 ) Balances at December 31, 2019 $ 67 ▪ Refocus of Innovative Product Efforts: During the fourth quarter of 2018, Altria refocused its innovative product efforts, which included Nu Mark’s discontinuation of production and distribution of all e-vapor products . During the year ended December 31, 2019, Altria incurred pre-tax charges of $9 million , consisting of asset impairment, exit and implementation costs. During 2018, Altria incurred pre-tax charges of $ 272 million , consisting of asset impairment and exit costs of $ 209 million primarily related to the impairment of goodwill and other intangible assets and other charges of $63 million related to inventory write-offs and accelerated depreciation. The pre-tax charges related to the refocus of innovative product efforts have been completed. The majority of the charges related to these efforts did not result in cash payments. ▪ Cost Reduction Program: In December 2018, Altria announced a cost reduction program that includes workforce reductions and third-party spending reductions across the businesses. As a result of the cost reduction program, Altria recorded total pre-tax restructuring charges of $254 million , which included employee benefit-related curtailment and settlement costs. Of this amount, Altria incurred pre-tax charges of $133 million in 2019 and $121 million in 2018. The total charges, the majority of which will result in cash expenditures, related primarily to employee separation costs of $202 million and other costs of $52 million . The pre-tax charges related to this cost reduction program have been substantially completed. Cash payments related to this cost reduction program of $136 million were made during the year ended December 31, 2019. There were no cash payments related to this program in 2018. ▪ Facilities Consolidation: In October 2016, Altria announced the consolidation of certain of its operating companies’ manufacturing facilities to streamline operations and achieve greater efficiencies. In the first quarter of 2018, Middleton completed the transfer of its Limerick, Pennsylvania operations to the Manufacturing Center site in Richmond, Virginia (“Richmond Manufacturing Center”), and USSTC completed the transfer of its Franklin Park, Illinois operations to its Nashville, Tennessee facility and the Richmond Manufacturing Center. At December 31, 2018, pre-tax charges related to the consolidation were completed. As a result of the consolidation, Altria recorded total pre-tax charges of $155 million . During 2018 and 2017, Altria recorded pre-tax charges of $6 million and $78 million , respectively. The total charges related primarily to accelerated depreciation and asset impairment ( $55 million ), employee separation costs ( $40 million ) and other exit and implementation costs ( $60 million ). Cash payments related to the consolidation of $3 million were made during the year ended December 31, 2019, for total cash payments of $100 million

Inventories

Inventories	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories The cost of approximately 56% and 58% of inventories at December 31, 2019 and 2018 , respectively, was determined using the LIFO method. The stated LIFO amounts of inventories were approximately $0.6 billion and $0.7 billion lower than the current cost of inventories at December 31, 2019 and 2018 , respectively.

Investments in Equity Securitie

Investments in Equity Securities	12 Months Ended
	Dec. 31, 2019
Equity Method Investments and Joint Ventures [Abstract]
Investments in Equity Securities	Investments in Equity Securities Altria’s investments at December 31, 2019 and 2018 consisted of the following: Carrying Amount (in millions) December 31, 2019 December 31, 2018 ABI $ 18,071 $ 17,696 JUUL 4,205 12,800 Cronos (1) 1,305 — Total $ 23,581 $ 30,496 ( 1) Includes investment in Acquired Common Shares ( $1,002 million ), the Cronos warrant ( $234 million ) and the Fixed-price Preemptive Rights ( $69 million ) as discussed further below. Earnings from equity investments accounted for under the equity method of accounting for the years ended December 31, 2019, 2018 and 2017 consisted of the following: (in millions) 2019 2018 2017 ABI $ 1,229 $ 890 $ 532 Cronos (1) 496 — — Total $ 1,725 $ 890 $ 532 ( 1) Represents Altria’s share of Cronos’s earnings, substantially all of which relate to the change in fair value of Cronos’s derivative financial instruments associated with the issuance of additional shares. Investment in ABI At December 31, 2019, Altria had a 10.1% economic and voting interest in ABI, consisting of 185 million restricted shares of ABI (the “Restricted Shares”) and 12 million ordinary shares of ABI. The Restricted Shares: ▪ are unlisted and not admitted to trading on any stock exchange; ▪ are subject to a five -year lock-up (subject to limited exceptions) ending October 10, 2021; ▪ are convertible into ordinary shares of ABI on a one-for-one basis after the end of this five -year lock-up period; ▪ rank equally with ordinary shares of ABI with regards to dividends and voting rights; and ▪ have director nomination rights with respect to ABI. Altria accounts for its investment in ABI under the equity method of accounting because Altria has the ability to exercise significant influence over the operating and financial policies of ABI, including having active representation on ABI’s Board of Directors (“ABI Board”) and certain ABI Board committees. Through this representation, Altria participates in ABI policy making processes. Altria reports its share of ABI’s results using a one-quarter lag because ABI’s results are not available in time for Altria to record them in the concurrent period. Summary financial data of ABI is as follows: For Altria’s Year Ended December 31, (in millions) 2019 (1) 2018 (1) 2017 (1) Net revenues $ 54,187 $ 55,500 $ 56,004 Gross profit $ 33,735 $ 34,986 $ 34,376 Earnings from continuing operations $ 10,530 $ 9,020 $ 6,769 Net earnings $ 10,530 $ 9,020 $ 6,845 Net earnings attributable to ABI $ 9,189 $ 7,641 $ 5,473 At September 30, (in millions) 2019 (1) 2018 (1) Current assets $ 27,353 $ 20,289 Long-term assets $ 199,591 $ 207,921 Current liabilities $ 36,819 $ 32,019 Long-term liabilities $ 119,025 $ 130,812 Noncontrolling interests $ 8,765 $ 7,251 (1) Reflects the one-quarter lag. At December 31, 2019, Altria’s carrying value of its equity investment in ABI exceeded its share of ABI’s net assets attributable to equity holders of ABI by approximately $11.8 billion . Substantially all of this difference is comprised of goodwill and other indefinite-lived intangible assets (consisting primarily of trademarks). The fair value of Altria’s equity investment in ABI is based on: (i) unadjusted quoted prices in active markets for ABI’s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets, for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy. Altria may, in certain instances, pledge or otherwise grant a security interest in all or part of its Restricted Shares. In the event the pledgee or security interest holder were to foreclose on the Restricted Shares, the encumbered Restricted Shares will be automatically converted, one-for-one, into ordinary shares. Therefore, the fair value of each Restricted Share is based on the value of an ordinary share. The fair value of Altria’s equity investment in ABI at December 31, 2019 and 2018 was $16.1 billion (carrying value of $18.1 billion ) and $13.1 billion (carrying value of $17.7 billion ), respectively, which was less than its carrying value by 11% and 26% , respectively, at December 31, 2019 and 2018. During 2019, the fair value increased and at September 30, 2019, the fair value of Altria’s equity investment in ABI exceeded its carrying value by 4% . In October 2019, the fair value of Altria’s equity investment in ABI declined below its carrying value. Based on Altria’s evaluation of the duration and magnitude of the fair value decline, Altria’s evaluation of ABI’s financial condition and near-term prospects, and Altria’s intent and ability to hold its investment in ABI until recovery, Altria concluded that the decline in fair value of its investment in ABI below its carrying value is temporary and, therefore, no impairment was recorded. In the fourth quarter of 2019, Altria recorded a net pre-tax gain of $284 million in earnings from equity investments in Altria’s consolidated statement of earnings (losses), related to the completion in September 2019 of ABI’s initial public offering of a minority stake of its Asia Pacific subsidiary, Budweiser Brewing Company APAC Limited. At September 30, 2019, ABI had derivative financial instruments used to hedge its share price related to 92.4 million of its share commitments. ABI’s share price in Euros at December 31, 2019 and September 30, 2019 was €72.71 and €87.42 , respectively. Consistent with the one-quarter lag for reporting ABI’s results in Altria’s financial results, Altria will record its share of ABI’s fourth quarter 2019 mark-to-market losses associated with these derivative financial instruments in the first quarter of 2020. At September 30, 2016, Altria had an approximate 27% ownership of SABMiller plc (“SABMiller”), which Altria accounted for under the equity method of accounting. In October 2016, Anheuser-Busch InBev SA/NV completed its business combination with SABMiller, and Altria received cash and shares representing a 9.6% ownership in the combined company. For the years ended December 31, 2018 and 2017, Altria recorded pre-tax losses of $33 million and gains of $445 million , respectively, related to the planned completion of the remaining ABI divestitures in (gain) loss on ABI/SABMiller business combination in Altria’s consolidated statements of earnings (losses). Investment in JUUL In December 2018, Altria, through a wholly-owned subsidiary, purchased shares of JUUL’s non-voting Class C-1 Common Stock for an aggregate price of $12.8 billion , which will convert automatically to shares of voting Class C Common Stock upon antitrust clearance (“Share Conversion”), and for no additional payment, a security convertible into additional shares of Class C-1 Common Stock or Class C Common Stock, as applicable, upon settlement or exercise of certain JUUL convertible securities (the “JUUL Transaction”). At December 31, 2019 and 2018, Altria owned 35% of the issued and outstanding capital stock of JUUL. Altria received a broad preemptive right to purchase JUUL shares, exercisable each quarter upon dilution, to maintain its ownership percentage. Altria is subject to a standstill restriction under which it may not acquire additional JUUL shares above its 35% interest. Furthermore, Altria agreed not to sell or transfer any of its JUUL shares until December 20, 2024. As part of the JUUL Transaction, Altria and JUUL entered into a services agreement pursuant to which Altria agreed to provide JUUL with certain commercial services, as requested by JUUL, for an initial term of six years . Altria also agreed to grant JUUL a non-exclusive, royalty-free perpetual, irrevocable, sublicensable license to Altria’s non-trademark licensable intellectual property rights in the e-vapor field, subject to the terms and conditions set forth in an intellectual property license agreement between the parties. Additionally, Altria agreed to non-competition obligations generally requiring that it participate in the e-vapor business only through JUUL as long as Altria is supplying JUUL services, which Altria is committed to doing until at least December 20, 2024. As previously disclosed, in April 2019 in connection with antitrust review, Altria and JUUL received a request for additional information (commonly referred to as a “second request”) from the U.S. Federal Trade Commission (the “FTC”). In October 2019, Altria and JUUL certified substantial compliance with the second request. Based on the timing agreement among Altria, JUUL and the FTC staff, Share Conversion will not occur before the end of the 70th calendar day following certification of substantial compliance by Altria and JUUL unless the FTC completes its review prior to that day. This agreement has been subject to extensions for the convenience of the parties; however, Altria believes the FTC will complete its review in the first half of 2020. On January 28, 2020, Altria and JUUL amended certain JUUL Transaction agreements and entered into a new cooperation agreement, which include the following provisions: ▪ Effective January 28, 2020: ▪ Altria will continue to provide regulatory affairs support for JUUL’s pursuit of its pre-market tobacco applications (PMTA) and/or its modified risk tobacco products authorization (MRTP) and will discontinue all other services by the end of the first quarter of 2020; ▪ Altria has the option to be released from its non-compete obligation (i) in the event JUUL is prohibited by federal law from selling e-vapor products in the U.S. for a continuous period of at least 12 months (subject to tolling of this period in certain circumstances) or (ii) if the carrying value of Altria’s investment in JUUL is not more than 10% of its initial carrying value of $12.8 billion ; ▪ Altria and JUUL agreed that for a period of one year they will not pursue any litigation against each other in connection with any conduct that occurred prior to the date of such agreement, with statutes of limitation being tolled during the one-year period; and ▪ with respect to certain litigation in which Altria and JUUL are both defendants against third-party plaintiffs, Altria will not pursue any claims against JUUL for indemnification or reimbursement except for any non-contractual claims for contribution or indemnity where a judgment has been entered against Altria and JUUL. ▪ Upon Share Conversion, JUUL will: ▪ restructure JUUL’s current seven -member Board of Directors to a nine -member board to include independent board members. The new structure will include: (i) three independent directors ( one of whom will be designated by Altria and two of whom will be designated by JUUL stockholders other than Altria) unanimously certified as independent by a nominating committee, which will include at least one Altria designee, (ii) two directors designated by Altria, (iii) three directors designated by JUUL stockholders other than Altria, and (iv) the JUUL Chief Executive Officer; and ▪ create a Litigation Oversight Committee, which will include two Altria designated directors ( one of whom will chair the Litigation Oversight Committee) that will have oversight authority and review of litigation management for matters in which JUUL and Altria are co-defendants and have or reasonably could have a written joint defense agreement in effect between them. Subject to certain limitations, the Litigation Oversight Committee will recommend to JUUL changes to outside counsel and litigation strategy by majority vote, with disagreements by JUUL’s management being resolved by majority vote of JUUL’s Board of Directors. Also, upon Share Conversion, Altria expects to account for its equity investment in JUUL under the fair value option. Under this option, Altria’s consolidated statement of earnings (losses) will include any cash dividends received from its investment in JUUL as well as any changes in the fair value of the investment, which will be calculated quarterly. At December 31, 2019 , Altria accounted for its investment in JUUL as an investment in an equity security. Since the JUUL shares do not have a readily determinable fair value, Altria has elected to measure its investment in JUUL at its cost minus any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There have been no upward or downward adjustments to the carrying value of Altria’s investment in JUUL resulting from observable price changes in orderly transactions since the JUUL Transaction through December 31, 2019 . Altria reviews its investment in JUUL for impairment by performing a qualitative assessment of impairment indicators on a quarterly basis in connection with the preparation of its financial statements. If this qualitative assessment indicates that Altria’s investment in JUUL may be impaired, a quantitative assessment is performed. If the quantitative assessment indicates the fair value of the investment is less than its carrying value, the investment is written down to its fair value. As part of the preparation of its financial statements for the periods ended September 30, 2019 and December 31, 2019, Altria performed its respective qualitative assessments of impairment indicators for its investment in JUUL and determined that indicators of impairment existed. At September 30, 2019, these indicators included recent significant adverse changes in both the e-vapor regulatory environment and the industry in which JUUL operates. While there was no single determinative event or factor, Altria considered in totality the following indicators of impairment: the increased likelihood of a United States Food and Drug Administration compliance policy prohibiting the sale of certain flavored e-vapor products in the U.S. market without a pre-market authorization; various e-vapor bans put in place by certain states and cities in the U.S. and in certain international markets, coupled with the increased potential for additional bans in the future; and the impact of heightened adverse publicity, including news reports and public health advisories concerning vaping-related lung injuries and deaths. At December 31, 2019, Altria determined that a significant increase in the number of legal cases pending against JUUL in the fourth quarter of 2019 resulted in an additional indicator of impairment. There were approximately 340 cases (an increase of over 80% since the filing of Altria’s 2019 Third Quarter Form 10-Q at October 31, 2019) outstanding against JUUL at December 31, 2019, including a variety of class action lawsuits and personal injury claims, as well as cases brought by state attorneys general and local governments. Following completion of Altria’s valuation of JUUL as of September 30, 2019, these incremental outstanding legal cases against JUUL, as well as the expectation that the number of legal cases against JUUL will continue to increase, have increased the risk that JUUL will not achieve Altria’s projection of JUUL’s future cash flows. While Altria has not made any assumptions, or drawn any conclusions, regarding the merits or likelihood of success of any of these cases, litigation is subject to uncertainty and it is possible that there could be adverse developments in pending or future cases. This uncertainty has increased the risk that JUUL may not be able to obtain financing and/or fund working capital requirements, financial obligations and international expansion plans. Given the existence of these impairment indicators, Altria performed quantitative valuations of its investment in JUUL as of September 30, 2019 and December 31, 2019 and recorded total pre-tax charges of $8.6 billion for the year ended December 31, 2019, reported as impairment of JUUL equity securities in its consolidated statement of earnings (losses). Of this amount, Altria recorded pre-tax charges of $4.5 billion in the third quarter of 2019 and $4.1 billion in the fourth quarter of 2019. The third-quarter impairment charge was due primarily to lower e-vapor sales volume assumptions in the U.S. and international markets and a delay in achieving operating margin performance, as compared to the assumptions at the time of the JUUL Transaction. The fourth-quarter impairment charge results substantially from increased discount rates applied to future cash flow projections, due to the significant risk created by the increase in number of legal cases pending against JUUL. Altria used an income approach to estimate the fair value of its investment in JUUL. The income approach reflects the discounting of future cash flows for the U.S. and international markets at a rate of return that incorporates the risk-free rate for the use of those funds, the expected rate of inflation and the risks associated with realizing future cash flows. Future cash flows in the U.S. were based on a range of scenarios that consider various potential regulatory and market outcomes. In determining the fair value of its investment in JUUL, Altria made various judgments, estimates and assumptions, the most significant of which were sales volume, operating margins, discount rates and perpetual growth rates. Additionally, Altria made significant assumptions regarding the likelihood and extent of various potential regulatory actions and the continued adverse public perception impacting the e-vapor category and specifically JUUL, as well as expectations of the future state of the e-vapor category. All significant inputs used in the valuation are classified in Level 3 of the fair value hierarchy. As disclosed in Note 9 . Short-term Borrowings and Borrowing Arrangements , Altria financed the JUUL Transaction through a senior unsecured term loan agreement (the “Term Loan Agreement”). Costs incurred to effect the investment in JUUL were recognized as expenses in Altria’s consolidated statements of earnings (losses). For the years ended December 31, 2019 and 2018, Altria incurred $8 million and $85 million , respectively, of pre-tax acquisition-related costs, consisting primarily of advisory fees, substantially all of which were recorded in marketing, administration and research costs. Investment in Cronos In March 2019, Altria, through a subsidiary, completed its acquisition of: ▪ 149.8 million newly issued common shares of Cronos (“Acquired Common Shares”), which represented a 45% economic and voting interest; ▪ anti-dilution protections to purchase Cronos common shares, exercisable each quarter upon dilution, to maintain its ownership percentage. Certain of the anti-dilution protections provide Altria the ability to purchase additional Cronos common shares at a per share exercise price of Canadian dollar (“CAD”) $16.25 upon the occurrence of specified events (“Fixed-price Preemptive Rights”). Based on Altria’s assumptions as of December 31, 2019, Altria estimates the Fixed-price Preemptive Rights will allow Altria to purchase up to an additional approximately 37 million common shares of Cronos; and ▪ a warrant providing Altria the ability to purchase up to an additional 10% of common shares of Cronos (approximately 78 million common shares at December 31, 2019) at a per share exercise price of CAD $19.00 , which expires on March 8, 2023. If exercised in full, the exercise prices for the warrant and Fixed-price Preemptive Rights are approximately CAD $1.5 billion and CAD $0.6 billion (approximately USD $1.1 billion and $0.5 billion , respectively, based on the CAD to USD exchange rate on January 27, 2020). The total purchase price for the Acquired Common Shares, Fixed-price Preemptive Rights and warrant (collectively, “Investment in Cronos”) was CAD $2.4 billion (U.S. dollar (“USD”) $1.8 billion ). Upon full exercise of the Fixed-price Preemptive Rights, to the extent such rights become available, and the warrant, Altria would own a maximum of 55% of the outstanding common shares of Cronos. In accounting for the acquisition of these assets as of the date of closing, the Fixed-price Preemptive Rights and warrant were recorded at each of their fair values using Black-Scholes option-pricing models, based on the assumptions described in Note 8 . Financial Instruments . In addition, a deferred tax liability related to the Fixed-price Preemptive Rights and warrant was recorded. The residual of the purchase price was allocated to the Acquired Common Shares. Accordingly, the CAD $2.4 billion (USD $1.8 billion ) purchase price was recorded in USD as follows: ▪ $1.2 billion to the warrant; ▪ $0.5 billion to the Fixed-price Preemptive Rights; ▪ $0.4 billion to the Acquired Common Shares; and ▪ $0.3 billion to a deferred tax liability. For a discussion of derivatives related to Altria’s investment in Cronos, including Altria’s accounting for changes in the fair value of these derivatives, see Note 8 . Financial Instruments . At December 31, 2019, Altria had a 45% economic and voting interest in Cronos, which Altria accounts for under the equity method of accounting. Altria reports its share of Cronos’s results using a one-quarter lag because Cronos’s results are not available in time for Altria to record them in the concurrent period. Altria nominated four directors, including one director who is independent from Altria, who serve on Cronos’s seven -member Board of Directors. Summary financial data of Cronos is as follows: For Altria’s Year Ended December 31, (in millions) 2019 (1) Net revenues $ 21 Gross profit $ 10 Net earnings (2) $ 1,117 (in millions) At September 30, 2019 (1) Current assets $ 1,575 Long-term assets $ 511 Current liabilities $ 457 Long-term liabilities $ 7 Noncontrolling interests $ — (1) Reflecting the one-quarter lag: (i) summary financial data of Cronos’s results for Altria’s year ended December 31, 2019 include Cronos’s results for the period March 8, 2019 through September 30, 2019, and (ii) summary financial data of Cronos’s financial position is disclosed at September 30, 2019. (2) Substantially all of Cronos’s net earnings related to changes in fair value of Cronos’s derivative financial instruments associated with the issuance of additional shares. At December 31, 2019, Altria’s carrying amount of its Acquired Common Shares in Cronos exceeded its share of Cronos’s net assets attributable to equity holders of Cronos by approximately $0.2 billion . Substantially all of this difference is comprised of definite-lived intangible assets (consisting of licenses, distribution agreements and developed technology). The fair value of Altria’s Acquired Common Shares in Cronos is based on unadjusted quoted prices in active markets for Cronos’s common shares and was classified in Level 1 of the fair value hierarchy. The fair value of Altria’s Acquired Common Shares in Cronos at December 31, 2019 was $1.2 billion compared with its carrying value of $1.0 billion .

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Financial Instruments Altria enters into derivative financial instruments to mitigate the potential impact of certain market risks, including foreign currency exchange rate risk. Altria uses various types of derivative financial instruments, including forward contracts, options and swaps. Altria does not enter into or hold derivative financial instruments for trading or speculative purposes. Altria’s investment in ABI, whose functional currency is the Euro, exposes Altria to foreign currency exchange risk on the carrying value of its investment. To manage this risk, Altria designates certain foreign exchange contracts, including cross-currency swap contracts and forward contracts (collectively, “foreign currency contracts”), and Euro denominated unsecured long-term notes (“foreign currency denominated debt”) as net investment hedges of Altria’s investment in ABI. At December 31, 2019 and December 31, 2018 , Altria had foreign currency contracts with aggregate notional amounts of $2,246 million and $1,226 million , respectively. At December 31, 2019 , Altria had foreign currency denominated debt with an aggregate fair value and carrying value of $5,057 million and $4,741 million , respectively. At December 31, 2018 , Altria had no foreign currency denominated debt. Altria’s estimates of the fair values of its foreign currency contracts are determined using valuation models with significant inputs that are readily available in public markets, or can be derived from observable market transactions, and therefore are classified in Level 2 of the fair value hierarchy. An adjustment for credit risk and nonperformance risk is included in the fair values of foreign currency contracts. Altria’s estimate of the fair value of its debt is based on observable market information derived from a third-party pricing source and is classified in Level 2 of the fair value hierarchy. The aggregate fair value of Altria’s total long-term debt at December 31, 2019 and 2018 , was $30.7 billion and $12.5 billion , respectively, as compared with its carrying value of $28.0 billion and $13.0 billion , respectively. Altria’s Fixed-price Preemptive Rights and warrant related to its investment in Cronos, which is further discussed in Note 7 . Investments in Equity Securities , are derivative financial instruments, which are required to be recorded at fair value. The fair values of the Fixed-price Preemptive Rights and warrant are estimated using Black-Scholes option-pricing models, adjusted for unobservable inputs, including probability factors and weighting of expected life, volatility levels and risk-free interest rates (which are classified in Level 3 of the fair value hierarchy) based on the following assumptions at: December 31, 2019 March 8, 2019 December 31, 2019 March 8, 2019 Fixed-price Preemptive Rights Warrant Expected life (1) 1.67 years 2.32 years 3.18 years 4 years Expected volatility (2) 81.61% 93.02% 81.61% 93.02% Risk-free interest rate (3)(4) 1.71% 1.61% 1.69% 1.67% Expected dividend yield (5) —% —% —% —% (1) Based on the weighted-average expected life of the Fixed-price Preemptive Rights (with a range from approximately 0.25 years to 7 years at December 31, 2019 and March 8, 2019) and the March 8, 2023 expiration date of the warrant. (2) Based on a blend of historical volatility levels of the underlying equity security and peer companies. (3) Based on the implied yield currently available on Canadian Treasury zero coupon issues weighted for the remaining expected life of the Fixed-price Preemptive Rights. (4) Based on the implied yield currently available on Canadian Treasury zero coupon issues and the expected life of the warrant. (5) Based on Cronos’s expected dividend payments . The following table provides a reconciliation of the beginning and ending balance of the Fixed-price Preemptive Rights and warrant, which are classified in Level 3 of the fair value hierarchy: (in millions) Balance at December 31, 2018 $ — Initial investment in Fixed-price Preemptive Rights and warrant 1,736 Exercise of Fixed-price Preemptive Rights (22 ) Pre-tax earnings (losses) recognized in net earnings (1,411 ) Balance at December 31, 2019 $ 303 Altria elects to record the gross assets and liabilities of derivative financial instruments executed with the same counterparty on its consolidated balance sheets. The fair values of Altria’s derivative financial instruments on a gross basis included on the consolidated balance sheets were as follows: Fair Value of Assets Fair Value of Liabilities (in millions) Balance Sheet Classification December 31, 2019 December 31, 2018 Balance Sheet Classification December 31, 2019 December 31, 2018 Derivatives designated as hedging instruments: Foreign currency contracts Other current assets $ 46 $ 37 Other accrued liabilities $ 7 $ — Foreign currency contracts Other assets — 4 Other liabilities 21 4 Total $ 46 $ 41 $ 28 $ 4 Derivatives not designated as hedging instruments: Cronos warrant Investments in equity securities $ 234 $ — Fixed-price Preemptive Rights Investments in equity securities 69 — Total $ 303 $ — Total derivatives $ 349 $ 41 $ 28 $ 4 Altria records in its consolidated statements of earnings (losses) any changes in the fair values of the Fixed-price Preemptive Rights and warrant as gains or losses on Cronos-related financial instruments in the periods in which the changes occur. For the year ended December 31, 2019 , Altria recognized pre-tax unrealized losses of $1,411 million , consisting of $434 million and $977 million , representing the changes in the fair values of the Fixed-price Preemptive Rights and warrant, respectively. In January and February 2019, Altria entered into derivative financial instruments in the form of forward contracts, which were settled on March 7, 2019, to hedge Altria’s exposure to CAD to USD foreign currency exchange rate movements, in relation to the CAD $2.4 billion purchase price for the Cronos transaction. The aggregate notional amounts of the forward contracts were USD $1.8 billion (CAD $2.4 billion ). The forward contracts did not qualify for hedge accounting; therefore, in the first quarter of 2019, pre-tax losses of USD $31 million representing changes in the fair values of the forward contracts were recorded in loss on Cronos-related financial instruments in Altria’s consolidated statement of earnings (losses). Counterparties to Altria’s foreign currency contracts are domestic and international financial institutions. Altria is exposed to potential losses due to non-performance by these counterparties. Altria manages its credit risk by entering into transactions with counterparties with investment grade credit ratings, limiting the amount of exposure Altria has with each counterparty and monitoring the financial condition of each counterparty. The counterparty agreements also contain provisions that require Altria to maintain an investment grade credit rating. In the event Altria’s credit rating falls below investment grade, counterparties to Altria’s foreign currency contracts can require Altria to post collateral. No collateral was received or posted related to derivative assets and liabilities at December 31, 2019 and December 31, 2018 . ▪ Net Investment Hedging: The pre-tax effects of Altria’s net investment hedges on accumulated other comprehensive losses and the consolidated statements of earnings (losses) were as follows: Gain (Loss) Recognized in Accumulated Other Comprehensive Losses (1) Gain (Loss) Recognized in Net Earnings (Losses) (1) (2) For the Years Ended December 31, (in millions) 2019 2018 2019 2018 Foreign currency contracts $ 23 $ 69 $ 36 $ 35 Foreign currency denominated debt 35 — — — Total $ 58 $ 69 $ 36 $ 35 (1) Net investment hedging activity was not material to Altria for the year ended December 31, 2017. (2) Related to amounts excluded from effectiveness testing. The changes in the fair value of the foreign currency contracts and in the carrying value of the foreign currency denominated debt due to changes in the Euro to USD exchange rate were recognized in accumulated other comprehensive losses related to ABI. Gains on the foreign currency contracts arising from components excluded from effectiveness testing were recognized in interest and other debt expense, net in the consolidated statements of earnings (losses) based on an amortization approach.

Short-Term Borrowings and Borro

Short-Term Borrowings and Borrowing Arrangements	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Short-Term Borrowings and Borrowing Arrangements	Short-Term Borrowings and Borrowing Arrangements At December 31, 2019 , Altria had no short-term borrowings. At December 31, 2018 , Altria had $12.7 billion of short-term borrowings, which was net of approximately $95 million of debt issuance costs, under the term loan agreement discussed below. In December 2018, Altria entered into a senior unsecured term loan agreement in connection with its investments in JUUL and Cronos (the “Term Loan Agreement”). At December 31, 2018, Altria had aggregate short-term borrowings under the Term Loan Agreement of $12.8 billion at an average interest rate of approximately 3.5% . Borrowings under the Term Loan Agreement were set to mature on December 19, 2019. In February 2019, Altria repaid all of the outstanding $12.8 billion of short-term borrowings under the Term Loan Agreement with net proceeds from the issuance of long-term senior unsecured notes. See Note 10 . Long-Term Debt . Upon repayment, the Term Loan Agreement terminated in accordance with its terms. In 2019, Altria recorded approximately $95 million of pre-tax acquisition-related costs for the write-off of the debt issuance costs related to the Term Loan Agreement, which were recorded in interest and other debt expense, net in Altria’s consolidated statement of earnings (losses). Altria’s estimate of the fair value of its short-term borrowings is derived from discounted future cash flows based on the contractual terms of the Term Loan Agreement and observable interest rates and is classified in Level 2 of the fair value hierarchy. The fair value of Altria’s short-term borrowings at December 31, 2018 approximated its carrying value. At December 31, 2018, accrued interest on short-term borrowings of $15 million was included in other accrued liabilities on Altria’s consolidated balance sheet. At December 31, 2019, Altria had a senior unsecured 5 -year revolving credit agreement (the “Credit Agreement”). The Credit Agreement, which is used for general corporate purposes, provides for borrowings up to an aggregate principal amount of $3.0 billion . The Credit Agreement expires on August 1, 2023 and includes an option, subject to certain conditions, for Altria to extend the Credit Agreement for two additional one -year periods. Pricing for interest and fees under the Credit Agreement may be modified in the event of a change in the rating of Altria’s long-term senior unsecured debt. Interest rates on borrowings under the Credit Agreement are expected to be based on the London Interbank Offered Rate (“LIBOR”), or a mutually agreed upon benchmark rate, plus a percentage based on the higher of the ratings of Altria’s long-term senior unsecured debt from Moody’s Investors Service, Inc. (“Moody’s”) and Standard & Poor’s Ratings Services (“Standard & Poor’s”). The applicable percentage based on Altria’s long-term senior unsecured debt ratings at December 31, 2019 for borrowings under the Credit Agreement was 1.0% . The Credit Agreement does not include any other rating triggers, or any provisions that could require the posting of collateral. At December 31, 2019 and 2018 , Altria had no borrowings under the Credit Agreement. The credit line available to Altria at December 31, 2019 under the Credit Agreement was $3.0 billion . The Credit Agreement includes various covenants, one of which requires Altria to maintain a ratio of consolidated earnings before interest, taxes, depreciation and amortization (“EBITDA”) to Consolidated Interest Expense of not less than 4.0 to 1.0, calculated as of the end of the applicable quarter on a rolling four quarters basis. At December 31, 2019 , the ratio of consolidated EBITDA to Consolidated Interest Expense, calculated in accordance with the Credit Agreement, was 8.2 to 1.0. At December 31, 2019 , Altria was in compliance with its covenants in the Credit Agreement. The terms “Consolidated EBITDA” and “Consolidated Interest Expense,” each as defined in the Credit Agreement, include certain adjustments. Any commercial paper issued by Altria and borrowings under the Credit Agreement are guaranteed by PM USA as further discussed in Note 20 . Condensed Consolidating Financial Information.

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt At December 31, 2019 and 2018 , Altria’s long-term debt consisted of the following: (in millions) 2019 2018 USD notes, 2.625% to 10.20%, interest payable semi-annually, due through 2059 (1) $ 23,259 $ 13,000 USD Debenture, 7.75%, interest payable semi-annually, due 2027 42 42 Euro notes, 1.000% to 3.125%, interest payable annually, due through 2031 (2) 4,741 — 28,042 13,042 Less current portion of long-term debt 1,000 1,144 $ 27,042 $ 11,898 (1) Weighted-average coupon interest rate of 4.6% at December 31, 2019 and 2018 . (2) Weighted-average coupon interest rate of 2.0% at December 31, 2019. At December 31, 2019 , aggregate maturities of Altria’s long-term debt were as follows: (in millions) 2020 $ 1,000 2021 1,500 2022 2,900 2023 1,752 2024 2,400 Thereafter 18,723 28,275 Less: debt issuance costs 154 debt discounts 79 $ 28,042 At December 31, 2019 and 2018 , accrued interest on long-term debt of $470 million and $207 million , respectively, was included in other accrued liabilities on Altria’s consolidated balance sheets. ▪ Altria Senior Notes: In February 2019, Altria issued USD denominated and Euro denominated long-term senior unsecured notes in the aggregate principal amounts of $11.5 billion and €4.25 billion , respectively. Altria immediately converted the proceeds of the Euro denominated notes into USD of $4.8 billion . The net proceeds from the Euro notes and a portion of the net proceeds from the USD notes were used to repay in full the $12.8 billion of short-term borrowings under the Term Loan Agreement, which were incurred to fund Altria’s investment in JUUL. The remaining net proceeds from the USD notes were used to fund Altria’s investment in Cronos in the first quarter of 2019 and for other general corporate purposes. The notes contain the following terms: USD denominated notes ▪ $1.0 billion at 3.490% , due 2022, interest payable semiannually beginning August 14, 2019; ▪ $1.0 billion at 3.800% , due 2024, interest payable semiannually beginning August 14, 2019; ▪ $1.5 billion at 4.400% , due 2026, interest payable semiannually beginning August 14, 2019; ▪ $3.0 billion at 4.800% , due 2029, interest payable semiannually beginning August 14, 2019; ▪ $2.0 billion at 5.800% , due 2039, interest payable semiannually beginning August 14, 2019; ▪ $2.5 billion at 5.950% , due 2049, interest payable semiannually beginning August 14, 2019; and ▪ $0.5 billion at 6.200% , due 2059, interest payable semiannually beginning August 14, 2019. Euro denominated notes ▪ €1.25 billion at 1.000% , due 2023, interest payable annually beginning February 15, 2020; ▪ €0.75 billion at 1.700% , due 2025, interest payable annually beginning June 15, 2020; ▪ €1.0 billion at 2.200% , due 2027, interest payable annually beginning June 15, 2020; and ▪ €1.25 billion at 3.125% , due 2031, interest payable annually beginning June 15, 2020. All of Altria’s outstanding notes are senior unsecured obligations and rank equally in right of payment with all of Altria’s existing and future senior unsecured indebtedness. Upon the occurrence of both (i) a change of control of Altria and (ii) the notes ceasing to be rated investment grade by each of Moody’s, Standard & Poor’s and Fitch Ratings Ltd. within a specified time period, Altria will be required to make an offer to purchase the notes at a price equal to 101% of the aggregate principal amount of the notes, plus accrued and unpaid interest to the date of repurchase as and to the extent set forth in the terms of the notes. During 2019, Altria repaid in full at maturity notes in the aggregate principal amount of $1,144 million . Altria designated its Euro denominated notes as a net investment hedge of its investment in ABI. For further discussion, see Note 8 . Financial Instruments . For discussion of the fair value of Altria’s long-term debt, see Note 8 . Financial Instruments . The obligations of Altria under the notes are guaranteed by PM USA as further discussed in Note 20 . Condensed Consolidating Financial Information .

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Capital Stock	Capital Stock At December 31, 2019 , Altria had 12 billion shares of authorized common stock; issued, repurchased and outstanding shares of common stock were as follows: Shares Issued Shares Repurchased Shares Outstanding Balances, December 31, 2016 2,805,961,317 (862,689,093 ) 1,943,272,224 Stock award activity — (408,891 ) (408,891 ) Repurchases of common stock — (41,604,141 ) (41,604,141 ) Balances, December 31, 2017 2,805,961,317 (904,702,125 ) 1,901,259,192 Stock award activity — 676,727 676,727 Repurchases of common stock — (27,878,324 ) (27,878,324 ) Balances, December 31, 2018 2,805,961,317 (931,903,722 ) 1,874,057,595 Stock award activity — 427,276 427,276 Repurchases of common stock — (16,503,317 ) (16,503,317 ) Balances, December 31, 2019 2,805,961,317 (947,979,763 ) 1,857,981,554 At December 31, 2019 , Altria had 39,288,323 shares of common stock reserved for stock-based awards under Altria’s stock plans. At December 31, 2019, 10 million shares of serial preferred stock, $ 1.00 par value, were authorized; no shares of serial preferred stock have been issued. ▪ Dividends: During the third quarter of 2019, Altria’s Board of Directors (the “Board of Directors”) approved a 5% increase in the quarterly dividend rate to $0.84 per share of Altria common stock versus the previous rate of $0.80 per share. The current annualized dividend rate is $3.36 per share. Future dividend payments remain subject to the discretion of the Board of Directors. ▪ Share Repurchases: In July 2015, the Board of Directors authorized a $1.0 billion share repurchase program that it expanded to $3.0 billion in October 2016 and to $4.0 billion in July 2017 (as expanded, the “July 2015 share repurchase program”). In January 2018, Altria completed the July 2015 share repurchase program, under which it purchased a total of 58.7 million shares of its common stock at an average price of $68.15 per share. Following the completion of the July 2015 share repurchase program, the Board of Directors authorized a new $1.0 billion share repurchase program in January 2018 that it expanded to $2.0 billion in May 2018 (as expanded, the “January 2018 share repurchase program”). In June 2019 , Altria completed the January 2018 share repurchase program, under which it purchased a total of 34.0 million shares of its common stock at an average price of $58.86 per share. In July 2019, the Board of Directors authorized a new $1.0 billion share repurchase program (the “July 2019 share repurchase program”). At December 31, 2019, Altria had $500 million remaining in the July 2019 share repurchase program. The timing of share repurchases under this program depends upon marketplace conditions and other factors, and the program remains subject to the discretion of the Board of Directors. For the years ended December 31, 2019 , 2018 and 2017 , Altria’s total share repurchase activity was as follows: July 2019 Share Repurchase Program January 2018 Share Repurchase Program July 2015 Share Repurchase Program Total (in millions, except per share data) 2019 2019 2018 2018 2017 2019 2018 2017 Total number of shares repurchased 10.1 6.4 27.6 0.3 41.6 16.5 27.9 41.6 Aggregate cost of shares repurchased $ 500 $ 345 $ 1,655 $ 18 $ 2,917 $ 845 $ 1,673 $ 2,917 Average price per share of shares repurchased $ 49.29 $ 54.36 $ 59.89 $ 71.68 $ 70.10 $ 51.24 $ 60.00 $ 70.10

Stock Plans

Stock Plans	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock Plans	Stock Plans Under the Altria 2015 Performance Incentive Plan (the “2015 Plan”), Altria may grant stock options, stock appreciation rights, restricted stock, restricted stock units (“RSUs”), deferred stock units and other stock-based awards, as well as cash-based annual and long-term incentive awards to employees of Altria or any of its subsidiaries or affiliates. Any awards granted pursuant to the 2015 Plan may be in the form of performance-based awards, including performance stock units (“PSUs”), which are subject to the achievement or satisfaction of performance goals and performance cycles. Up to 40 million shares of common stock may be issued under the 2015 Plan. In addition, under the 2015 Stock Compensation Plan for Non-Employee Directors (the “Directors Plan”), Altria may grant up to one million shares of common stock to members of the Board of Directors who are not employees of Altria. Shares available to be granted under the 2015 Plan and the Directors Plan at December 31, 2019 , were 36,078,232 and 831,560 , respectively. ▪ Restricted Stock and RSUs: During the vesting period, these shares include nonforfeitable rights to dividends or dividend equivalents and may not be sold, assigned, pledged or otherwise encumbered. Such shares are subject to forfeiture if certain employment conditions are not met. Altria estimates the number of awards expected to be forfeited and adjusts this estimate when subsequent information indicates that the actual number of forfeitures is likely to differ from previous estimates. Shares of restricted stock and RSUs generally vest three years after the grant date. The fair value of the shares of restricted stock and RSUs at the date of grant, net of estimated forfeitures, is amortized to expense ratably over the restriction period, which is generally three years . Altria recorded pre-tax compensation expense related to restricted stock and RSUs for the years ended December 31, 2019 , 2018 and 2017 of $28 million , $39 million and $49 million , respectively. The deferred tax benefit recorded related to this compensation expense was $7 million , $9 million and $18 million for the years ended December 31, 2019 , 2018 and 2017 , respectively. The unamortized compensation expense related to RSUs was $50 million at December 31, 2019 and is expected to be recognized over a weighted-average period of approximately two years . Altria has not granted any restricted stock since 2014 and had no restricted stock outstanding at December 31, 2017. RSU activity was as follows for the year ended December 31, 2019 : Number of Shares Weighted-Average Grant Date Fair Value Per Share Balance at December 31, 2018 2,129,626 $ 64.94 Granted 719,677 $ 52.03 Vested (611,657 ) $ 59.78 Forfeited (328,004 ) $ 66.52 Balance at December 31, 2019 1,909,642 $ 61.46 The weighted-average grant date fair value of RSUs granted during the years ended December 31, 2019 , 2018 and 2017 was $37 million , $60 million and $46 million , respectively, or $52.03 , $67.17 and $71.05 per RSU, respectively. The total fair value of restricted stock and RSUs that vested during the years ended December 31, 2019 , 2018 and 2017 was $30 million , $65 million and $95 million , respectively. ▪ PSUs: Altria granted an aggregate of 181,409 , 177,338 and 187,886 of PSUs during 2019 , 2018 and 2017, respectively. The payout of PSUs requires the achievement of certain performance measures, which were predetermined at the time of grant, over a three -year performance cycle. These performance measures consist of Altria’s adjusted diluted earnings per share compounded annual growth rate and Altria’s total shareholder return relative to a predetermined peer group. PSUs are also subject to forfeiture if certain employment conditions are not met. At December 31, 2019 , Altria had 360,685 PSUs outstanding, with a weighted-average grant date fair value of $58.41 per PSU. The fair value of PSUs at the date of grant, net of estimated forfeitures, is amortized to expense over the performance period. Altria recorded pre-tax compensation expense related to PSUs for the years ended December 31, 2019 , 2018 and 2017 of $4 million , $7 million and $6 million , respectively. The unamortized compensation expense related to PSUs was $10 million at both December 31, 2019 and 2018.

Earnings (Losses) per Share

Earnings (Losses) per Share	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Earnings (Losses) per Share	Earnings (Losses) per Share Basic and diluted earnings (losses) per share (“EPS”) were calculated using the following: For the Years Ended December 31, (in millions) 2019 2018 2017 Net earnings (losses) attributable to Altria $ (1,293 ) $ 6,963 $ 10,222 Less: Distributed and undistributed earnings attributable to share-based awards (7 ) (8 ) (14 ) Earnings (losses) for basic and diluted EPS $ (1,300 ) $ 6,955 $ 10,208 Weighted-average shares for basic EPS 1,869 1,887 1,921 Plus: contingently issuable PSUs — 1 — Weighted-average shares for diluted EPS 1,869 1,888 1,921

Other Comprehensive Earnings_Lo

Other Comprehensive Earnings/Losses	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Other Comprehensive Earnings/Losses	Other Comprehensive Earnings/Losses The following tables set forth the changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria: (in millions) Benefit Plans ABI Currency Translation Adjustments and Other Accumulated Other Comprehensive Losses Balances, December 31, 2016 $ (2,048 ) $ — $ (4 ) $ (2,052 ) Other comprehensive earnings (losses) before reclassifications 52 (91 ) — (39 ) Deferred income taxes (21 ) 32 — 11 Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes 31 (59 ) — (28 ) Amounts reclassified to net earnings (losses) 291 8 — 299 Deferred income taxes (113 ) (3 ) — (116 ) Amounts reclassified to net earnings (losses), net of deferred income taxes 178 5 — 183 Other comprehensive earnings (losses), net of deferred income taxes 209 (54 ) (1) — 155 Balances, December 31, 2017 (1,839 ) (54 ) (4 ) (1,897 ) Adoption of ASU No. 2018-02 (2) (397 ) (11 ) — (408 ) Other comprehensive earnings (losses) before reclassifications (151 ) (323 ) (1 ) (475 ) Deferred income taxes 39 64 — 103 Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes (112 ) (259 ) (1 ) (372 ) Amounts reclassified to net earnings (losses) 241 (64 ) — 177 Deferred income taxes (61 ) 14 — (47 ) Amounts reclassified to net earnings (losses), net of deferred income taxes 180 (50 ) — 130 Other comprehensive earnings (losses), net of deferred income taxes 68 (309 ) (1) (1 ) (242 ) Balances, December 31, 2018 (2,168 ) (374 ) (5 ) (2,547 ) Other comprehensive earnings (losses) before reclassifications (204 ) (367 ) 26 (545 ) Deferred income taxes 51 75 — 126 Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes (153 ) (292 ) 26 (419 ) Amounts reclassified to net earnings (losses) 173 (34 ) — 139 Deferred income taxes (44 ) 7 — (37 ) Amounts reclassified to net earnings (losses), net of deferred income taxes 129 (27 ) — 102 Other comprehensive earnings (losses), net of deferred income taxes (24 ) (319 ) (1) 26 (317 ) Balances, December 31, 2019 $ (2,192 ) $ (693 ) $ 21 $ (2,864 ) (1) Primarily reflects currency translation adjustments. (2) Reflects the reclassification of the stranded income tax effects of the Tax Reform Act. The following table sets forth pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings (losses): For the Years Ended December 31, (in millions) 2019 2018 2017 Benefit Plans: (1) Net loss $ 200 $ 276 $ 325 Prior service cost/credit (27 ) (35 ) (34 ) 173 241 291 ABI (2) (34 ) (64 ) 8 Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses) $ 139 $ 177 $ 299 ( 1) Amounts are included in net defined benefit plan costs. For further details, see Note 17 . Benefit Plans. (2) Amounts are primarily included in earnings from equity investments. For further information, see Note 7 . Investments in Equity Securities.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes In December 2017, the U.S. Government enacted comprehensive tax legislation commonly referred to as the Tax Reform Act. As a result of the Tax Reform Act, Altria recorded net tax benefits of approximately $3.4 billion in the fourth quarter of 2017 as discussed below. The main provisions of the Tax Reform Act that impacted Altria included: (i) a reduction in the U.S. federal statutory corporate income tax rate from 35% to 21% effective January 1, 2018, and (ii) changes in the treatment of foreign-source income, commonly referred to as a modified territorial tax system. The transition to a modified territorial tax system required Altria to record a deemed repatriation tax and an associated tax basis benefit in 2017. Substantially all of the deemed repatriation tax was related to Altria’s share of ABI’s accumulated earnings. Dividends received from ABI beginning in 2017, to the extent that such dividends represent previously taxed income attributable to the deemed repatriation tax, result in an associated tax basis expense, which reverses the tax basis benefit recorded in 2017. Earnings before income taxes and provision (benefit) for income taxes consisted of the following for the years ended December 31, 2019 , 2018 and 2017 : (in millions) 2019 2018 2017 Earnings (losses) before income taxes: United States $ 266 $ 9,441 $ 9,809 Outside United States 500 (100 ) 19 Total $ 766 $ 9,341 $ 9,828 Provision (benefit) for income taxes: Current: Federal $ 1,686 $ 1,911 $ 2,346 State and local 470 519 366 Outside United States 3 1 15 2,159 2,431 2,727 Deferred: Federal (78 ) (18 ) (3,213 ) State and local (19 ) (42 ) 86 Outside United States 2 3 1 (95 ) (57 ) (3,126 ) Total provision (benefit) for income taxes $ 2,064 $ 2,374 $ (399 ) Altria’s U.S. subsidiaries join in the filing of a U.S. federal consolidated income tax return. The U.S. federal income tax statute of limitations remains open for the year 2016 and forward, with years 2016 through 2018 currently under examination by the Internal Revenue Service (“IRS”) as part of an audit conducted in the ordinary course of business. With the exception of corresponding federal audit adjustments, state statutes of limitations generally remain open for the year 2015 and forward. Certain of Altria’s state tax returns are currently under examination by various states as part of routine audits conducted in the ordinary course of business. A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December 31, 2019 , 2018 and 2017 was as follows: (in millions) 2019 2018 2017 Balance at beginning of year $ 85 $ 66 $ 169 Additions based on tax positions related to the current year — — — Additions for tax positions of prior years 32 22 129 Reductions for tax positions due to lapse of statutes of limitations — — (4 ) Reductions for tax positions of prior years (16 ) (1 ) (208 ) Tax settlements (37 ) (2 ) (20 ) Balance at end of year $ 64 $ 85 $ 66 Unrecognized tax benefits and Altria’s consolidated liability for tax contingencies at December 31, 2019 and 2018 were as follows: (in millions) 2019 2018 Unrecognized tax benefits $ 64 $ 85 Accrued interest and penalties 11 13 Tax credits and other indirect benefits (1 ) (1 ) Liability for tax contingencies $ 74 $ 97 The amount of unrecognized tax benefits that, if recognized, would impact the effective tax rate at December 31, 2019 was $40 million , along with $24 million affecting deferred taxes. The amount of unrecognized tax benefits that, if recognized, would impact the effective tax rate at December 31, 2018 was $59 million , along with $26 million affecting deferred taxes. Altria recognizes accrued interest and penalties associated with uncertain tax positions as part of the tax provision. For the years ended December 31, 2019 , 2018 and 2017 , Altria recognized in its consolidated statements of earnings (losses) $6 million , $5 million and $(13) million , respectively, of gross interest expense (income) associated with uncertain tax positions. Altria is subject to income taxation in many jurisdictions. Unrecognized tax benefits reflect the difference between tax positions taken or expected to be taken on income tax returns and the amounts recognized in the financial statements. Resolution of the related tax positions with the relevant tax authorities may take many years to complete, and such timing is not entirely within the control of Altria. It is reasonably possible that within the next 12 months certain examinations will be resolved, which could result in a decrease in unrecognized tax benefits of approximately $28 million . A reconciliation between actual income taxes and amounts computed by applying the federal statutory rate to earnings (losses) before income taxes for the years ended December 31, 2019 , 2018 and 2017 is as follows: 2019 2018 2017 (dollars in millions) $ % $ % $ % U.S. federal statutory rate $ 161 21.0 % $ 1,962 21.0 % $ 3,440 35.0 % Increase (decrease) resulting from: State and local income taxes, net of federal tax benefit 356 46.5 377 4.0 345 3.5 Re-measurement of net deferred tax liabilities — — — — (3,063 ) (31.2 ) Tax basis in foreign investments 84 11.0 140 1.5 (763 ) (7.8 ) Deemed repatriation tax — — 14 0.1 413 4.2 Uncertain tax positions (40 ) (5.2 ) 8 0.1 (89 ) (0.9 ) Investment in ABI (210 ) (27.4 ) (104 ) (1.1 ) (580 ) (5.9 ) Investment in JUUL 1,808 236.0 15 0.2 — — Investment in Cronos (66 ) (8.6 ) — — — — Domestic manufacturing deduction — — — — (181 ) (1.8 ) Other (1) (29 ) (3.8 ) (38 ) (0.4 ) 79 0.8 Effective tax rate $ 2,064 269.5 % $ 2,374 25.4 % $ (399 ) (4.1 )% (1) Other in 2019 is primarily deferred profit sharing dividends tax benefit of $21 million and miscellaneous immaterial items. The tax provision in 2019 included tax expense of $2,024 million for a valuation allowance on a deferred tax asset related to Altria’s impairment of its investment in JUUL equity securities, tax expense of $84 million resulting from a partial reversal of the tax basis benefit associated with the deemed repatriation tax recorded in 2017 and tax expense of $38 million for a valuation allowance against foreign tax credits not realizable. These amounts were partially offset by a tax benefit of $105 million for amended tax returns and audit adjustments relating to a prior year, a tax benefit of $100 million for accruals no longer required and a net tax benefit of $79 million related to Altria’s equity investment in Cronos, including a valuation allowance release on a deferred tax asset. The tax provision in 2018 included tax expense of $188 million related to the Tax Reform Act as follows: (i) tax expense of $140 million resulting from a partial reversal of the tax basis benefit associated with the deemed repatriation tax recorded in 2017; (ii) tax expense of $34 million for a valuation allowance on foreign tax credit carryforwards that are not realizable as a result of updates to the provisional estimates recorded in 2017; and (iii) tax expense of $14 million for an adjustment to the provisional estimates for the repatriation tax recorded in 2017. Substantially all of the 2018 amounts related to the tax basis adjustment, valuation allowance on foreign tax credits and repatriation tax relate to Altria’s share of ABI’s accumulated earnings and associated taxes. The adjustments recorded in 2018 to the provisional estimates recorded in 2017 were based on (i) additional guidance related to, or interpretation of, the Tax Reform Act and associated tax laws and (ii) additional information received from ABI, including information regarding ABI’s accumulated earnings and associated taxes for the 2016 and 2017 tax years. The accounting for the repatriation tax is complete; therefore, no further adjustments to the provisional estimates are required. The tax benefit in 2017 included net tax benefits of $3,367 million related to the Tax Reform Act recorded in the fourth quarter of 2017 as follows: (i) a tax benefit of $3,017 million to re-measure Altria and its consolidated subsidiaries’ net deferred tax liabilities based on the new U.S. federal statutory rate and (ii) a net tax benefit of $763 million for a tax basis adjustment associated with the deemed repatriation tax, partially offset by tax expense of $413 million for the deemed repatriation tax. The 2017 amounts related to the tax basis adjustment and the deemed repatriation tax were based on provisional estimates, substantially all of which were related to Altria’s share of ABI’s accumulated earnings and associated taxes. The tax benefit in 2017 also included tax benefits of $232 million for the release of a valuation allowance in the third quarter of 2017 related to deferred income tax assets for foreign tax credit carryforwards, which is included in investment in ABI in the table above; and tax benefits of $152 million related primarily to the effective settlement in the second quarter of 2017 of the IRS audit of Altria and its consolidated subsidiaries’ 2010-2013 tax years, partially offset by tax expense of $114 million in the third quarter of 2017 for tax reserves related to the calculation of certain foreign tax credits. The tax effects of temporary differences that gave rise to deferred income tax assets and liabilities consisted of the following at December 31, 2019 and 2018 : (in millions) 2019 2018 Deferred income tax assets: Accrued postretirement and postemployment benefits $ 491 $ 500 Settlement charges 833 864 Accrued pension costs 131 155 Investment in JUUL 2,047 — Investment in Cronos 197 — Net operating losses and tax credit carryforwards 92 57 Total deferred income tax assets 3,791 1,576 Deferred income tax liabilities: Property, plant and equipment (255 ) (251 ) Intangible assets (2,758 ) (2,689 ) Investment in ABI (3,115 ) (3,038 ) Finance assets, net (204 ) (313 ) Other (158 ) (115 ) Total deferred income tax liabilities (6,490 ) (6,406 ) Valuation allowances (2,324 ) (71 ) Net deferred income tax liabilities $ (5,023 ) $ (4,901 ) At December 31, 2019, Altria had estimated gross state tax net operating losses of $655 million that, if unused, will expire in 2020 through 2038. A reconciliation of the beginning and ending valuation allowances for the years ended December 31, 2019 , 2018 and 2017 was as follows: (in millions) 2019 2018 2017 Balance at beginning of year $ 71 $ — $ 240 Additions to valuation allowance related to Altria’s initial investment in Cronos 352 — — Additions to valuation allowance charged to income tax expense 2,063 71 — Reductions to valuation allowance credited to income tax benefit (159 ) — (240 ) Foreign currency translation (3 ) — — Balance at end of year $ 2,324 $ 71 $ — The 2019 valuation allowance was primarily attributable to the deferred tax asset recorded in connection with the impairment of Altria’s investment in JUUL equity securities. Altria determined, based on the weight of available evidence, that it is more-likely-than-not that the deferred tax asset related to the impairment of its investment in JUUL equity securities will not be realized; therefore, Altria recorded a full valuation allowance of $2,024 million against this deferred tax asset. In reaching this determination, Altria considered all available positive and negative evidence, including the character of the loss, carryback and carryforward considerations, future reversals of temporary differences and available tax planning strategies. For a discussion regarding the impairment of Altria’s investment in JUUL equity securities, see Note 7. Investments in Equity Securities .

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting The products of Altria’s subsidiaries include smokeable tobacco products, consisting of combustible cigarettes manufactured and sold by PM USA and Nat Sherman, machine-made large cigars and pipe tobacco manufactured and sold by Middleton and premium cigars sold by Nat Sherman; smokeless tobacco products, consisting of moist smokeless tobacco and snus products manufactured and sold by USSTC, and oral nicotine pouches sold by Helix; and wine produced and/or distributed by Ste. Michelle. The products and services of these subsidiaries constitute Altria’s reportable segments of smokeable products, smokeless products and wine. The financial services and the innovative tobacco products businesses are included in all other. Altria’s chief operating decision maker (the “CODM”) reviews operating companies income to evaluate the performance of, and allocate resources to, the segments. Operating companies income for the segments is defined as operating income before general corporate expenses and amortization of intangibles. Interest and other debt expense, net, net periodic benefit income/cost, excluding service cost, and provision for income taxes are centrally managed at the corporate level and, accordingly, such items are not presented by segment since they are excluded from the measure of segment profitability reviewed by the CODM. Information about total assets by segment is not disclosed because such information is not reported to or used by the CODM. Substantially all of Altria’s long-lived assets are located in the United States. Segment goodwill and other intangible assets, net, are disclosed in Note 4 . Goodwill and Other Intangible Assets, net. The accounting policies of the segments are the same as those described in Note 2 . Summary of Significant Accounting Policies. Segment data were as follows: For the Years Ended December 31, (in millions) 2019 2018 2017 Net revenues: Smokeable products $ 21,996 $ 22,297 $ 22,636 Smokeless products 2,367 2,262 2,155 Wine 689 691 698 All other 58 114 87 Net revenues $ 25,110 $ 25,364 $ 25,576 Earnings (losses) before income taxes: Operating companies income (loss): Smokeable products $ 9,009 $ 8,408 $ 8,426 Smokeless products 1,580 1,431 1,306 Wine (3 ) 50 146 All other (16 ) (421 ) (51 ) Amortization of intangibles (44 ) (38 ) (21 ) General corporate expenses (199 ) (315 ) (213 ) Corporate asset impairment and exit costs (1 ) — — Operating income 10,326 9,115 9,593 Interest and other debt expense, net (1,280 ) (665 ) (705 ) Net periodic benefit income (cost), excluding service cost 37 34 (37 ) Earnings from equity investments 1,725 890 532 Impairment of JUUL equity securities (8,600 ) — — Loss on Cronos-related financial instruments (1,442 ) — — Gain (loss) on ABI/SABMiller business combination — (33 ) 445 Earnings (losses) before income taxes $ 766 $ 9,341 $ 9,828 The smokeable products segment included net revenues of $21,158 million , $21,506 million and $21,900 million for the years ended December 31, 2019 , 2018 and 2017 , respectively, related to cigarettes and net revenues of $838 million , $791 million and $736 million for the years ended December 31, 2019 , 2018 and 2017 , respectively, related to cigars. Substantially all of Altria’s net revenues are from sales generated in the United States for the years ended December 31, 2019 , 2018 and 2017 . PM USA, USSTC, Helix, Middleton and Nat Sherman’s largest customer, McLane Company, Inc., accounted for approximately 25% , 27% and 26% of Altria’s consolidated net revenues for the years ended December 31, 2019 , 2018 and 2017 , respectively. In addition, Core-Mark Holding Company, Inc. accounted for approximately 15% , 14% and 14% of Altria’s consolidated net revenues for the years ended December 31, 2019 , 2018 and 2017 , respectively. Substantially all of these net revenues were reported in the smokeable products and smokeless products segments. Sales to two distributors accounted for approximately 67% and 64% of net revenues for the wine segment for the years ended December 31, 2019 and 2018 , respectively. Sales to three distributors accounted for approximately 67% of net revenues for the wine segment for the year ended December 31, 2017 . Details of Altria’s depreciation expense and capital expenditures were as follows: For the Years Ended December 31, (in millions) 2019 2018 2017 Depreciation expense: Smokeable products $ 88 $ 90 $ 93 Smokeless products 27 28 29 Wine 41 40 40 General corporate and other 26 31 26 Total depreciation expense $ 182 $ 189 $ 188 Capital expenditures: Smokeable products $ 61 $ 81 $ 39 Smokeless products 44 73 61 Wine 63 40 53 General corporate and other 78 44 46 Total capital expenditures $ 246 $ 238 $ 199 The comparability of operating companies income for the reportable segments was affected by the following: ▪ Non-Participating Manufacturer (“NPM”) Adjustment Items: For the years ended December 31, 2018 and 2017 , pre-tax (income) expense for NPM adjustment items was recorded in Altria’s consolidated statements of earnings (losses) as follows: (in millions) 2018 2017 Smokeable products segment $ (145 ) $ (5 ) Interest and other debt expense, net — 9 Total $ (145 ) $ 4 NPM adjustment items result from the resolutions of certain disputes with states and territories related to the NPM adjustment provision under the 1998 Master Settlement Agreement (such dispute resolutions are referred to as “NPM Adjustment Items” and are more fully described in Health Care Cost Recovery Litigation - NPM Adjustment Disputes in Note 19 . Contingencies ). The amounts shown in the table above for the smokeable products segment were recorded by PM USA as reductions to cost of sales, which increased operating companies income in the smokeable products segment. ▪ Tobacco and Health Litigation Items: For the years ended December 31, 2019 , 2018 and 2017 , pre-tax charges related to certain tobacco and health litigation items were recorded in Altria’s consolidated statements of earnings (losses) as follows: (in millions) 2019 2018 2017 Smokeable products segment $ 72 $ 103 $ 72 Smokeless products segment — 10 — Interest and other debt expense, net 5 18 8 Total $ 77 $ 131 $ 80 The amounts shown in the table above for the smokeable and smokeless products segments were recorded in marketing, administration and research costs. For further discussion, see Note 19 . Contingencies . ▪ Smokeless Products Recall: During 2017, USSTC voluntarily recalled certain smokeless tobacco products manufactured at its Franklin Park, Illinois facility due to a product tampering incident (the “Recall”). USSTC estimated that the Recall reduced smokeless products segment operating companies income by approximately $60 million in 2017. ▪ Asset Impairment, Exit and Implementation Costs: See Note 5 . Asset Impairment, Exit and Implementation Costs for a breakdown of these costs by segment.

Benefit Plans

Benefit Plans	12 Months Ended
	Dec. 31, 2019
Retirement Benefits [Abstract]
Benefit Plans	Benefit Plans Subsidiaries of Altria sponsor noncontributory defined benefit pension plans covering certain employees of Altria and its subsidiaries. Employees hired on or after a date specific to their employee group are not eligible to participate in these noncontributory defined benefit pension plans but are instead eligible to participate in a defined contribution plan with enhanced benefits. This transition for new hires occurred from October 1, 2006 to January 1, 2008. In addition, effective January 1, 2010, certain employees of UST’s subsidiaries and Middleton who were participants in noncontributory defined benefit pension plans ceased to earn additional benefit service under those plans and became eligible to participate in a defined contribution plan with enhanced benefits. Altria and its subsidiaries also provide postretirement health care and other benefits to certain retired employees. The plan assets and benefit obligations of Altria’s pension plans and postretirement plans are measured at December 31 of each year. The discount rates for Altria’s plans were based on a yield curve developed from a model portfolio of high-quality corporate bonds with durations that match the expected future cash flows of the pension and postretirement benefit obligations. On December 31, 2019, Altria adopted ASU No. 2018-14, which amends certain defined benefit plan disclosures. Altria elected early adoption of this update, which is permitted for all entities and applied on a retrospective basis to all periods presented. The adoption of ASU No. 2018-14 had no impact on the amount of defined benefit plan assets, obligations or expenses recognized by Altria’s businesses. ▪ Obligations and Funded Status: The benefit obligations, plan assets and funded status of Altria’s pension and postretirement plans at December 31, 2019 and 2018 were as follows: Pension Postretirement (in millions) 2019 2018 2019 2018 Change in benefit obligation: Benefit obligation at beginning of year $ 7,726 $ 8,510 $ 2,040 $ 2,335 Service cost 70 81 16 18 Interest cost 306 276 76 70 Benefits paid (493 ) (488 ) (126 ) (130 ) Actuarial (gains) losses 1,025 (660 ) 78 (298 ) Settlement and curtailment 25 (18 ) 7 — Other — 25 — 45 Benefit obligation at end of year 8,659 7,726 2,091 2,040 Change in plan assets: Fair value of plan assets at beginning of year 7,138 8,015 211 270 Actual return on plan assets 1,466 (430 ) 45 (14 ) Employer contributions 56 41 — — Benefits paid (493 ) (488 ) (43 ) (45 ) Fair value of plan assets at end of year 8,167 7,138 213 211 Funded status at December 31 $ (492 ) $ (588 ) $ (1,878 ) $ (1,829 ) Amounts recognized on Altria’s consolidated balance sheets were as follows: Other accrued liabilities $ (26 ) $ (44 ) $ (81 ) $ (80 ) Accrued pension costs (473 ) (544 ) — — Other assets 7 — — — Accrued postretirement health care costs — — (1,797 ) (1,749 ) $ (492 ) $ (588 ) $ (1,878 ) $ (1,829 ) The table above presents the projected benefit obligation for Altria’s pension plans. The accumulated benefit obligation, which represents benefits earned to date, for the pension plans was $8.4 billion and $ 7.4 billion at December 31, 2019 and 2018 , respectively. Actuarial (gains) losses for the years ended December 31, 2019 and 2018 for the pension and postretirement plans were due primarily to changes in the discount rate assumptions. For pension plans with accumulated benefit obligations in excess of plan assets at December 31, 2019 , the accumulated benefit obligation and fair value of plan assets were $ 357 million and $ 134 million , respectively. For pension plans with accumulated benefit obligations in excess of plan assets at December 31, 2018 , the accumulated benefit obligation and fair value of plan assets were $ 7,239 million and $ 7,012 million , respectively. For pension plans with projected benefit obligations in excess of plan assets at December 31, 2019 , the projected benefit obligation and fair value of plan assets were $ 8,522 million and $ 8,023 million , respectively. At December 31, 2018 , the projected benefit obligations were in excess of plan assets for all pension plans. At December 31, 2019 and 2018 , the accumulated postretirement benefit obligations were in excess of plan assets for all postretirement plans. The Patient Protection and Affordable Care Act (“PPACA”), as amended by the Health Care and Education Reconciliation Act of 2010, mandated health care reforms, including the imposition of an excise tax on high cost health care plans. The excise tax provision was repealed on December 20, 2019; therefore, the additional accumulated postretirement liability resulting from the PPACA, which was not material to Altria, has been excluded from Altria’s accumulated postretirement benefit obligation at December 31, 2019 . The following assumptions were used to determine Altria’s pension and postretirement benefit obligations at December 31: Pension Postretirement 2019 2018 2019 2018 Discount rate 3.4 % 4.4 % 3.4 % 4.4 % Rate of compensation increase 4.0 4.0 — — Health care cost trend rate assumed for next year — — 6.5 6.5 Ultimate trend rate — — 5.0 5.0 Year that the rate reaches the ultimate trend rate — — 2025 2025 ▪ Components of Net Periodic Benefit Cost (Income): Net periodic benefit cost (income) consisted of the following for the years ended December 31, 2019 , 2018 and 2017 : Pension Postretirement (in millions) 2019 2018 2017 2019 2018 2017 Service cost $ 70 $ 81 $ 75 $ 16 $ 18 $ 16 Interest cost 306 276 288 76 70 76 Expected return on plan assets (576 ) (585 ) (601 ) (15 ) (19 ) — Amortization: Net loss 159 225 197 5 21 25 Prior service cost (credit) 6 4 4 (30 ) (42 ) (38 ) Settlement and curtailment 27 16 86 5 — — Net periodic benefit cost (income) $ (8 ) $ 17 $ 49 $ 57 $ 48 $ 79 Settlement and curtailment shown in the table above primarily relate to the settlement charge discussed below, and the cost reduction program discussed in Note 5 . Asset Impairment, Exit and Implementation Costs . In the third quarter of 2017, Altria made a voluntary, limited-time offer to former employees with vested benefits in the Altria Retirement Plan who had not commenced receiving benefit payments and who met certain other conditions. Eligible participants were offered the opportunity to make a one-time election to receive their pension benefit as a single lump sum payment or as a monthly annuity. Distributions to former employees who elected to receive lump sum payments totaled approximately $277 million , substantially all of which were made in December 2017 from the Altria Retirement Plan’s assets. Payments began on January 1, 2018 to former employees who elected a monthly annuity. As a result of the lump sum distributions, Altria recorded a one-time settlement charge of $81 million in 2017. The amounts included in settlement and curtailment in the table above were comprised of the following changes: Pension Postretirement (in millions) 2019 2018 2017 2019 Benefit obligation $ 6 $ — $ — $ 10 Other comprehensive earnings/losses: Net loss 20 13 86 — Prior service cost (credit) 1 3 — (5 ) $ 27 $ 16 $ 86 $ 5 The following assumptions were used to determine Altria’s net periodic benefit cost for the years ended December 31: Pension Postretirement 2019 2018 2017 2019 2018 2017 Discount rates: Service cost 4.6 % 3.8 % 4.3 % 4.5 % 3.8 % 4.3 % Interest cost 4.0 3.3 3.5 4.0 3.3 3.5 Expected rate of return on plan assets 7.8 7.8 8.0 7.8 7.8 — Rate of compensation increase 4.0 4.0 4.0 — — — Health care cost trend rate — — — 6.5 7.0 7.0 ▪ Defined Contribution Plans: Altria sponsors deferred profit-sharing plans covering certain salaried, non-union and union employees. Contributions and costs are determined generally as a percentage of earnings, as defined by the plans. Amounts charged to expense for these defined contribution plans totaled $78 million , $85 million and $83 million in 2019 , 2018 and 2017 , respectively. ▪ Pension and Postretirement Plan Assets: Altria’s investment strategy for its pension and postretirement plan assets is based on an expectation that equity securities will outperform debt securities over the long term and reflects the maturity structure of the benefit obligation. Altria believes that it implements the investment strategy in a prudent and risk-controlled manner, consistent with the fiduciary requirements of the Employee Retirement Income Security Act of 1974, by investing retirement plan assets in a well-diversified mix of equities, fixed income and other securities. In the fourth quarter of 2019, Altria changed its target asset allocation for the majority of its pension plan assets from an equity/fixed income mix of 55% / 45% to a 30% / 70% mix. The objective of this change is to reduce the overall exposure to equity volatility and more closely align the values of plan assets with the liabilities. The equity/fixed income target allocation for postretirement plan assets remains at 55% / 45% . The actual composition of Altria’s plan assets at December 31, 2019 was broadly characterized with the following allocation: Pension Postretirement Equity securities 35 % 56 % Corporate bonds 52 % 34 % U.S. Treasury and foreign government securities 13 % 10 % Altria’s pension and postretirement plan asset performance is monitored on an ongoing basis to adjust the mix as necessary. Substantially all pension and all postretirement assets can be used to make monthly benefit payments. Altria’s investment objective for its pension and postretirement plan assets is accomplished by investing in long-duration fixed income securities that primarily include U.S. corporate bonds of companies from diversified industries and U.S. Treasury securities that mirror Altria’s pension obligation benchmark, the Bloomberg Barclays Capital U.S. Long Credit Index, as well as U.S. and international equity index strategies that are intended to mirror indices, including, the Standard & Poor’s 500 Index and Morgan Stanley Capital International (“MSCI”) Europe, Australasia, and the Far East (“EAFE”) Index. Altria’s pension plans also invest in actively managed international equity securities of large, mid and small cap companies located in developed and emerging markets. For pension plan assets, the allocation to below investment grade securities represented 8% of the fixed income holdings or 5% of the total plan assets at December 31, 2019 . The allocation to emerging markets represented 1% of equity holdings or less than 1% of total plan assets at December 31, 2019 . For postretirement plan assets, the allocation to below investment grade securities represented 8% of the fixed income holdings or 4% of the total plan assets at December 31, 2019 . There were no postretirement plan assets invested in emerging markets at December 31, 2019 . Altria’s risk management practices for its pension and postretirement plans include ongoing monitoring of asset allocation, investment performance and investment managers’ compliance with their investment guidelines, periodic rebalancing between equity and debt asset classes and annual actuarial re-measurement of plan liabilities. Altria’s expected rate of return on pension and postretirement plan assets is determined by the plan assets’ historical long-term investment performance, current asset allocation and estimates of future long-term returns by asset class. The forward-looking estimates are consistent with the long-term historical averages exhibited by returns on equity and fixed income securities. As a result of the pension plan asset re-allocation described above, Altria has reduced its expected rate of return assumption from 7.8% in 2019 to 6.6% in 2020 for determining its pension net periodic benefit cost. For determining its postretirement net periodic benefit cost, Altria has reduced the expected rate of return assumption from 7.8% in 2019 to 7.7% in 2020. The fair values of the pension plan assets by asset category at December 31, 2019 and 2018 were as follows: 2019 2018 (in millions) Level 1 Level 2 Total Level 1 Level 2 Total U.S. and foreign government securities or their agencies: U.S. government and agencies $ — $ 811 $ 811 $ — $ 868 $ 868 U.S. municipal bonds — 57 57 — 73 73 Foreign government and agencies — 98 98 — 115 115 Corporate debt instruments: Above investment grade — 3,523 3,523 — 1,726 1,726 Below investment grade and no rating — 521 521 — 478 478 Common stock: International equities 296 — 296 237 — 237 U.S. equities 1,263 — 1,263 1,082 — 1,082 Other, net (4 ) 479 475 36 339 375 $ 1,555 $ 5,489 $ 7,044 $ 1,355 $ 3,599 $ 4,954 Investments measured at NAV as a practical expedient for fair value: Collective investment funds U.S. large cap $ 825 $ 1,722 U.S. small cap 386 328 International developed markets 106 86 Total investments measured at NAV $ 1,317 $ 2,136 Other (194 ) 48 Fair value of plan assets, net $ 8,167 $ 7,138 Level 3 holdings and transactions were immaterial to total plan assets at December 31, 2019 and 2018 . The fair value of the postretirement plan assets at December 31, 2019 and 2018 were as follows: 2019 2018 (in millions) Level 1 Level 2 Total Level 1 Level 2 Total U.S. and foreign government securities or their agencies: U.S. government and agencies $ — $ 11 $ 11 $ — $ 13 $ 13 Foreign government and agencies — 5 5 — 3 3 Corporate debt instruments: Above investment grade — 63 63 — 71 71 Below investment grade and no rating — 9 9 — 8 8 Other, net — 7 7 2 2 4 $ — $ 95 $ 95 $ 2 $ 97 $ 99 Investments measured at NAV as a practical expedient for fair value: Collective investment funds: U.S. large cap $ 97 $ 77 International developed markets 24 26 Total investments measured at NAV $ 121 $ 103 Other (3 ) 9 Fair value of plan assets, net $ 213 $ 211 There were no Level 3 postretirement plan holdings or transactions during 2019 and 2018. For a description of the fair value hierarchy and the three levels of inputs used to measure fair value, see Note 2 . Summary of Significant Accounting Policies . Following is a description of the valuation methodologies used for investments measured at fair value. ▪ U.S. and Foreign Government Securities : U.S. and foreign government securities consist of investments in Treasury Nominal Bonds and Inflation Protected Securities and municipal securities. Government securities are valued at a price that is based on a compilation of primarily observable market information, such as broker quotes. Matrix pricing, yield curves and indices are used when broker quotes are not available. ▪ Corporate Debt Instruments : Corporate debt instruments are valued at a price that is based on a compilation of primarily observable market information, such as broker quotes. Matrix pricing, yield curves and indices are used when broker quotes are not available. ▪ Common Stock : Common stocks are valued based on the price of the security as listed on an open active exchange on last trade date. ▪ Collective Investment Funds : Collective investment funds consist of funds that are intended to mirror indices such as Standard & Poor’s 500 Index and MSCI EAFE Index. They are valued on the basis of the relative interest of each participating investor in the fair value of the underlying assets of each of the respective collective investment funds. The underlying assets are valued based on the net asset value (“NAV”), which is provided by the investment account manager as a practical expedient to estimate fair value. These investments are not classified by level but are disclosed to permit reconciliation to the fair value of plan assets. Cash Flows: Altria makes contributions to the pension plans to the extent that the contributions are tax deductible and pays benefits that relate to plans for salaried employees that cannot be funded under IRS regulations. Currently, Altria anticipates making employer contributions to its pension plans of up to approximately $ 30 million in 2020 based on current tax law. However, this estimate is subject to change as a result of changes in tax and other benefit laws, as well as asset performance significantly above or below the assumed long-term rate of return on pension plan assets, or changes in interest rates. Currently, Altria anticipates making employer contributions to its postretirement plans of up to approximately $ 60 million in 2020. However, this estimate is subject to change as a result of changes in tax and other benefit laws, as well as asset performance significantly above or below the assumed long-term rate of return on postretirement plan assets. Estimated future benefit payments at December 31, 2019 were as follows: (in millions) Pension Postretirement 2020 $ 472 $ 126 2021 477 124 2022 479 121 2023 483 117 2024 481 115 2025-2029 2,430 555 Comprehensive Earnings/Losses The amounts recorded in accumulated other comprehensive losses at December 31, 2019 consisted of the following: (in millions) Pension Post- retirement Post- employment Total Net loss $ (2,565 ) $ (389 ) $ (45 ) $ (2,999 ) Prior service (cost) credit (27 ) 72 (5 ) 40 Deferred income taxes 670 86 11 767 Amounts recorded in accumulated other comprehensive losses $ (1,922 ) $ (231 ) $ (39 ) $ (2,192 ) The amounts recorded in accumulated other comprehensive losses at December 31, 2018 consisted of the following: (in millions) Pension Post- retirement Post- employment Total Net loss $ (2,591 ) $ (327 ) $ (78 ) $ (2,996 ) Prior service (cost) credit (34 ) 108 (6 ) 68 Deferred income taxes 679 61 20 760 Amounts recorded in accumulated other comprehensive losses $ (1,946 ) $ (158 ) $ (64 ) $ (2,168 ) The movements in other comprehensive earnings/losses during the year ended December 31, 2019 were as follows: (in millions) Pension Post- retirement Post- employment Total Amounts reclassified to net earnings as components of net periodic benefit cost: Amortization: Net loss $ 159 $ 5 $ 20 $ 184 Prior service cost/credit 6 (30 ) 1 (23 ) Other expense (income): Net loss 20 — (4 ) 16 Prior service cost/credit 1 (5 ) — (4 ) Deferred income taxes (47 ) 7 (4 ) (44 ) $ 139 $ (23 ) $ 13 $ 129 Other movements during the year: Net loss $ (153 ) $ (67 ) $ 17 $ (203 ) Prior service cost/credit — (1 ) — (1 ) Deferred income taxes 38 18 (5 ) 51 $ (115 ) $ (50 ) $ 12 $ (153 ) Total movements in other comprehensive earnings/losses $ 24 $ (73 ) $ 25 $ (24 ) The movements in other comprehensive earnings/losses during the year ended December 31, 2018 were as follows: (in millions) Pension Post-retirement Post-employment Total Amounts reclassified to net earnings as components of net periodic benefit cost: Amortization: Net loss $ 225 $ 21 $ 17 $ 263 Prior service cost/credit 4 (42 ) — (38 ) Other expense (income): Net loss 13 — — 13 Prior service cost/credit 3 — — 3 Deferred income taxes (61 ) 4 (4 ) (61 ) $ 184 $ (17 ) $ 13 $ 180 Other movements during the year: Adoption of ASU 2018-02 (1) $ (330 ) $ (55 ) $ (12 ) $ (397 ) Net loss (336 ) 264 (2 ) (74 ) Prior service cost/credit (26 ) (45 ) (6 ) (77 ) Deferred income taxes 91 (54 ) 2 39 $ (601 ) $ 110 $ (18 ) $ (509 ) Total movements in other comprehensive earnings/losses $ (417 ) $ 93 $ (5 ) $ (329 ) (1) Reflects the reclassification of the stranded income tax effects of the Tax Reform Act. The movements in other comprehensive earnings/losses during the year ended December 31, 2017 were as follows: (in millions) Pension Post- retirement Post- employment Total Amounts reclassified to net earnings as components of net periodic benefit cost: Amortization: Net loss $ 197 $ 25 $ 17 $ 239 Prior service cost/credit 4 (38 ) — (34 ) Other expense (income): Net loss 86 — — 86 Deferred income taxes (113 ) 6 (6 ) (113 ) $ 174 $ (7 ) $ 11 $ 178 Other movements during the year: Net loss $ 81 $ (56 ) $ (11 ) $ 14 Prior service cost/credit — 38 — 38 Deferred income taxes (32 ) 7 4 (21 ) $ 49 $ (11 ) $ (7 ) $ 31 Total movements in other comprehensive earnings/losses $ 223 $ (18 ) $ 4 $ 209

Additional Information

Additional Information	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Additional Information	Additional Information For the Years Ended December 31, (in millions) 2019 2018 2017 Research and development expense $ 168 $ 252 $ 241 Advertising expense $ 33 $ 37 $ 29 Interest and other debt expense, net: Interest expense $ 1,322 $ 697 $ 736 Interest income (42 ) (32 ) (31 ) $ 1,280 $ 665 $ 705 The activity in the allowance for discounts and allowance for returned goods for the years ended December 31, 2019 , 2018 and 2017 was as follows: (in millions) 2019 2018 2017 Discounts Returned Goods Discounts Returned Goods Discounts Returned Goods Balance at beginning of year $ — $ 32 $ — $ 40 $ — $ 49 Charged to costs and expenses 604 127 620 97 626 130 Deductions (1) (604 ) (127 ) (620 ) (105 ) (626 ) (139 ) Balance at end of year $ — $ 32 $ — $ 32 $ — $ 40 (1) Represents the recording of discounts and returns for which allowances were created . The activity in the allowance for losses on finance assets for the years ended December 31, 2019 , 2018 and 2017 was as follows: (in millions) 2019 2018 2017 Balance at beginning of year $ 19 $ 23 $ 32 Decrease to allowance — (4 ) (9 ) Balance at end of year $ 19 $ 19 $ 23

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies Legal proceedings covering a wide range of matters are pending or threatened in various U.S. and foreign jurisdictions against Altria and its subsidiaries, including PM USA and USSTC, as well as their respective indemnitees and Altria’s investees. Various types of claims may be raised in these proceedings, including product liability, unfair trade practices, antitrust, tax, contraband shipments, patent infringement, employment matters, claims for contribution and claims of competitors, shareholders or distributors. Litigation is subject to uncertainty and it is possible that there could be adverse developments in pending or future cases. An unfavorable outcome or settlement of pending tobacco-related or other litigation could encourage the commencement of additional litigation. Damages claimed in some tobacco-related and other litigation are or can be significant and, in certain cases, have ranged in the billions of dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrate that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. In certain cases, plaintiffs claim that defendants’ liability is joint and several. In such cases, Altria or its subsidiaries may face the risk that one or more co-defendants decline or otherwise fail to participate in the bonding required for an appeal or to pay their proportionate or jury-allocated share of a judgment. As a result, Altria or its subsidiaries under certain circumstances may have to pay more than their proportionate share of any bonding- or judgment-related amounts. Furthermore, in those cases where plaintiffs are successful, Altria or its subsidiaries may also be required to pay interest and attorneys’ fees. Although PM USA has historically been able to obtain required bonds or relief from bonding requirements in order to prevent plaintiffs from seeking to collect judgments while adverse verdicts have been appealed, there remains a risk that such relief may not be obtainable in all cases. This risk has been substantially reduced given that 47 states and Puerto Rico limit the dollar amount of bonds or require no bond at all. As discussed below, however, tobacco litigation plaintiffs have challenged the constitutionality of Florida’s bond cap statute in several cases and plaintiffs may challenge state bond cap statutes in other jurisdictions as well. Such challenges may include the applicability of state bond caps in federal court. States, including Florida, may also seek to repeal or alter bond cap statutes through legislation. Although Altria cannot predict the outcome of such challenges, it is possible that the consolidated results of operations, cash flows or financial position of Altria, or one or more of its subsidiaries, could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome of one or more such challenges. Altria and its subsidiaries record provisions in the consolidated financial statements for pending litigation when they determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. At the present time, while it is reasonably possible that an unfavorable outcome in a case may occur, except to the extent discussed elsewhere in this Note 19 . Contingencies : (i) management has concluded that it is not probable that a loss has been incurred in any of the pending cases; (ii) management is unable to estimate the possible loss or range of loss that could result from an unfavorable outcome in any of the pending cases; and (iii) accordingly, management has not provided any amounts in the consolidated financial statements for unfavorable outcomes, if any. Litigation defense costs are expensed as incurred. Altria and its subsidiaries have achieved substantial success in managing litigation. Nevertheless, litigation is subject to uncertainty and significant challenges remain. It is possible that the consolidated results of operations, cash flows or financial position of Altria, or one or more of its subsidiaries, could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. Altria and each of its subsidiaries named as a defendant believe, and each has been so advised by counsel handling the respective cases, that it has valid defenses to the litigation pending against it, as well as valid bases for appeal of adverse verdicts. Each of the companies has defended, and will continue to defend, vigorously against litigation challenges. However, Altria and its subsidiaries may enter into settlement discussions in particular cases if they believe it is in the best interests of Altria to do so. Overview of Altria and/or PM USA Tobacco-Related Litigation Types and Number of U.S. Cases: Claims related to tobacco products generally fall within the following categories: (i) smoking and health cases alleging personal injury brought on behalf of individual plaintiffs; (ii) health care cost recovery cases brought by governmental (both domestic and foreign) plaintiffs seeking reimbursement for health care expenditures allegedly caused by cigarette smoking and/or disgorgement of profits; (iii) e-vapor cases alleging violation of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), fraud, failure to warn, design defect, negligence and unfair trade practices; and (iv) other tobacco-related litigation described below. Plaintiffs’ theories of recovery and the defenses raised in tobacco-related litigation are discussed below. The table below lists the number of certain tobacco-related cases pending in the U.S. against PM USA and, in some instances, Altria as of December 31, 2019, 2018 and 2017: 2019 2018 2017 Individual Smoking and Health Cases (1) 104 100 92 Health Care Cost Recovery Actions (2) 1 1 1 E-vapor Cases (3) 101 — — Other Tobacco-Related Cases (4) 4 4 7 (1) Includes 21 cases filed in Massachusetts and 43 non- Engle cases filed in Florida. Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the Engle case (these Engle progeny cases are discussed below in Smoking and Health Litigation - Engle Class Action ). Also does not include 1,472 cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (“ETS”). The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 ( Broin ). The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages, but prohibited them from seeking punitive damages. In March 2018, 923 of these cases were voluntarily dismissed without prejudice. (2) See Health Care Cost Recovery Litigation - Federal Government’s Lawsuit below. (3) Includes 22 class action lawsuits, 76 individual lawsuits, two state or local government lawsuits and one lawsuit filed by a school district relating to JUUL e-vapor products. JUUL is an additional named defendant in each of these lawsuits. (4) For 2019, includes two inactive smoking and health cases alleging personal injury or seeking court-supervised programs or ongoing medical monitoring and purporting to be brought on behalf of a class of individual plaintiffs, including one case in which the aggregated claims of a number of individual plaintiffs are to be tried in a single proceeding, and two inactive class action lawsuits alleging that use of the terms “Lights” and “Ultra Lights” constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO. International Tobacco-Related Cases: As of January 27, 2020, PM USA is a named defendant in 10 health care cost recovery actions in Canada, eight of which also name Altria as a defendant. PM USA and Altria are also named defendants in seven smoking and health class actions filed in various Canadian provinces. See Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement between Altria and Philip Morris International Inc. (“PMI”) that provides for indemnities for certain liabilities concerning tobacco products. Tobacco-Related Cases Set for Trial: As of January 27, 2020, four Engle progeny cases are set for trial through March 31, 2020. In addition, there is one individual smoking and health case against PM USA set for trial during this period. Cases against other companies in the tobacco industry may also be scheduled for trial during this period. Trial dates are subject to change. Trial Results: Since January 1999, excluding the Engle progeny cases (separately discussed below), verdicts have been returned in 68 tobacco-related cases in which PM USA was a defendant. Verdicts in favor of PM USA and other defendants were returned in 44 of the 68 cases. These 44 cases were tried in Alaska ( 1 ), California ( 7 ), Connecticut ( 1 ), Florida ( 10 ), Louisiana ( 1 ), Massachusetts ( 4 ), Mississippi ( 1 ), Missouri ( 4 ), New Hampshire ( 1 ), New Jersey ( 1 ), New York ( 5 ), Ohio ( 2 ), Pennsylvania ( 1 ), Rhode Island ( 1 ), Tennessee ( 2 ) and West Virginia ( 2 ). Of the 24 non- Engle progeny cases in which verdicts were returned in favor of plaintiffs, 20 have reached final resolution, and one case ( Gentile ) that was initially returned in favor of plaintiff was reversed post-trial and remains pending. See Smoking and Health Litigation - Engle Progeny Trial Results below for a discussion of verdicts in state and federal Engle progeny cases involving PM USA as of January 27, 2020. Judgments Paid and Provisions for Tobacco and Health Litigation Items (Including Engle Progeny Litigation): After exhausting all appeals in those cases resulting in adverse verdicts associated with tobacco-related litigation, since October 2004, PM USA has paid judgments and settlements (including related costs and fees) totaling approximately $724 million and interest totaling approximately $214 million as of December 31, 2019. These amounts include payments for Engle progeny judgments (and related costs and fees) totaling approximately $312 million and related interest totaling approximately $52 million . The changes in Altria’s accrued liability for tobacco and health litigation items, including related interest costs, for the periods specified below are as follows: (in millions) 2019 2018 2017 Accrued liability for tobacco and health litigation items at beginning of year (1) $ 112 $ 106 $ 47 Pre-tax charges for: Tobacco and health litigation 72 (1)(2) 113 72 Related interest costs 5 18 8 Payments (1) (175 ) (3) (125 ) (21 ) Accrued liability for tobacco and health litigation items at end of period (1) $ 14 $ 112 $ 106 (1) Includes amounts related to the costs of implementing the corrective communications remedy related to the Federal Government’s Lawsuit discussed below. (2) Includes approximately $22 million related to pre-trial resolution of approximately 300 tobacco and health cases. (3) Includes approximately $20 million in payments related to above-mentioned pre-trial resolution of approximately 300 tobacco and health cases (the remaining approximately $2 million was accrued but not paid in 2019). The accrued liability for tobacco and health litigation items, including related interest costs, was included in accrued liabilities on Altria’s consolidated balance sheets. Pre-tax charges for tobacco and health litigation were included in marketing, administration and research costs on Altria’s consolidated statements of earnings (losses). Pre-tax charges for related interest costs were included in interest and other debt expense, net on Altria’s consolidated statements of earnings (losses). Security for Judgments: To obtain stays of judgments pending appeal, PM USA has posted various forms of security. As of December 31, 2019, PM USA has posted appeal bonds totaling approximately $43 million , which have been collateralized with restricted cash that are included in assets on the consolidated balance sheet. Smoking and Health Litigation Overview: Plaintiffs’ allegations of liability in smoking and health cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, nuisance, breach of express and implied warranties, breach of special duty, conspiracy, concert of action, violations of unfair trade practice laws and consumer protection statutes, and claims under the federal and state anti-racketeering statutes. Plaintiffs in the smoking and health cases seek various forms of relief, including compensatory and punitive damages, treble/multiple damages and other statutory damages and penalties, creation of medical monitoring and smoking cessation funds, disgorgement of profits, and injunctive and equitable relief. Defenses raised in these cases include lack of proximate cause, assumption of the risk, comparative fault and/or contributory negligence, statutes of limitations and preemption by the Federal Cigarette Labeling and Advertising Act. Non- Engle Progeny Litigation: Summarized below are the non- Engle progeny smoking and health cases pending during 2019 in which a verdict was returned in favor of plaintiff and against PM USA. Charts listing certain verdicts for plaintiffs in the Engle progeny cases can be found in Smoking and Health Litigation - Engle Progeny Trial Results below. Greene: In September 2019, a jury in a Massachusetts state court returned a verdict against PM USA, awarding plaintiffs approximately $10 million in compensatory damages. An additional claim by plaintiffs remains pending. Laramie : In August 2019, a jury in a Massachusetts state court returned a verdict in favor of plaintiff, awarding $11 million in compensatory damages and $10 million in punitive damages. PM USA and plaintiff appealed. Capone : In December 2018, a jury in a Florida state court returned a verdict in favor of plaintiff, awarding $225,000 in compensatory damages. In the first quarter of 2019, PM USA recorded a provision on its consolidated balance sheet of approximately $325,000 for the judgment and related costs and paid this amount in April 2019, concluding this litigation. Gentile : In October 2017, a jury in a Florida state court returned a verdict in favor of plaintiff, awarding approximately $7.1 million in compensatory damages and allocating 75% of the fault to PM USA (an amount of approximately $5.3 million ). PM USA appealed. In September 2019, the Florida Fourth District Court of Appeal reversed the judgment entered by the trial court, granted PM USA judgment on certain claims and remanded for a new trial on the remaining claims. Plaintiff has petitioned the Florida Supreme Court for further review. Federal Government’s Lawsuit : See Health Care Cost Recovery Litigation - Federal Government’s Lawsuit below for a discussion of the verdict and post-trial developments in the United States of America health care cost recovery case. Engle Class Action: In July 2000, in the second phase of the Engle smoking and health class action in Florida, a jury returned a verdict assessing punitive damages totaling approximately $145 billion against various defendants, including $74 billion against PM USA. Following entry of judgment, PM USA appealed. In May 2003, the Florida Third District Court of Appeal reversed the judgment entered by the trial court and instructed the trial court to order the decertification of the class. Plaintiffs petitioned the Florida Supreme Court for further review. In July 2006, the Florida Supreme Court ordered that the punitive damages award be vacated, that the class approved by the trial court be decertified and that members of the decertified class could file individual actions against defendants within one year of issuance of the mandate. The court further declared the following Phase I findings are entitled to res judicata effect in such individual actions brought within one year of the issuance of the mandate: (i) that smoking causes various diseases; (ii) that nicotine in cigarettes is addictive; (iii) that defendants’ cigarettes were defective and unreasonably dangerous; (iv) that defendants concealed or omitted material information not otherwise known or available knowing that the material was false or misleading or failed to disclose a material fact concerning the health effects or addictive nature of smoking; (v) that defendants agreed to misrepresent information regarding the health effects or addictive nature of cigarettes with the intention of causing the public to rely on this information to their detriment; (vi) that defendants agreed to conceal or omit information regarding the health effects of cigarettes or their addictive nature with the intention that smokers would rely on the information to their detriment; (vii) that all defendants sold or supplied cigarettes that were defective; and (viii) that defendants were negligent. In August 2006, PM USA and plaintiffs sought rehearing from the Florida Supreme Court on parts of its July 2006 opinion. In December 2006, the Florida Supreme Court refused to revise its July 2006 ruling, except that it revised the set of Phase I findings entitled to res judicata effect by excluding finding (v) listed above (relating to agreement to misrepresent information), and added the finding that defendants sold or supplied cigarettes that, at the time of sale or supply, did not conform to the representations of fact made by defendants. In February 2008, the trial court decertified the class. Pending Engle Progeny Cases: The deadline for filing Engle progeny cases expired in January 2008, at which point a total of approximately 9,300 federal and state claims were pending. As of January 27, 2020, approximately 1,700 state court cases were pending against PM USA or Altria asserting individual claims by or on behalf of approximately 2,100 state court plaintiffs. Because of a number of factors, including docketing delays, duplicated filings and overlapping dismissal orders, these numbers are estimates. While the Federal Engle Agreement (discussed below) resolved nearly all Engle progeny cases pending in federal court, as of January 27, 2020, four cases were pending against PM USA in federal court representing the cases excluded from that agreement. Agreement to Resolve Federal Engle Progeny Cases: In 2015, PM USA, R.J. Reynolds Tobacco Company (“R.J. Reynolds”) and Lorillard Tobacco Company (“Lorillard”) resolved approximately 415 pending federal Engle progeny cases (the “Federal Engle Agreement”). Federal cases that were in trial and those that previously reached final verdict were not included in the Federal Engle Agreement. Engle Progeny Trial Results: As of January 27, 2020, 134 federal and state Engle progeny cases involving PM USA have resulted in verdicts since the Florida Supreme Court Engle decision. Seventy-seven verdicts were returned in favor of plaintiffs and six verdicts ( Skolnick , Calloway , McCoy , Duignan , Oshinsky-Blacker and Freeman ) that were initially returned in favor of plaintiffs were reversed post-trial or on appeal and remain pending. Forty-seven verdicts were returned in favor of PM USA, of which 42 were state cases. In addition, there have been a number of mistrials, only some of which have resulted in new trials as of January 27, 2020. Four verdicts ( Pearson, D. Cohen , Collar and Chacon ) that were returned in favor of PM USA were subsequently reversed for new trials. Juries in two cases ( Reider and Banks ) returned zero damages verdicts in favor of PM USA . Juries in two other cases ( Weingart and Hancock ) returned verdicts against PM USA awarding no damages, but the trial court in each case decided to award plaintiffs damages. One case, Pollari, resulted in a verdict in favor of PM USA following a retrial of an initial verdict returned in favor of plaintiff. Appeals by plaintiff and defendants are pending. Two cases, Gloger and Rintoul ( Caprio ), resulted in verdicts in favor of plaintiffs following retrial of initial verdicts returned in favor of plaintiffs. Post-trial motions or appeals are pending. The charts below list the verdicts and post-trial developments in certain Engle progeny cases in which verdicts were returned in favor of plaintiffs. The first chart lists such cases that are pending as of January 27, 2020 where PM USA has recorded a provision in its consolidated financial statements because we have determined that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated; the second chart lists other such cases that are pending as of January 27, 2020 but where we have determined an unfavorable outcome is not probable and the amount of loss cannot be reasonably estimated; and the third chart lists other such cases that have concluded within the previous 12 months. Unless otherwise noted for a particular case, the jury’s award for compensatory damages will not be reduced by any finding of plaintiff’s comparative fault. Further, the damages noted reflect adjustments based on post-trial or appellate rulings. Currently Pending Engle Cases with Accrued Liabilities (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Compensatory Damages (All Defendants) Punitive Damages (PM USA) Appeal Status Accrual (1) Berger ( Cote ) September 2014 PM USA Federal Court - Middle District of Florida $6 million $21 million The Eleventh Circuit Court of Appeals reinstated the punitive and compensatory damages awards and remanded the case to the district court. PM USA’s challenge to the punitive damages award was denied by the district court. PM USA’s appeal to the Eleventh Circuit Court of Appeals is pending. $6 million accrual in the fourth quarter of 2018 (1) Accrual amounts include interest and associated costs, if applicable. For cases with multiple defendants, if any, accrual amounts reflect the portion of compensatory damages PM USA believes it will have to pay if the case is ultimately decided in plaintiff’s favor after taking into account any portion potentially payable by the other defendant(s). Other Currently Pending Engle Cases with Verdicts Against PM USA (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Compensatory Damages (1) Punitive Damages Appeal Status Cuddihee January 2020 PM USA Duval $3 million $0 Trial court entered final judgment. Defendant to file one or more post-trial motions. Rintoul (Caprio) November 2019 PM USA and R.J. Reynolds Broward $9 million ($5 million PM USA) $74 million Defendants’ post-trial motions pending. Gloger November 2019 PM USA and R.J. Reynolds Miami-Dade $15 million ($5 million PM USA) $11 million Appeal by defendants to Third District Court of Appeal pending. McCall March 2019 PM USA Broward <$1 million (<$1 million PM USA) <$1 million New trial ordered on punitive damages. Neff March 2019 PM USA and R.J. Reynolds Broward $4 million $2 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Frogel March 2019 PM USA Palm Beach <$1 million (<$1 million PM USA) $0 Appeals by plaintiff and defendant to Fourth District Court of Appeal pending. Mahfuz February 2019 PM USA and R.J. Reynolds Broward $12 million $10 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Holliman February 2019 PM USA Miami-Dade $3 million $0 Defendant’s appeal to Third District Court of Appeal pending. Chadwell September 2018 PM USA Miami-Dade $2 million $0 Appeals by defendant and plaintiff to Third District Court of Appeal pending. Kaplan July 2018 PM USA and R.J. Reynolds Broward $2 million $2 million Appeals by defendants and plaintiff to Fourth District Court of Appeal pending. Landi June 2018 PM USA and R.J. Reynolds Broward $8 million $5 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Theis May 2018 PM USA and R.J. Reynolds Sarasota $7 million $10 million Second District Court of Appeal affirmed judgment. Defendants’ post-appeal motion pending. Freeman March 2018 PM USA Alachua $4 million $0 First District Court of Appeal reversed judgment against PM USA. Plaintiff petitioned Florida Supreme Court for review. This case is currently stayed . R. Douglas November 2017 PM USA Duval <$1 million $0 Awaiting entry of final judgment by the trial court. Sommers April 2017 PM USA Miami-Dade $1 million $0 Third District Court of Appeal affirmed compensatory damages award and granted new trial on punitive damages. Defendant petitioned Florida Supreme Court for review. Other Currently Pending Engle Cases with Verdicts Against PM USA (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Compensatory Damages (1) Punitive Damages Appeal Status Santoro March 2017 PM USA, R.J. Reynolds and Liggett Group Broward $2 million $0 Trial court set aside punitive damages award; appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Cooper (Blackwood) September 2015 PM USA and R.J. Reynolds Broward $5 million $0 Fourth District Court of Appeal affirmed judgment and granted a new trial on punitive damages. D. Brown January 2015 PM USA Federal Court - Middle District of Florida $8 million $9 million Appeal by defendant to U.S. Court of Appeals for the Eleventh Circuit pending. Kerrivan October 2014 PM USA and R.J. Reynolds Federal Court - Middle District of Florida $16 million $16 million Appeal by defendants to U.S. Court of Appeals for the Eleventh Circuit pending. Harris July 2014 PM USA, Federal Court - Middle District of Florida $2 million (<$ 1 million PM USA) $0 Appeals by plaintiff and defendants to U.S. Court of Appeals for the Eleventh Circuit pending. (1) PM USA’s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies. Engle Cases Concluded Within Past 12 Months (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Accrual Date Payment Amount (if any) Payment Date Alvarez Del Real September 2019 PM USA Miami-Dade Fourth quarter of 2019 <$1 million October 2019 Zingaro May 2019 PM USA and Broward Third quarter of 2019 <$1 million October 2019 Bryant December 2017 PM USA Escambia Second quarter of 2019 <$1 million July 2019 Wallace October 2017 PM USA and Brevard Second quarter of 2019 $26 million May 2019 J. Brown February 2017 PM USA and Pinellas First quarter of 2019 $4 million April 2019 L. Martin May 2017 PM USA Miami-Dade First quarter of 2019 $2 million April 2019 Danielson November 2015 PM USA Escambia First quarter of 2019 $3 million March 2019 S. Martin November 2016 PM USA and Broward First quarter of 2019 $5 million March 2019 Searcy April 2013 PM USA and Federal Court - Middle District of Florida Third quarter of 2018 $2 million March 2019 Boatright November 2014 PM USA and Liggett Group Polk Second quarter of 2018 $42 million March 2019 M. Brown May 2015 PM USA Duval Second quarter of 2018 $8 million March 2019 Jordan (1) August 2015 PM USA Duval Second quarter of 2018 $11 million March 2019 Pardue December 2016 PM USA and Alachua Second and Third quarters of 2018 $11 million March 2019 McKeever February 2015 PM USA Broward Fourth quarter of 2017 $21 million March 2019 Boulter December 2018 PM USA and Lee Fourth quarter of 2018 <$1 million January 2019 (1) The trial court also awarded plaintiff approximately $4 million in fees and costs, which PM USA has appealed. Florida Bond Statute: In June 2009, Florida amended its existing bond cap statute by adding a $200 million bond cap that applies to all state Engle progeny lawsuits in the aggregate and establishes individual bond caps for individual Engle progeny cases in amounts that vary depending on the number of judgments in effect at a given time. Plaintiffs have been unsuccessful in various challenges to the bond cap statute in Florida state court. No federal court has yet addressed the constitutionality of the bond cap statute or the applicability of the bond cap to Engle progeny cases tried in federal court. From time to time, legislation has been presented to the Florida legislature that would repeal the bond cap statute; however to date, no legislation repealing the statute has passed. Other Smoking and Health Class Actions: Since the dismissal in May 1996 of a purported nationwide class action brought on behalf of allegedly addicted smokers, plaintiffs have filed numerous putative smoking and health class action suits in various state and federal courts. In general, these cases purport to be brought on behalf of residents of a particular state or states (although a few cases purport to be nationwide in scope) and raise addiction claims and, in many cases, claims of physical injury as well. Class certification has been denied or reversed by courts in 61 smoking and health class actions involving PM USA in Arkansas ( 1 ), California ( 1 ), Delaware ( 1 ), the District of Columbia ( 2 ), Florida ( 2 ), Illinois ( 3 ), Iowa ( 1 ), Kansas ( 1 ), Louisiana ( 1 ), Maryland ( 1 ), Michigan ( 1 ), Minnesota ( 1 ), Nevada ( 29 ), New Jersey ( 6 ), New York ( 2 ), Ohio ( 1 ), Oklahoma ( 1 ), Oregon ( 1 ), Pennsylvania ( 1 ), Puerto Rico ( 1 ), South Carolina ( 1 ), Texas ( 1 ) and Wisconsin ( 1 ). See Certain Other Tobacco-Related Litigation below for a discussion of “Lights” and “Ultra Lights” class action cases and medical monitoring class action cases pending against PM USA. As of January 27, 2020, PM USA and Altria are named as defendants, along with other cigarette manufacturers, in seven class actions filed in the Canadian provinces of Alberta, Manitoba, Nova Scotia, Saskatchewan, British Columbia and Ontario. In Saskatchewan, British Columbia ( two separate cases) and Ontario, plaintiffs seek class certification on behalf of individuals who suffer or have suffered from various diseases, including chronic obstructive pulmonary disease, emphysema, heart disease or cancer, after smoking defendants’ cigarettes. In the actions filed in Alberta, Manitoba and Nova Scotia, plaintiffs seek certification of classes of all individuals who smoked defendants’ cigarettes. In March 2019, all of these class actions were stayed as a result of three Canadian tobacco manufacturers (none of which is related to Altria or its subsidiaries) seeking protection under Canada’s Companies’ Creditors Arrangement Act (which is similar to Chapter 11 bankruptcy in the U.S.). The companies entered into these proceedings following a Canadian appellate court upholding two smoking and health class action verdicts against those companies totaling approximately CAD $13 billion . See Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement between Altria and PMI, which provides for indemnities for certain liabilities concerning tobacco products. Health Care Cost Recovery Litigation Overview: In the health care cost recovery litigation, governmental entities seek reimbursement of health care cost expenditures allegedly caused by tobacco products and, in some cases, of future expenditures and damages. Relief sought by some but not all plaintiffs includes punitive damages, multiple damages and other statutory damages and penalties, injunctions prohibiting alleged marketing and sales to minors, disclosure of research, disgorgement of profits, funding of anti-smoking programs, additional disclosure of nicotine yields, and payment of attorney and expert witness fees. Although there have been some decisions to the contrary, most judicial decisions in the U.S. have dismissed all or most health care cost recovery claims against cigarette manufacturers. Nine federal circuit courts of appeals and eight state appellate courts, relying primarily on grounds that plaintiffs’ claims were too remote, have ordered or affirmed dismissals of health care cost recovery actions. The United States Supreme Court has refused to consider plaintiffs’ appeals from the cases decided by five federal circuit courts of appeal. In addition to the cases brought in the U.S., health care cost recovery actions have also been brought against tobacco industry participants, including PM USA and Altria in Israel (dismissed), the Marshall Islands (dismissed) and Canada ( 10 cases), and other entities have stated that they are considering filing such actions. Since the beginning of 2008, the Canadian Provinces of British Columbia, New Brunsw

Condensed Consolidating Financi

Condensed Consolidating Financial Information	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Financial Information	Condensed Consolidating Financial Information PM USA, which is a 100% owned subsidiary of Altria, has guaranteed Altria’s obligations under its outstanding debt securities, borrowings under its Credit Agreement and amounts outstanding under its commercial paper program (the “Guarantees”). Pursuant to the Guarantees, PM USA fully and unconditionally guarantees, as primary obligor, the payment and performance of Altria’s obligations under the guaranteed debt instruments (the “Obligations”), subject to release under certain customary circumstances as noted below. The Guarantees provide that PM USA guarantees the punctual payment when due, whether at stated maturity, by acceleration or otherwise, of the Obligations. The liability of PM USA under the Guarantees is absolute and unconditional irrespective of: any lack of validity, enforceability or genuineness of any provision of any agreement or instrument relating thereto; any change in the time, manner or place of payment of, or in any other term of, all or any of the Obligations, or any other amendment or waiver of or any consent to departure from any agreement or instrument relating thereto; any exchange, release or non-perfection of any collateral, or any release or amendment or waiver of or consent to departure from any other guarantee, for all or any of the Obligations; or any other circumstance that might otherwise constitute a defense available to, or a discharge of, Altria or PM USA. The obligations of PM USA under the Guarantees are limited to the maximum amount as will not result in PM USA’s obligations under the Guarantees constituting a fraudulent transfer or conveyance, after giving effect to such maximum amount and all other contingent and fixed liabilities of PM USA that are relevant under Bankruptcy Law, the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act or any similar federal or state law to the extent applicable to the Guarantees. For this purpose, “Bankruptcy Law” means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors. PM USA will be unconditionally released and discharged from the Obligations upon the earliest to occur of: ▪ the date, if any, on which PM USA consolidates with or merges into Altria or any successor; ▪ the date, if any, on which Altria or any successor consolidates with or merges into PM USA; ▪ the payment in full of the Obligations pertaining to such Guarantees; and ▪ the rating of Altria’s long-term senior unsecured debt by Standard & Poor’s of A or higher. At December 31, 2019 , the respective principal 100% owned subsidiaries of Altria and PM USA were not limited by long-term debt or other agreements in their ability to pay cash dividends or make other distributions with respect to their equity interests. The following sets forth the condensed consolidating balance sheets as of December 31, 2019 and 2018 , condensed consolidating statements of earnings (losses) and comprehensive earnings (losses) for the years ended December 31, 2019 , 2018 and 2017 , and condensed consolidating statements of cash flows for the years ended December 31, 2019 , 2018 and 2017 for Altria, PM USA and, collectively, Altria’s other subsidiaries that are not guarantors of Altria’s debt instruments (the “Non-Guarantor Subsidiaries”). The financial information may not necessarily be indicative of results of operations or financial position had PM USA and the Non-Guarantor Subsidiaries operated as independent entities. Altria and PM USA account for investments in their subsidiaries under the equity method of accounting. Condensed Consolidating Balance Sheets (in millions of dollars) ____________________________ at December 31, 2019 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Assets Cash and cash equivalents $ 2,022 $ — $ 95 $ — $ 2,117 Receivables — 30 122 — 152 Inventories: Leaf tobacco — 494 380 — 874 Other raw materials — 120 72 — 192 Work in process — 4 692 — 696 Finished product — 119 412 — 531 — 737 1,556 — 2,293 Due from Altria and subsidiaries 88 4,005 1,359 (5,452 ) — Income taxes 80 47 38 (49 ) 116 Other current assets 53 17 76 — 146 Total current assets 2,243 4,836 3,246 (5,501 ) 4,824 Property, plant and equipment, at cost — 2,956 2,118 — 5,074 Less accumulated depreciation — 2,166 909 — 3,075 — 790 1,209 — 1,999 Goodwill — — 5,177 — 5,177 Other intangible assets, net — 2 12,685 — 12,687 Investments in equity securities 18,071 — 5,510 — 23,581 Investment in consolidated subsidiaries 19,312 2,831 — (22,143 ) — Due from Altria and subsidiaries 4,790 — — (4,790 ) — Other assets 58 951 603 (609 ) 1,003 Total Assets $ 44,474 $ 9,410 $ 28,430 $ (33,043 ) $ 49,271 Condensed Consolidating Balance Sheets (Continued) (in millions of dollars) ____________________________ at December 31, 2019 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Liabilities Current portion of long-term debt $ 1,000 $ — $ — $ — $ 1,000 Accounts payable — 146 179 — 325 Accrued liabilities: Marketing — 320 73 — 393 Settlement charges — 3,340 6 — 3,346 Other 576 482 536 (49 ) 1,545 Dividends payable 1,565 — — — 1,565 Due to Altria and subsidiaries 4,693 514 245 (5,452 ) — Total current liabilities 7,834 4,802 1,039 (5,501 ) 8,174 Long-term debt 27,042 — — — 27,042 Deferred income taxes 3,099 — 2,593 (609 ) 5,083 Accrued pension costs 197 — 276 — 473 Accrued postretirement health care costs — 1,078 719 — 1,797 Due to Altria and subsidiaries — — 4,790 (4,790 ) — Other liabilities 80 87 178 — 345 Total liabilities 38,252 5,967 9,595 (10,900 ) 42,914 Contingencies Redeemable noncontrolling interest — — 38 — 38 Stockholders’ Equity Common stock 935 — 9 (9 ) 935 Additional paid-in capital 5,970 3,310 27,565 (30,875 ) 5,970 Earnings reinvested in the business 36,539 352 (6,997 ) 6,645 36,539 Accumulated other comprehensive losses (2,864 ) (219 ) (1,877 ) 2,096 (2,864 ) Cost of repurchased stock (34,358 ) — — — (34,358 ) Total stockholders’ equity attributable to Altria 6,222 3,443 18,700 (22,143 ) 6,222 Noncontrolling interests — — 97 — 97 Total stockholders’ equity 6,222 3,443 18,797 (22,143 ) 6,319 Total Liabilities and Stockholders’ Equity $ 44,474 $ 9,410 $ 28,430 $ (33,043 ) $ 49,271 Condensed Consolidating Balance Sheets (in millions of dollars) ____________________________ at December 31, 2018 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Assets Cash and cash equivalents $ 1,277 $ — $ 56 $ — $ 1,333 Receivables — 18 124 — 142 Inventories: Leaf tobacco — 561 379 — 940 Other raw materials — 123 63 — 186 Work in process — 2 645 — 647 Finished product — 128 430 — 558 — 814 1,517 — 2,331 Due from Altria and subsidiaries 46 3,828 1,194 (5,068 ) — Income taxes 100 94 — (27 ) 167 Other current assets 41 167 118 — 326 Total current assets 1,464 4,921 3,009 (5,095 ) 4,299 Property, plant and equipment, at cost — 2,928 2,022 — 4,950 Less accumulated depreciation — 2,111 901 — 3,012 — 817 1,121 — 1,938 Goodwill — — 5,196 — 5,196 Other intangible assets, net — 2 12,277 — 12,279 Investments in equity securities 17,696 — 12,800 — 30,496 Investment in consolidated subsidiaries 25,996 2,825 — (28,821 ) — Due from Altria and subsidiaries 4,790 — — (4,790 ) — Other assets 193 955 773 (670 ) 1,251 Total Assets $ 50,139 $ 9,520 $ 35,176 $ (39,376 ) $ 55,459 Condensed Consolidating Balance Sheets (Continued) (in millions of dollars) ____________________________ at December 31, 2018 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Liabilities Short-term borrowings 12,704 — — — 12,704 Current portion of long-term debt $ 1,144 $ — $ — $ — $ 1,144 Accounts payable 1 91 307 — 399 Accrued liabilities: Marketing — 483 103 — 586 Settlement charges — 3,448 6 — 3,454 Other 295 524 611 (27 ) 1,403 Dividends payable 1,503 — — — 1,503 Due to Altria and subsidiaries 4,499 407 162 (5,068 ) — Total current liabilities 20,146 4,953 1,189 (5,095 ) 21,193 Long-term debt 11,898 — — — 11,898 Deferred income taxes 3,010 — 2,653 (670 ) 4,993 Accrued pension costs 187 — 357 — 544 Accrued postretirement health care costs — 1,072 677 — 1,749 Due to Altria and subsidiaries — — 4,790 (4,790 ) — Other liabilities 111 47 96 — 254 Total liabilities 35,352 6,072 9,762 (10,555 ) 40,631 Contingencies Redeemable noncontrolling interest — — 39 — 39 Stockholders’ Equity Common stock 935 — 9 (9 ) 935 Additional paid-in capital 5,961 3,310 25,047 (28,357 ) 5,961 Earnings reinvested in the business 43,962 359 2,201 (2,560 ) 43,962 Accumulated other comprehensive losses (2,547 ) (221 ) (1,884 ) 2,105 (2,547 ) Cost of repurchased stock (33,524 ) — — — (33,524 ) Total stockholders’ equity attributable to Altria 14,787 3,448 25,373 (28,821 ) 14,787 Noncontrolling interests — — 2 — 2 Total stockholders’ equity 14,787 3,448 25,375 (28,821 ) 14,789 Total Liabilities and Stockholders’ Equity $ 50,139 $ 9,520 $ 35,176 $ (39,376 ) $ 55,459 Condensed Consolidating Statements of Earnings (Losses) and Comprehensive Earnings (Losses) (in millions of dollars) _____________________________ for the year ended December 31, 2019 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Net revenues $ — $ 21,065 $ 4,081 $ (36 ) $ 25,110 Cost of sales — 5,997 1,124 (36 ) 7,085 Excise taxes on products — 5,111 203 — 5,314 Gross profit — 9,957 2,754 — 12,711 Marketing, administration and research costs 182 1,591 453 — 2,226 Asset impairment and exit costs 1 39 119 — 159 Operating (expense) income (183 ) 8,327 2,182 — 10,326 Interest and other debt expense (income), net 1,152 (85 ) 213 — 1,280 Net periodic benefit (income) cost, excluding service cost 5 (34 ) (8 ) — (37 ) Earnings from equity investments (1,229 ) — (496 ) — (1,725 ) Impairment of JUUL equity securities — — 8,600 — 8,600 Loss on Cronos-related financial instruments — — 1,442 — 1,442 Earnings (losses) before income taxes and equity earnings of subsidiaries (111 ) 8,446 (7,569 ) — 766 Provision (benefit) for income taxes (243 ) 2,102 205 — 2,064 Equity earnings (losses) of subsidiaries (1,425 ) 450 — 975 — Net earnings (losses) (1,293 ) 6,794 (7,774 ) 975 (1,298 ) Net (earnings) losses attributable to noncontrolling interests — — 5 — 5 Net earnings (losses) attributable to Altria $ (1,293 ) $ 6,794 $ (7,769 ) $ 975 $ (1,293 ) Net earnings (losses) $ (1,293 ) $ 6,794 $ (7,774 ) $ 975 $ (1,298 ) Other comprehensive earnings (losses), net of deferred income taxes (317 ) 2 7 (9 ) (317 ) Comprehensive earnings (losses) (1,610 ) 6,796 (7,767 ) 966 (1,615 ) Comprehensive (earnings) losses attributable to noncontrolling interests — — 5 — 5 Comprehensive earnings (losses) attributable to Altria $ (1,610 ) $ 6,796 $ (7,762 ) $ 966 $ (1,610 ) Condensed Consolidating Statements of Earnings (Losses) and Comprehensive Earnings (Losses) (in millions of dollars) _____________________________ for the year ended December 31, 2018 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Net revenues $ — $ 21,422 $ 3,980 $ (38 ) $ 25,364 Cost of sales — 6,153 1,258 (38 ) 7,373 Excise taxes on products — 5,517 220 — 5,737 Gross profit — 9,752 2,502 — 12,254 Marketing, administration and research costs 219 1,892 645 — 2,756 Asset impairment and exit costs — 81 302 — 383 Operating (expense) income (219 ) 7,779 1,555 — 9,115 Interest and other debt expense (income), net 511 (61 ) 215 — 665 Net periodic benefit (income) cost, excluding service cost 16 (41 ) (9 ) — (34 ) Earnings from equity investments (890 ) — — — (890 ) (Gain) loss on ABI/SABMiller business combination 33 — — — 33 Earnings (losses) before income taxes and equity earnings of subsidiaries 111 7,881 1,349 — 9,341 Provision (benefit) for income taxes 36 1,980 358 — 2,374 Equity earnings (losses) of subsidiaries 6,888 402 — (7,290 ) — Net earnings (losses) 6,963 6,303 991 (7,290 ) 6,967 Net (earnings) losses attributable to noncontrolling interests — — (4 ) — (4 ) Net earnings (losses) attributable to Altria $ 6,963 $ 6,303 $ 987 $ (7,290 ) $ 6,963 Net earnings (losses) $ 6,963 $ 6,303 $ 991 $ (7,290 ) $ 6,967 Other comprehensive earnings (losses), net of deferred income taxes (242 ) 104 (54 ) (50 ) (242 ) Comprehensive earnings (losses) 6,721 6,407 937 (7,340 ) 6,725 Comprehensive (earnings) losses attributable to noncontrolling interests — — (4 ) — (4 ) Comprehensive earnings (losses) attributable to Altria $ 6,721 $ 6,407 $ 933 $ (7,340 ) $ 6,721 Condensed Consolidating Statements of Earnings (Losses) and Comprehensive Earnings (Losses) (in millions of dollars) _____________________________ for the year ended December 31, 2017 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Net revenues $ — $ 21,826 $ 3,787 $ (37 ) $ 25,576 Cost of sales — 6,394 1,174 (37 ) 7,531 Excise taxes on products — 5,864 218 — 6,082 Gross profit — 9,568 2,395 — 11,963 Marketing, administration and research costs 161 1,713 464 — 2,338 Asset impairment and exit costs — — 32 — 32 Operating (expense) income (161 ) 7,855 1,899 — 9,593 Interest and other debt expense (income), net 510 (20 ) 215 — 705 Net periodic benefit (income) cost, excluding service cost 12 18 7 — 37 Earnings from equity investments (532 ) — — — (532 ) (Gain) loss on ABI/SABMiller business combination (445 ) — — — (445 ) Earnings (losses) before income taxes and equity earnings of subsidiaries 294 7,857 1,677 — 9,828 Provision (benefit) for income taxes (2,624 ) 3,127 (902 ) — (399 ) Equity earnings (losses) of subsidiaries 7,304 558 — (7,862 ) — Net earnings (losses) 10,222 5,288 2,579 (7,862 ) 10,227 Net (earnings) losses attributable to noncontrolling interests — — (5 ) — (5 ) Net earnings (losses) attributable to Altria $ 10,222 $ 5,288 $ 2,574 $ (7,862 ) $ 10,222 Net earnings (losses) $ 10,222 $ 5,288 $ 2,579 $ (7,862 ) $ 10,227 Other comprehensive earnings (losses), net of deferred income taxes 155 3 214 (217 ) 155 Comprehensive earnings (losses) 10,377 5,291 2,793 (8,079 ) 10,382 Comprehensive (earnings) losses attributable to noncontrolling interests — — (5 ) — (5 ) Comprehensive earnings (losses) attributable to Altria $ 10,377 $ 5,291 $ 2,788 $ (8,079 ) $ 10,377 Condensed Consolidating Statements of Cash Flows (in millions of dollars) _____________________________ for the year ended December 31, 2019 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Cash Provided by (Used In) Operating Activities Net cash provided by (used in) operating activities $ 7,769 $ 6,936 $ 1,362 $ (8,230 ) $ 7,837 Cash Provided by (Used in) Investing Activities Capital expenditures — (56 ) (190 ) — (246 ) Investment in Cronos — — (1,899 ) — (1,899 ) Acquisitions of businesses and assets — — (421 ) — (421 ) Investment in JUUL — — (5 ) — (5 ) Investment in consolidated subsidiaries (2,518 ) — — 2,518 — Other, net 41 1 131 — 173 Net cash provided by (used in) investing activities (2,477 ) (55 ) (2,384 ) 2,518 (2,398 ) Cash Provided by (Used in) Financing Activities Repayment of short-term borrowings (12,800 ) — — — (12,800 ) Long-term debt issued 16,265 — — — 16,265 Long-term debt repaid (1,144 ) — — — (1,144 ) Repurchases of common stock (845 ) — — — (845 ) Dividends paid on common stock (6,069 ) — — — (6,069 ) Changes in amounts due to/from Altria and subsidiaries 169 (137 ) 2,486 (2,518 ) — Cash dividends paid to parent — (6,801 ) (1,429 ) 8,230 — Other, net (123 ) — 4 — (119 ) Net cash provided by (used in) financing activities (4,547 ) (6,938 ) 1,061 5,712 (4,712 ) Cash, cash equivalents and restricted cash (1) : Increase (decrease) 745 (57 ) 39 — 727 Balance at beginning of year 1,277 100 56 — 1,433 Balance at end of year $ 2,022 $ 43 $ 95 $ — $ 2,160 (1) Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 19 . Contingencies . Condensed Consolidating Statements of Cash Flows (in millions of dollars) _____________________________ for the year ended December 31, 2018 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Cash Provided by (Used In) Operating Activities Net cash provided by (used in) operating activities $ 6,907 $ 7,580 $ 1,354 $ (7,450 ) $ 8,391 Cash Provided by (Used in) Investing Activities Capital expenditures — (57 ) (181 ) — (238 ) Acquisitions of businesses and assets — — (15 ) — (15 ) Investment in JUUL — — (12,800 ) — (12,800 ) Investment in consolidated subsidiaries (13,003 ) — — 13,003 — Other, net 35 — 30 — 65 Net cash provided by (used in) investing activities (12,968 ) (57 ) (12,966 ) 13,003 (12,988 ) Cash Provided by (Used in) Financing Activities Proceeds from short-term borrowings 12,800 — — — 12,800 Long-term debt repaid (864 ) — — — (864 ) Repurchases of common stock (1,673 ) — — — (1,673 ) Dividends paid on common stock (5,415 ) — — — (5,415 ) Changes in amounts due to/from Altria and subsidiaries 1,415 (1,388 ) 12,976 (13,003 ) — Cash dividends paid to parent — (6,097 ) (1,353 ) 7,450 — Other (128 ) — (4 ) — (132 ) Net cash provided by (used in) financing activities 6,135 (7,485 ) 11,619 (5,553 ) 4,716 Cash, cash equivalents and restricted cash (1) : Increase (decrease) 74 38 7 — 119 Balance at beginning of year 1,203 62 49 — 1,314 Balance at end of year $ 1,277 $ 100 $ 56 $ — $ 1,433 (1) Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 19 . Contingencies . Condensed Consolidating Statements of Cash Flows (in millions of dollars) _____________________________ for the year ended December 31, 2017 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Cash Provided by (Used In) Operating Activities Net cash provided by (used in) operating activities $ 6,910 $ 4,028 $ 841 $ (6,878 ) $ 4,901 Cash Provided by (Used in) Investing Activities Capital expenditures — (34 ) (165 ) — (199 ) Acquisitions of businesses and assets — — (415 ) — (415 ) Investment in consolidated subsidiaries (460 ) — — 460 — Other, net (5 ) 4 148 — 147 Net cash provided by (used in) investing activities (465 ) (30 ) (432 ) 460 (467 ) Cash Provided by (Used in) Financing Activities Repurchases of common stock (2,917 ) — — — (2,917 ) Dividends paid on common stock (4,807 ) — — — (4,807 ) Changes in amounts due to/from Altria and subsidiaries (1,999 ) 1,410 1,049 (460 ) — Cash dividends paid to parent — (5,429 ) (1,449 ) 6,878 — Other (40 ) — (7 ) — (47 ) Net cash provided by (used in) financing activities (9,763 ) (4,019 ) (407 ) 6,418 (7,771 ) Cash, cash equivalents and restricted cash (1) : Increase (decrease) (3,318 ) (21 ) 2 — (3,337 ) Balance at beginning of year 4,521 83 47 — 4,651 Balance at end of year $ 1,203 $ 62 $ 49 $ — $ 1,314 (1) Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 19 . Contingencies .

Quarterly Financial Data (Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Data [Abstract]
Quarterly Financial Data (Unaudited)	Quarterly Financial Data (Unaudited) 2019 Quarters (in millions, except per share data) 1st 2nd 3rd 4th Net revenues $ 5,628 $ 6,619 $ 6,856 $ 6,007 Gross profit $ 2,811 $ 3,319 $ 3,497 $ 3,084 Net earnings (losses) $ 1,121 $ 1,997 $ (2,602 ) $ (1,814 ) Net earnings (losses) attributable to Altria $ 1,120 $ 1,996 $ (2,600 ) $ (1,809 ) Per share data: Basic earnings (losses) per share attributable to Altria $ 0.60 $ 1.07 $ (1.39 ) $ (0.97 ) Diluted earnings (losses) per share attributable to Altria $ 0.60 $ 1.07 $ (1.39 ) $ (1.00 ) 2018 Quarters (in millions, except per share data) 1st 2nd 3rd 4th Net revenues $ 6,108 $ 6,305 $ 6,837 $ 6,114 Gross profit $ 2,936 $ 3,141 $ 3,255 $ 2,922 Net earnings (losses) $ 1,895 $ 1,877 $ 1,944 $ 1,251 Net earnings (losses) attributable to Altria $ 1,894 $ 1,876 $ 1,943 $ 1,250 Per share data: Basic earnings (losses) per share attributable to Altria $ 1.00 $ 0.99 $ 1.03 $ 0.67 Diluted earnings (losses) per share attributable to Altria $ 1.00 $ 0.99 $ 1.03 $ 0.66 During 2019 and 2018 , the following pre-tax (gains) or charges were included in net earnings attributable to Altria: 2019 Quarters (in millions) 1st 2nd 3rd 4th Impairment of JUUL equity securities $ — $ — $ 4,500 $ 4,100 Tobacco and health litigation items, including accrued interest 17 28 3 29 Asset impairment, exit, implementation and acquisition-related costs 159 45 11 116 ABI-related special items 114 (90 ) (14 ) (364 ) Cronos-related special items 425 119 549 (165 ) $ 715 $ 102 $ 5,049 $ 3,716 2018 Quarters (in millions) 1st 2nd 3rd 4th NPM Adjustment Items $ (68 ) $ (77 ) $ — $ — Tobacco and health litigation items, including accrued interest 28 70 21 12 Asset impairment, exit, implementation and acquisition-related costs 3 6 (3 ) 532 (Gain) loss on ABI/SABMiller business combination 33 — — — ABI-related special items (117 ) (72 ) 35 69 $ (121 ) $ (73 ) $ 53 $ 613 As discussed in Note 15 . Income Taxes , Altria has recognized income tax benefits and charges in the consolidated statements of earnings (losses) during 2019 and 2018 as a result of various tax events, including the impact of the Tax Reform Act in 2018.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Cash and Cash Equivalents	Cash equivalents include demand deposits with banks and all highly liquid investments with original maturities of three months or less. Cash equivalents are stated at cost plus accrued interest, which approximates fair value.
Depreciation and Amortization	Property, plant and equipment are stated at historical costs and depreciated by the straight-line method over the estimated useful lives of the assets. Machinery and equipment are depreciated over periods up to 25 years, and buildings and building improvements over periods up to 50 years. Definite-lived intangible assets are amortized over their estimated useful lives up to 25 years.
Impairment Testing and Asset Valuation	Altria reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in business circumstances indicate that the carrying value of the assets may not be fully recoverable. Altria performs undiscounted operating cash flow analyses to determine if an impairment exists. For purposes of recognition and measurement of an impairment for assets held for use, Altria groups assets and liabilities at the lowest level for which cash flows are separately identifiable. If Altria determines that an impairment exists, any related impairment loss is calculated based on fair value. Impairment losses on assets to be disposed of, if any, are based on the estimated proceeds to be received, less costs of disposal. Altria also reviews the estimated remaining useful lives of long-lived assets whenever events or changes in business circumstances indicate the lives may have changed. Altria conducts a required annual review of goodwill and indefinite-lived intangible assets for potential impairment, and more frequently if an event occurs or circumstances change that would require Altria to perform an interim review. If the carrying value of a reporting unit that includes goodwill exceeds its fair value, which is determined using discounted cash flows, goodwill is considered impaired. The amount of impairment loss is measured as the difference between the carrying value and the fair value of a reporting unit, but is limited to the total amount of goodwill allocated to a reporting unit. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, which is determined using discounted cash flows, the intangible asset is considered impaired and is reduced to fair value in the period identified. Altria reviews its equity investments accounted for under the equity method of accounting (ABI and Cronos) for impairment by comparing the fair value of each of its investments to their carrying value. If the carrying value of an investment exceeds its fair value and the loss in value is other than temporary, the investment is considered impaired and reduced to fair value, and the impairment is recognized in the period identified. The factors used to make this determination include the duration and magnitude of the fair value decline, the financial condition and near-term prospects of the investee, and Altria’s intent and ability to hold its investment until recovery. Altria reviews its equity investment in JUUL (which is accounted for as an equity security without a readily determinable fair value) for impairment by performing a qualitative assessment of impairment indicators. If a qualitative assessment indicates that Altria’s investment in JUUL is impaired, a quantitative assessment is performed. If the quantitative assessment indicates the fair value of the investment is less than its carrying value, the investment is written down to its fair value in the period identified.
Derivative Financial Instruments	Altria enters into derivatives to mitigate the potential impact of certain market risks, including foreign currency exchange rate risk. Altria uses various types of derivative financial instruments, including forward contracts, options and swaps. Derivative financial instruments are recorded at fair value on the consolidated balance sheets as either assets or liabilities. Derivative financial instruments that qualify for hedge accounting are designated as either fair value hedges, cash flow hedges or net investment hedges at the inception of the contracts. For fair value hedges, changes in the fair value of the derivative, as well as the offsetting changes in the fair value of the hedged item, are recorded in the consolidated statements of earnings (losses) each period. For cash flow hedges, changes in the fair value of the derivative are recorded each period in accumulated other comprehensive earnings (losses) and are reclassified to the consolidated statements of earnings (losses) in the same periods in which operating results are affected by the respective hedged item. For net investment hedges, changes in the fair value of the derivative or foreign currency transaction gains or losses on a nonderivative hedging instrument are recorded in accumulated other comprehensive earnings (losses) to offset the change in the value of the net investment being hedged. Such amounts remain in accumulated other comprehensive earnings (losses) until the complete or substantially complete liquidation of the underlying foreign operations occurs or, for investments in foreign entities accounted for under the equity method of accounting, Altria’s economic interest in the underlying foreign entity decreases. Cash flows from hedging instruments are classified in the same manner as the respective hedged item in the consolidated statements of cash flows. To qualify for hedge accounting, the hedging relationship, both at inception of the hedge and on an ongoing basis, is expected to be highly effective at offsetting changes in the fair value of the hedged risk during the period that the hedge is designated. Altria formally designates and documents, at inception, the financial instrument as a hedge of a specific underlying exposure, the risk management objective, the strategy for undertaking the hedge transaction and method for assessing hedge effectiveness. Additionally, for qualified hedges of forecasted transactions, if it becomes probable that a forecasted transaction will not occur, the hedge would no longer be considered effective and all of the derivative gains and losses would be recorded in the consolidated statement of earnings (losses) in the current period. For financial instruments that are not designated as hedging instruments or do not qualify for hedge accounting, changes in fair value are recorded in the consolidated statements of earnings (losses) each period. Altria does not enter into or hold derivative financial instruments for trading or speculative purposes.
Employee Benefit Plans	Altria provides a range of benefits to certain employees and retired employees, including pension, postretirement health care and postemployment benefits. Altria records annual amounts relating to these plans based on calculations specified by U.S. GAAP, which include various actuarial assumptions as to discount rates, assumed rates of return on plan assets, mortality, compensation increases, turnover rates and health care cost trend rates. Altria recognizes the funded status of its defined benefit pension and other postretirement plans on the consolidated balance sheet and records as a component of other comprehensive earnings (losses), net of deferred income taxes, the gains or losses and prior service costs or credits that have not been recognized as components of net periodic benefit cost. The gains or losses and prior service costs or credits recorded as components of other comprehensive earnings (losses) are subsequently amortized into net periodic benefit cost in future years.
Environmental Costs	Altria is subject to laws and regulations relating to the protection of the environment. Altria provides for expenses associated with environmental remediation obligations on an undiscounted basis when such amounts are probable and can be reasonably estimated. Such accruals are adjusted as new information develops or circumstances change.Compliance with environmental laws and regulations, including the payment of any remediation and compliance costs or damages and the making of related expenditures, has not had, and is not expected to have, a material adverse effect on Altria’s consolidated results of operations, capital expenditures, financial position or cash flows
Fair Value Measurements	Altria measures certain assets and liabilities at fair value. Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Altria uses a fair value hierarchy, which gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of inputs used to measure fair value are: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Guarantees	Altria recognizes a liability for the fair value of the obligation of qualifying guarantee activities.
Income Taxes	Significant judgment is required in determining income tax provisions and in evaluating tax positions. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse. Altria records a valuation allowance when it is more-likely-than-not that some portion or all of a deferred tax asset will not be realized. Altria recognizes a benefit for uncertain tax positions when a tax position taken or expected to be taken in a tax return is more-likely-than-not to be sustained upon examination by taxing authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Altria recognizes accrued interest and penalties associated with uncertain tax positions as part of the provision for income taxes in its consolidated statements of earnings (losses).
Inventories	The last-in, first-out (“LIFO”) method is used to determine the cost of substantially all tobacco inventories. The cost of the remaining inventories is determined using the first-in, first-out (“FIFO”) and average cost methods. Inventories that are measured using the LIFO method are stated at the lower of cost or market. Inventories that are measured using the FIFO and average cost methods are stated at the lower of cost and net realizable value. It is a generally recognized industry practice to classify leaf tobacco and wine inventories as current assets although part of such inventory, because of the duration of the curing and aging process, ordinarily would not be used within one year .
Litigation Contingencies and Costs	Altria and its subsidiaries record provisions in the consolidated financial statements for pending litigation when it is determined that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. Litigation defense costs are expensed as incurred and included in marketing, administration and research costs in the consolidated statements of earnings (losses).
Marketing Costs	Altria’s businesses promote their products with consumer incentives, trade promotions and consumer engagement programs. These consumer incentive and trade promotion activities, which include discounts, coupons, rebates, in-store display incentives and volume-based incentives, do not create a distinct deliverable and are, therefore, recorded as a reduction of revenues. Consumer engagement program payments are made to third parties. Altria’s businesses expense these consumer engagement programs, which include event marketing, as incurred and such expenses are included in marketing, administration and research costs in Altria’s consolidated statements of earnings (losses). For interim reporting purposes, Altria’s businesses charge consumer engagement programs and certain consumer incentive expenses to operations as a percentage of sales, based on estimated sales and related expenses for the full year.
Revenue Recognition	Altria’s businesses generate substantially all of their revenue from sales contracts with customers. While Altria’s businesses enter into separate sales contracts with each customer for each product type, all sales contracts are similarly structured. These contracts create an obligation to transfer product to the customer. All performance obligations are satisfied within one year ; therefore, costs to obtain contracts are expensed as incurred and unsatisfied performance obligations are not disclosed. There is no financing component because Altria expects, at contract inception, that the period between when Altria’s businesses transfer product to the customer and when the customer pays for that product will be one year or less. Altria’s businesses define net revenues as revenues, which include excise taxes and shipping and handling charges billed to customers, net of cash discounts for prompt payment, sales returns (also referred to as returned goods) and sales incentives. Altria’s businesses exclude from the transaction price sales taxes and value-added taxes imposed at the time of sale (which do not include excise taxes on cigarettes, cigars, smokeless tobacco or wine billed to customers). Altria’s businesses recognize revenues from sales contracts with customers upon shipment of goods when control of such products is obtained by the customer. Altria’s businesses determine that a customer obtains control of the product upon shipment when title of such product and risk of loss transfers to the customer. Altria’s businesses account for shipping and handling costs as fulfillment costs and such amounts are classified as part of cost of sales in Altria’s consolidated statements of earnings (losses). Altria’s businesses record an allowance for returned goods, based principally on historical volume and return rates, which is included in other accrued liabilities on Altria’s consolidated balance sheets. Altria’s businesses record sales incentives, which consist of consumer incentives and trade promotion activities, as a reduction to revenues (a portion of which is based on amounts estimated as being due to wholesalers, retailers and consumers at the end of a period) based principally on historical volume, utilization and redemption rates. Expected payments for sales incentives are included in accrued marketing liabilities on Altria’s consolidated balance sheets. Payment terms vary depending on product type. Altria’s businesses consider payments received in advance of product shipment as deferred revenue, which is included in other accrued liabilities on Altria’s consolidated balance sheets until revenue is recognized. PM USA receives payment in advance of a customer obtaining control of the product. USSTC receives substantially all payments within one business day of the customer obtaining control of the product. Ste. Michelle receives substantially all payments from customers within 45 days of the customer obtaining control of the product. Amounts due from customers are included in receivables on Altria’s consolidated balance sheets.
New Accounting Pronouncements and New Accounting Guidance Not Yet Adopted	On January 1, 2019, Altria adopted ASU No. 2016-02, Leases (Topic 842) The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, Altria: Standards Description Effective Date for Public Entity Effect on Financial Statements ASU Nos. 2016-13; 2018-19; 2019-04; 2019-05; 2019-10; 2019-11 Measurement of Credit Losses on Financial Instruments (Topic 326) The guidance replaces the current incurred loss impairment methodology for recognizing credit losses for financial assets with a methodology that reflects the entity’s current estimate of all expected credit losses and requires consideration of a broader range of reasonable and supportable information for estimating credit losses. The guidance is effective for annual reporting periods beginning after December 15, 2019, including interim periods within that reporting period. Altria’s adoption of this guidance is not expected to have a material impact on its consolidated financial statements. ASU No. 2018-15 Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (Subtopic 350-40) The guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The guidance is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Altria’s adoption of this guidance is not expected to have a material impact on its consolidated financial statements. ASU 2019-12 Simplifying the Accounting for Income Taxes (Topic 740) The guidance removes certain exceptions for investments, intraperiod allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is permitted, including adoption in any interim period. Altria is in the process of evaluating the impact of this guidance on its consolidated financial statements and related disclosures. ASU 2020-01 Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is permitted, including adoption in any interim period. Altria is in the process of evaluating the impact of this guidance on its consolidated financial statements and related disclosures. On December 31, 2019, Altria adopted ASU No. 2018-14, which amends certain defined benefit plan disclosures. Altria elected early adoption of this update, which is permitted for all entities and applied on a retrospective basis to all periods presented. The adoption of ASU No. 2018-14 had no impact on the amount of defined benefit plan assets, obligations or expenses recognized by Altria’s businesses.
Equity Method Investments	The fair value of Altria’s equity investment in ABI is based on: (i) unadjusted quoted prices in active markets for ABI’s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets, for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy. Altria may, in certain instances, pledge or otherwise grant a security interest in all or part of its Restricted Shares. In the event the pledgee or security interest holder were to foreclose on the Restricted Shares, the encumbered Restricted Shares will be automatically converted, one-for-one, into ordinary shares. Therefore, the fair value of each Restricted Share is based on the value of an ordinary share.
Equity Securities without Readily Determinable Fair Value	Also, upon Share Conversion, Altria expects to account for its equity investment in JUUL under the fair value option. Under this option, Altria’s consolidated statement of earnings (losses) will include any cash dividends received from its investment in JUUL as well as any changes in the fair value of the investment, which will be calculated quarterly. At December 31, 2019 , Altria accounted for its investment in JUUL as an investment in an equity security. Since the JUUL shares do not have a readily determinable fair value, Altria has elected to measure its investment in JUUL at its cost minus any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There have been no upward or downward adjustments to the carrying value of Altria’s investment in JUUL resulting from observable price changes in orderly transactions since the JUUL Transaction through December 31, 2019 . Altria used an income approach to estimate the fair value of its investment in JUUL. The income approach reflects the discounting of future cash flows for the U.S. and international markets at a rate of return that incorporates the risk-free rate for the use of those funds, the expected rate of inflation and the risks associated with realizing future cash flows. Future cash flows in the U.S. were based on a range of scenarios that consider various potential regulatory and market outcomes. In determining the fair value of its investment in JUUL, Altria made various judgments, estimates and assumptions, the most significant of which were sales volume, operating margins, discount rates and perpetual growth rates. Additionally, Altria made significant assumptions regarding the likelihood and extent of various potential regulatory actions and the continued adverse public perception impacting the e-vapor category and specifically JUUL, as well as expectations of the future state of the e-vapor category. All significant inputs used in the valuation are classified in Level 3 of the fair value hierarchy.
Methodology of Determining Fair Value of Pension Assets	Following is a description of the valuation methodologies used for investments measured at fair value. ▪ U.S. and Foreign Government Securities : U.S. and foreign government securities consist of investments in Treasury Nominal Bonds and Inflation Protected Securities and municipal securities. Government securities are valued at a price that is based on a compilation of primarily observable market information, such as broker quotes. Matrix pricing, yield curves and indices are used when broker quotes are not available. ▪ Corporate Debt Instruments : Corporate debt instruments are valued at a price that is based on a compilation of primarily observable market information, such as broker quotes. Matrix pricing, yield curves and indices are used when broker quotes are not available. ▪ Common Stock : Common stocks are valued based on the price of the security as listed on an open active exchange on last trade date. ▪ Collective Investment Funds : Collective investment funds consist of funds that are intended to mirror indices such as Standard & Poor’s 500 Index and MSCI EAFE Index. They are valued on the basis of the relative interest of each participating investor in the fair value of the underlying assets of each of the respective collective investment funds. The underlying assets are valued based on the net asset value (“NAV”), which is provided by the investment account manager as a practical expedient to estimate fair value. These investments are not classified by level but are disclosed to permit reconciliation to the fair value of plan assets.
Income Tax Uncertainties, Policy	Altria recognizes accrued interest and penalties associated with uncertain tax positions as part of the tax provision.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of New Accounting Pronouncements and Changes in Accounting Principles	The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, Altria: Standards Description Effective Date for Public Entity Effect on Financial Statements ASU Nos. 2016-13; 2018-19; 2019-04; 2019-05; 2019-10; 2019-11 Measurement of Credit Losses on Financial Instruments (Topic 326) The guidance replaces the current incurred loss impairment methodology for recognizing credit losses for financial assets with a methodology that reflects the entity’s current estimate of all expected credit losses and requires consideration of a broader range of reasonable and supportable information for estimating credit losses. The guidance is effective for annual reporting periods beginning after December 15, 2019, including interim periods within that reporting period. Altria’s adoption of this guidance is not expected to have a material impact on its consolidated financial statements. ASU No. 2018-15 Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (Subtopic 350-40) The guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The guidance is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Altria’s adoption of this guidance is not expected to have a material impact on its consolidated financial statements. ASU 2019-12 Simplifying the Accounting for Income Taxes (Topic 740) The guidance removes certain exceptions for investments, intraperiod allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is permitted, including adoption in any interim period. Altria is in the process of evaluating the impact of this guidance on its consolidated financial statements and related disclosures. ASU 2020-01 Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is permitted, including adoption in any interim period. Altria is in the process of evaluating the impact of this guidance on its consolidated financial statements and related disclosures.

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets, net (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill	The changes in goodwill and net carrying amount of intangible assets were as follows: 2019 2018 (in millions) Goodwill Other Intangible Assets, net Goodwill Other Intangible Assets, net Balance at January 1 $ 5,196 $ 12,279 $ 5,307 $ 12,400 Changes due to: Acquisitions (1) 55 451 — 15 Asset impairment (74 ) — (111 ) (98 ) Amortization — (43 ) — (38 ) Balance at December 31 $ 5,177 $ 12,687 $ 5,196 $ 12,279 (1) Substantially all of the 2019 changes reflect Helix’s acquisition of the Burger Group, which held assets consisting primarily of intellectual property. For further discussion, see Note 1 . Background and Basis of Presentation . Goodwill and other intangible assets, net, by segment were as follows: Goodwill Other Intangible Assets, net (in millions) December 31, 2019 December 31, 2018 December 31, 2019 December 31, 2018 Smokeable products $ 99 $ 99 $ 3,071 $ 3,037 Smokeless products 5,078 5,023 9,196 8,825 Wine — 74 238 239 Other — — 182 178 Total $ 5,177 $ 5,196 $ 12,687 $ 12,279
Schedule of Indefinite-Lived Intangible Assets	Other intangible assets consisted of the following: December 31, 2019 December 31, 2018 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Indefinite-lived intangible assets $ 11,676 $ — $ 11,846 $ — Definite-lived intangible assets 1,275 264 654 221 Total other intangible assets $ 12,951 $ 264 $ 12,500 $ 221
Schedule of Definite-Lived Intangible Assets	Other intangible assets consisted of the following: December 31, 2019 December 31, 2018 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Indefinite-lived intangible assets $ 11,676 $ — $ 11,846 $ — Definite-lived intangible assets 1,275 264 654 221 Total other intangible assets $ 12,951 $ 264 $ 12,500 $ 221

Asset Impairment, Exit and Im_2

Asset Impairment, Exit and Implementation Costs (Tables)	12 Months Ended
	Dec. 31, 2019
Restructuring and Related Activities [Abstract]
Pre-tax Asset Impairment, Exit, and Implementation Costs	Pre-tax asset impairment, exit and implementation costs consisted of the following: (in millions) Asset Impairment and Exit Costs Implementation Costs Total For the year ended December 31, 2019 2018 2017 2019 (1) 2018 (2) 2017 (2) 2019 2018 2017 Smokeable products $ 59 $ 79 $ 4 $ 33 $ 1 $ 17 $ 92 $ 80 $ 21 Smokeless products 9 20 28 5 3 28 14 23 56 Wine (3) 76 54 — — — — 76 54 — All other 14 227 — (10 ) 63 — 4 290 — General corporate 1 3 — — — — 1 3 — Total 159 383 32 28 67 45 187 450 77 Plus amounts included in net periodic benefit (income) cost, excluding service cost (4) 29 3 1 — — — 29 3 1 Total $ 188 $ 386 $ 33 $ 28 $ 67 $ 45 $ 216 $ 453 $ 78 (1) Included in cost of sales ( $2 million ) and marketing, administration and research costs ( $26 million ) in Altria’s consolidated statement of earnings (losses). (2) Included in cost of sales in Altria’s consolidated statements of earnings (losses). (3) Includes impairment of goodwill for the wine reporting unit in 2019 and impairment of the Columbia Crest trademark in 2018. See Note 4 . Goodwill and Other Intangible Assets, net . (4) Represents settlement and curtailment costs. See Note 17 . Benefit Plans .
Schedule of Movement in Restructuring Liabilities	The movement in the restructuring liabilities, substantially all of which were severance liabilities, for the years ended December 31, 2019 and 2018 was as follows: (in millions) Balances at December 31, 2017 $ 33 Charges 154 Cash spent (32 ) Balances at December 31, 2018 155 Charges 59 Cash spent (147 ) Balances at December 31, 2019 $ 67

Investments in Equity Securit_2

Investments in Equity Securities (Tables)	12 Months Ended
	Dec. 31, 2019
Equity Method Investments and Joint Ventures [Abstract]
Investment	Altria’s investments at December 31, 2019 and 2018 consisted of the following: Carrying Amount (in millions) December 31, 2019 December 31, 2018 ABI $ 18,071 $ 17,696 JUUL 4,205 12,800 Cronos (1) 1,305 — Total $ 23,581 $ 30,496 ( 1) Includes investment in Acquired Common Shares ( $1,002 million ), the Cronos warrant ( $234 million ) and the Fixed-price Preemptive Rights ( $69 million ) as discussed further below.
Equity Method Investments	Summary financial data of ABI is as follows: For Altria’s Year Ended December 31, (in millions) 2019 (1) 2018 (1) 2017 (1) Net revenues $ 54,187 $ 55,500 $ 56,004 Gross profit $ 33,735 $ 34,986 $ 34,376 Earnings from continuing operations $ 10,530 $ 9,020 $ 6,769 Net earnings $ 10,530 $ 9,020 $ 6,845 Net earnings attributable to ABI $ 9,189 $ 7,641 $ 5,473 At September 30, (in millions) 2019 (1) 2018 (1) Current assets $ 27,353 $ 20,289 Long-term assets $ 199,591 $ 207,921 Current liabilities $ 36,819 $ 32,019 Long-term liabilities $ 119,025 $ 130,812 Noncontrolling interests $ 8,765 $ 7,251 (1) Reflects the one-quarter lag. Earnings from equity investments accounted for under the equity method of accounting for the years ended December 31, 2019, 2018 and 2017 consisted of the following: (in millions) 2019 2018 2017 ABI $ 1,229 $ 890 $ 532 Cronos (1) 496 — — Total $ 1,725 $ 890 $ 532 ( 1) Represents Altria’s share of Cronos’s earnings, substantially all of which relate to the change in fair value of Cronos’s derivative financial instruments associated with the issuance of additional shares. Summary financial data of Cronos is as follows: For Altria’s Year Ended December 31, (in millions) 2019 (1) Net revenues $ 21 Gross profit $ 10 Net earnings (2) $ 1,117 (in millions) At September 30, 2019 (1) Current assets $ 1,575 Long-term assets $ 511 Current liabilities $ 457 Long-term liabilities $ 7 Noncontrolling interests $ — (1) Reflecting the one-quarter lag: (i) summary financial data of Cronos’s results for Altria’s year ended December 31, 2019 include Cronos’s results for the period March 8, 2019 through September 30, 2019, and (ii) summary financial data of Cronos’s financial position is disclosed at September 30, 2019. (2) Substantially all of Cronos’s net earnings related to changes in fair value of Cronos’s derivative financial instruments associated with the issuance of additional shares.

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Value Measurement Inputs and Valuation Techniques	The fair values of the Fixed-price Preemptive Rights and warrant are estimated using Black-Scholes option-pricing models, adjusted for unobservable inputs, including probability factors and weighting of expected life, volatility levels and risk-free interest rates (which are classified in Level 3 of the fair value hierarchy) based on the following assumptions at: December 31, 2019 March 8, 2019 December 31, 2019 March 8, 2019 Fixed-price Preemptive Rights Warrant Expected life (1) 1.67 years 2.32 years 3.18 years 4 years Expected volatility (2) 81.61% 93.02% 81.61% 93.02% Risk-free interest rate (3)(4) 1.71% 1.61% 1.69% 1.67% Expected dividend yield (5) —% —% —% —% (1) Based on the weighted-average expected life of the Fixed-price Preemptive Rights (with a range from approximately 0.25 years to 7 years at December 31, 2019 and March 8, 2019) and the March 8, 2023 expiration date of the warrant. (2) Based on a blend of historical volatility levels of the underlying equity security and peer companies. (3) Based on the implied yield currently available on Canadian Treasury zero coupon issues weighted for the remaining expected life of the Fixed-price Preemptive Rights. (4) Based on the implied yield currently available on Canadian Treasury zero coupon issues and the expected life of the warrant. (5) Based on Cronos’s expected dividend payments .
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation	The following table provides a reconciliation of the beginning and ending balance of the Fixed-price Preemptive Rights and warrant, which are classified in Level 3 of the fair value hierarchy: (in millions) Balance at December 31, 2018 $ — Initial investment in Fixed-price Preemptive Rights and warrant 1,736 Exercise of Fixed-price Preemptive Rights (22 ) Pre-tax earnings (losses) recognized in net earnings (1,411 ) Balance at December 31, 2019 $ 303
Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location	The fair values of Altria’s derivative financial instruments on a gross basis included on the consolidated balance sheets were as follows: Fair Value of Assets Fair Value of Liabilities (in millions) Balance Sheet Classification December 31, 2019 December 31, 2018 Balance Sheet Classification December 31, 2019 December 31, 2018 Derivatives designated as hedging instruments: Foreign currency contracts Other current assets $ 46 $ 37 Other accrued liabilities $ 7 $ — Foreign currency contracts Other assets — 4 Other liabilities 21 4 Total $ 46 $ 41 $ 28 $ 4 Derivatives not designated as hedging instruments: Cronos warrant Investments in equity securities $ 234 $ — Fixed-price Preemptive Rights Investments in equity securities 69 — Total $ 303 $ — Total derivatives $ 349 $ 41 $ 28 $ 4
Derivative Instruments, Gain (Loss)	The pre-tax effects of Altria’s net investment hedges on accumulated other comprehensive losses and the consolidated statements of earnings (losses) were as follows: Gain (Loss) Recognized in Accumulated Other Comprehensive Losses (1) Gain (Loss) Recognized in Net Earnings (Losses) (1) (2) For the Years Ended December 31, (in millions) 2019 2018 2019 2018 Foreign currency contracts $ 23 $ 69 $ 36 $ 35 Foreign currency denominated debt 35 — — — Total $ 58 $ 69 $ 36 $ 35 (1) Net investment hedging activity was not material to Altria for the year ended December 31, 2017. (2) Related to amounts excluded from effectiveness testing.

Long-term Debt (Tables)

Long-term Debt (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Components of Long-Term Debt	At December 31, 2019 and 2018 , Altria’s long-term debt consisted of the following: (in millions) 2019 2018 USD notes, 2.625% to 10.20%, interest payable semi-annually, due through 2059 (1) $ 23,259 $ 13,000 USD Debenture, 7.75%, interest payable semi-annually, due 2027 42 42 Euro notes, 1.000% to 3.125%, interest payable annually, due through 2031 (2) 4,741 — 28,042 13,042 Less current portion of long-term debt 1,000 1,144 $ 27,042 $ 11,898 (1) Weighted-average coupon interest rate of 4.6% at December 31, 2019 and 2018 . (2) Weighted-average coupon interest rate of 2.0% at December 31, 2019.
Aggregate Maturities of Long-Term Debt	At December 31, 2019 , aggregate maturities of Altria’s long-term debt were as follows: (in millions) 2020 $ 1,000 2021 1,500 2022 2,900 2023 1,752 2024 2,400 Thereafter 18,723 28,275 Less: debt issuance costs 154 debt discounts 79 $ 28,042

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Schedule Components of Issued, Repurchased and Outstanding Shares	At December 31, 2019 , Altria had 12 billion shares of authorized common stock; issued, repurchased and outstanding shares of common stock were as follows: Shares Issued Shares Repurchased Shares Outstanding Balances, December 31, 2016 2,805,961,317 (862,689,093 ) 1,943,272,224 Stock award activity — (408,891 ) (408,891 ) Repurchases of common stock — (41,604,141 ) (41,604,141 ) Balances, December 31, 2017 2,805,961,317 (904,702,125 ) 1,901,259,192 Stock award activity — 676,727 676,727 Repurchases of common stock — (27,878,324 ) (27,878,324 ) Balances, December 31, 2018 2,805,961,317 (931,903,722 ) 1,874,057,595 Stock award activity — 427,276 427,276 Repurchases of common stock — (16,503,317 ) (16,503,317 ) Balances, December 31, 2019 2,805,961,317 (947,979,763 ) 1,857,981,554
Share Repurchases	For the years ended December 31, 2019 , 2018 and 2017 , Altria’s total share repurchase activity was as follows: July 2019 Share Repurchase Program January 2018 Share Repurchase Program July 2015 Share Repurchase Program Total (in millions, except per share data) 2019 2019 2018 2018 2017 2019 2018 2017 Total number of shares repurchased 10.1 6.4 27.6 0.3 41.6 16.5 27.9 41.6 Aggregate cost of shares repurchased $ 500 $ 345 $ 1,655 $ 18 $ 2,917 $ 845 $ 1,673 $ 2,917 Average price per share of shares repurchased $ 49.29 $ 54.36 $ 59.89 $ 71.68 $ 70.10 $ 51.24 $ 60.00 $ 70.10

Stock Plans (Tables)

Stock Plans (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock Activity	RSU activity was as follows for the year ended December 31, 2019 : Number of Shares Weighted-Average Grant Date Fair Value Per Share Balance at December 31, 2018 2,129,626 $ 64.94 Granted 719,677 $ 52.03 Vested (611,657 ) $ 59.78 Forfeited (328,004 ) $ 66.52 Balance at December 31, 2019 1,909,642 $ 61.46

Earnings per Share (Tables)

Earnings per Share (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Earnings (Losses) Per Share	Basic and diluted earnings (losses) per share (“EPS”) were calculated using the following: For the Years Ended December 31, (in millions) 2019 2018 2017 Net earnings (losses) attributable to Altria $ (1,293 ) $ 6,963 $ 10,222 Less: Distributed and undistributed earnings attributable to share-based awards (7 ) (8 ) (14 ) Earnings (losses) for basic and diluted EPS $ (1,300 ) $ 6,955 $ 10,208 Weighted-average shares for basic EPS 1,869 1,887 1,921 Plus: contingently issuable PSUs — 1 — Weighted-average shares for diluted EPS 1,869 1,888 1,921

Other Comprehensive Earnings__2

Other Comprehensive Earnings/losses (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The following tables set forth the changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria: (in millions) Benefit Plans ABI Currency Translation Adjustments and Other Accumulated Other Comprehensive Losses Balances, December 31, 2016 $ (2,048 ) $ — $ (4 ) $ (2,052 ) Other comprehensive earnings (losses) before reclassifications 52 (91 ) — (39 ) Deferred income taxes (21 ) 32 — 11 Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes 31 (59 ) — (28 ) Amounts reclassified to net earnings (losses) 291 8 — 299 Deferred income taxes (113 ) (3 ) — (116 ) Amounts reclassified to net earnings (losses), net of deferred income taxes 178 5 — 183 Other comprehensive earnings (losses), net of deferred income taxes 209 (54 ) (1) — 155 Balances, December 31, 2017 (1,839 ) (54 ) (4 ) (1,897 ) Adoption of ASU No. 2018-02 (2) (397 ) (11 ) — (408 ) Other comprehensive earnings (losses) before reclassifications (151 ) (323 ) (1 ) (475 ) Deferred income taxes 39 64 — 103 Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes (112 ) (259 ) (1 ) (372 ) Amounts reclassified to net earnings (losses) 241 (64 ) — 177 Deferred income taxes (61 ) 14 — (47 ) Amounts reclassified to net earnings (losses), net of deferred income taxes 180 (50 ) — 130 Other comprehensive earnings (losses), net of deferred income taxes 68 (309 ) (1) (1 ) (242 ) Balances, December 31, 2018 (2,168 ) (374 ) (5 ) (2,547 ) Other comprehensive earnings (losses) before reclassifications (204 ) (367 ) 26 (545 ) Deferred income taxes 51 75 — 126 Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes (153 ) (292 ) 26 (419 ) Amounts reclassified to net earnings (losses) 173 (34 ) — 139 Deferred income taxes (44 ) 7 — (37 ) Amounts reclassified to net earnings (losses), net of deferred income taxes 129 (27 ) — 102 Other comprehensive earnings (losses), net of deferred income taxes (24 ) (319 ) (1) 26 (317 ) Balances, December 31, 2019 $ (2,192 ) $ (693 ) $ 21 $ (2,864 ) (1) Primarily reflects currency translation adjustments. (2) Reflects the reclassification of the stranded income tax effects of the Tax Reform Act.
Reclassification out of Accumulated Other Comprehensive Income	The following table sets forth pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings (losses): For the Years Ended December 31, (in millions) 2019 2018 2017 Benefit Plans: (1) Net loss $ 200 $ 276 $ 325 Prior service cost/credit (27 ) (35 ) (34 ) 173 241 291 ABI (2) (34 ) (64 ) 8 Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses) $ 139 $ 177 $ 299 ( 1) Amounts are included in net defined benefit plan costs. For further details, see Note 17 . Benefit Plans. (2) Amounts are primarily included in earnings from equity investments. For further information, see Note 7 . Investments in Equity Securities.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Summary of Valuation Allowance [Table Text Block]	A reconciliation of the beginning and ending valuation allowances for the years ended December 31, 2019 , 2018 and 2017 was as follows: (in millions) 2019 2018 2017 Balance at beginning of year $ 71 $ — $ 240 Additions to valuation allowance related to Altria’s initial investment in Cronos 352 — — Additions to valuation allowance charged to income tax expense 2,063 71 — Reductions to valuation allowance credited to income tax benefit (159 ) — (240 ) Foreign currency translation (3 ) — — Balance at end of year $ 2,324 $ 71 $ —
Schedule of Earnings Before Income Taxes and Provision for Income Taxes	Earnings before income taxes and provision (benefit) for income taxes consisted of the following for the years ended December 31, 2019 , 2018 and 2017 : (in millions) 2019 2018 2017 Earnings (losses) before income taxes: United States $ 266 $ 9,441 $ 9,809 Outside United States 500 (100 ) 19 Total $ 766 $ 9,341 $ 9,828 Provision (benefit) for income taxes: Current: Federal $ 1,686 $ 1,911 $ 2,346 State and local 470 519 366 Outside United States 3 1 15 2,159 2,431 2,727 Deferred: Federal (78 ) (18 ) (3,213 ) State and local (19 ) (42 ) 86 Outside United States 2 3 1 (95 ) (57 ) (3,126 ) Total provision (benefit) for income taxes $ 2,064 $ 2,374 $ (399 )
Reconciliation of Beginning and Ending Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December 31, 2019 , 2018 and 2017 was as follows: (in millions) 2019 2018 2017 Balance at beginning of year $ 85 $ 66 $ 169 Additions based on tax positions related to the current year — — — Additions for tax positions of prior years 32 22 129 Reductions for tax positions due to lapse of statutes of limitations — — (4 ) Reductions for tax positions of prior years (16 ) (1 ) (208 ) Tax settlements (37 ) (2 ) (20 ) Balance at end of year $ 64 $ 85 $ 66
Schedule of Unrecognized Tax Benefits and Consolidated Liability for Tax Contingencies	Unrecognized tax benefits and Altria’s consolidated liability for tax contingencies at December 31, 2019 and 2018 were as follows: (in millions) 2019 2018 Unrecognized tax benefits $ 64 $ 85 Accrued interest and penalties 11 13 Tax credits and other indirect benefits (1 ) (1 ) Liability for tax contingencies $ 74 $ 97
Reconciliation of Effective Tax Rate and U.S. Federal Statutory Rate	A reconciliation between actual income taxes and amounts computed by applying the federal statutory rate to earnings (losses) before income taxes for the years ended December 31, 2019 , 2018 and 2017 is as follows: 2019 2018 2017 (dollars in millions) $ % $ % $ % U.S. federal statutory rate $ 161 21.0 % $ 1,962 21.0 % $ 3,440 35.0 % Increase (decrease) resulting from: State and local income taxes, net of federal tax benefit 356 46.5 377 4.0 345 3.5 Re-measurement of net deferred tax liabilities — — — — (3,063 ) (31.2 ) Tax basis in foreign investments 84 11.0 140 1.5 (763 ) (7.8 ) Deemed repatriation tax — — 14 0.1 413 4.2 Uncertain tax positions (40 ) (5.2 ) 8 0.1 (89 ) (0.9 ) Investment in ABI (210 ) (27.4 ) (104 ) (1.1 ) (580 ) (5.9 ) Investment in JUUL 1,808 236.0 15 0.2 — — Investment in Cronos (66 ) (8.6 ) — — — — Domestic manufacturing deduction — — — — (181 ) (1.8 ) Other (1) (29 ) (3.8 ) (38 ) (0.4 ) 79 0.8 Effective tax rate $ 2,064 269.5 % $ 2,374 25.4 % $ (399 ) (4.1 )% (1) Other in 2019 is primarily deferred profit sharing dividends tax benefit of $21 million and miscellaneous immaterial items.
Schedule of Deferred Income Tax Assets and Liabilities	The tax effects of temporary differences that gave rise to deferred income tax assets and liabilities consisted of the following at December 31, 2019 and 2018 : (in millions) 2019 2018 Deferred income tax assets: Accrued postretirement and postemployment benefits $ 491 $ 500 Settlement charges 833 864 Accrued pension costs 131 155 Investment in JUUL 2,047 — Investment in Cronos 197 — Net operating losses and tax credit carryforwards 92 57 Total deferred income tax assets 3,791 1,576 Deferred income tax liabilities: Property, plant and equipment (255 ) (251 ) Intangible assets (2,758 ) (2,689 ) Investment in ABI (3,115 ) (3,038 ) Finance assets, net (204 ) (313 ) Other (158 ) (115 ) Total deferred income tax liabilities (6,490 ) (6,406 ) Valuation allowances (2,324 ) (71 ) Net deferred income tax liabilities $ (5,023 ) $ (4,901 )

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Segment Data Schedule	Segment data were as follows: For the Years Ended December 31, (in millions) 2019 2018 2017 Net revenues: Smokeable products $ 21,996 $ 22,297 $ 22,636 Smokeless products 2,367 2,262 2,155 Wine 689 691 698 All other 58 114 87 Net revenues $ 25,110 $ 25,364 $ 25,576 Earnings (losses) before income taxes: Operating companies income (loss): Smokeable products $ 9,009 $ 8,408 $ 8,426 Smokeless products 1,580 1,431 1,306 Wine (3 ) 50 146 All other (16 ) (421 ) (51 ) Amortization of intangibles (44 ) (38 ) (21 ) General corporate expenses (199 ) (315 ) (213 ) Corporate asset impairment and exit costs (1 ) — — Operating income 10,326 9,115 9,593 Interest and other debt expense, net (1,280 ) (665 ) (705 ) Net periodic benefit income (cost), excluding service cost 37 34 (37 ) Earnings from equity investments 1,725 890 532 Impairment of JUUL equity securities (8,600 ) — — Loss on Cronos-related financial instruments (1,442 ) — — Gain (loss) on ABI/SABMiller business combination — (33 ) 445 Earnings (losses) before income taxes $ 766 $ 9,341 $ 9,828
Schedule of Depreciation Expense and Capital Expenditures of Segments	Details of Altria’s depreciation expense and capital expenditures were as follows: For the Years Ended December 31, (in millions) 2019 2018 2017 Depreciation expense: Smokeable products $ 88 $ 90 $ 93 Smokeless products 27 28 29 Wine 41 40 40 General corporate and other 26 31 26 Total depreciation expense $ 182 $ 189 $ 188 Capital expenditures: Smokeable products $ 61 $ 81 $ 39 Smokeless products 44 73 61 Wine 63 40 53 General corporate and other 78 44 46 Total capital expenditures $ 246 $ 238 $ 199
Schedule of NPM Adjustment Items	For the years ended December 31, 2018 and 2017 , pre-tax (income) expense for NPM adjustment items was recorded in Altria’s consolidated statements of earnings (losses) as follows: (in millions) 2018 2017 Smokeable products segment $ (145 ) $ (5 ) Interest and other debt expense, net — 9 Total $ (145 ) $ 4
Schedule of Pre-tax Tobacco and Health Litigation Charges	For the years ended December 31, 2019 , 2018 and 2017 , pre-tax charges related to certain tobacco and health litigation items were recorded in Altria’s consolidated statements of earnings (losses) as follows: (in millions) 2019 2018 2017 Smokeable products segment $ 72 $ 103 $ 72 Smokeless products segment — 10 — Interest and other debt expense, net 5 18 8 Total $ 77 $ 131 $ 80

Benefit Plans (Tables)

Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2019
Retirement Benefits [Abstract]
Projected Benefit Obligations, Plan Assets and Funded Status of Pension Plans	The benefit obligations, plan assets and funded status of Altria’s pension and postretirement plans at December 31, 2019 and 2018 were as follows: Pension Postretirement (in millions) 2019 2018 2019 2018 Change in benefit obligation: Benefit obligation at beginning of year $ 7,726 $ 8,510 $ 2,040 $ 2,335 Service cost 70 81 16 18 Interest cost 306 276 76 70 Benefits paid (493 ) (488 ) (126 ) (130 ) Actuarial (gains) losses 1,025 (660 ) 78 (298 ) Settlement and curtailment 25 (18 ) 7 — Other — 25 — 45 Benefit obligation at end of year 8,659 7,726 2,091 2,040 Change in plan assets: Fair value of plan assets at beginning of year 7,138 8,015 211 270 Actual return on plan assets 1,466 (430 ) 45 (14 ) Employer contributions 56 41 — — Benefits paid (493 ) (488 ) (43 ) (45 ) Fair value of plan assets at end of year 8,167 7,138 213 211 Funded status at December 31 $ (492 ) $ (588 ) $ (1,878 ) $ (1,829 ) Amounts recognized on Altria’s consolidated balance sheets were as follows: Other accrued liabilities $ (26 ) $ (44 ) $ (81 ) $ (80 ) Accrued pension costs (473 ) (544 ) — — Other assets 7 — — — Accrued postretirement health care costs — — (1,797 ) (1,749 ) $ (492 ) $ (588 ) $ (1,878 ) $ (1,829 )
Net Pension Liability Recognized in Consolidated Balance Sheets	The benefit obligations, plan assets and funded status of Altria’s pension and postretirement plans at December 31, 2019 and 2018 were as follows: Pension Postretirement (in millions) 2019 2018 2019 2018 Change in benefit obligation: Benefit obligation at beginning of year $ 7,726 $ 8,510 $ 2,040 $ 2,335 Service cost 70 81 16 18 Interest cost 306 276 76 70 Benefits paid (493 ) (488 ) (126 ) (130 ) Actuarial (gains) losses 1,025 (660 ) 78 (298 ) Settlement and curtailment 25 (18 ) 7 — Other — 25 — 45 Benefit obligation at end of year 8,659 7,726 2,091 2,040 Change in plan assets: Fair value of plan assets at beginning of year 7,138 8,015 211 270 Actual return on plan assets 1,466 (430 ) 45 (14 ) Employer contributions 56 41 — — Benefits paid (493 ) (488 ) (43 ) (45 ) Fair value of plan assets at end of year 8,167 7,138 213 211 Funded status at December 31 $ (492 ) $ (588 ) $ (1,878 ) $ (1,829 ) Amounts recognized on Altria’s consolidated balance sheets were as follows: Other accrued liabilities $ (26 ) $ (44 ) $ (81 ) $ (80 ) Accrued pension costs (473 ) (544 ) — — Other assets 7 — — — Accrued postretirement health care costs — — (1,797 ) (1,749 ) $ (492 ) $ (588 ) $ (1,878 ) $ (1,829 )
Assumptions used to Determine Benefit Obligations	The following assumptions were used to determine Altria’s pension and postretirement benefit obligations at December 31: Pension Postretirement 2019 2018 2019 2018 Discount rate 3.4 % 4.4 % 3.4 % 4.4 % Rate of compensation increase 4.0 4.0 — — Health care cost trend rate assumed for next year — — 6.5 6.5 Ultimate trend rate — — 5.0 5.0 Year that the rate reaches the ultimate trend rate — — 2025 2025
Schedule of Net Benefit Costs	Net periodic benefit cost (income) consisted of the following for the years ended December 31, 2019 , 2018 and 2017 : Pension Postretirement (in millions) 2019 2018 2017 2019 2018 2017 Service cost $ 70 $ 81 $ 75 $ 16 $ 18 $ 16 Interest cost 306 276 288 76 70 76 Expected return on plan assets (576 ) (585 ) (601 ) (15 ) (19 ) — Amortization: Net loss 159 225 197 5 21 25 Prior service cost (credit) 6 4 4 (30 ) (42 ) (38 ) Settlement and curtailment 27 16 86 5 — — Net periodic benefit cost (income) $ (8 ) $ 17 $ 49 $ 57 $ 48 $ 79
Schedule Of Termination Settlement And Curtailment Cost	The amounts included in settlement and curtailment in the table above were comprised of the following changes: Pension Postretirement (in millions) 2019 2018 2017 2019 Benefit obligation $ 6 $ — $ — $ 10 Other comprehensive earnings/losses: Net loss 20 13 86 — Prior service cost (credit) 1 3 — (5 ) $ 27 $ 16 $ 86 $ 5
Schedule Of Assumptions To Determine Net Periodic Benefit Cost	The following assumptions were used to determine Altria’s net periodic benefit cost for the years ended December 31: Pension Postretirement 2019 2018 2017 2019 2018 2017 Discount rates: Service cost 4.6 % 3.8 % 4.3 % 4.5 % 3.8 % 4.3 % Interest cost 4.0 3.3 3.5 4.0 3.3 3.5 Expected rate of return on plan assets 7.8 7.8 8.0 7.8 7.8 — Rate of compensation increase 4.0 4.0 4.0 — — — Health care cost trend rate — — — 6.5 7.0 7.0
Schedule of Fair Value of Plan Assets by Asset Category	The fair values of the pension plan assets by asset category at December 31, 2019 and 2018 were as follows: 2019 2018 (in millions) Level 1 Level 2 Total Level 1 Level 2 Total U.S. and foreign government securities or their agencies: U.S. government and agencies $ — $ 811 $ 811 $ — $ 868 $ 868 U.S. municipal bonds — 57 57 — 73 73 Foreign government and agencies — 98 98 — 115 115 Corporate debt instruments: Above investment grade — 3,523 3,523 — 1,726 1,726 Below investment grade and no rating — 521 521 — 478 478 Common stock: International equities 296 — 296 237 — 237 U.S. equities 1,263 — 1,263 1,082 — 1,082 Other, net (4 ) 479 475 36 339 375 $ 1,555 $ 5,489 $ 7,044 $ 1,355 $ 3,599 $ 4,954 Investments measured at NAV as a practical expedient for fair value: Collective investment funds U.S. large cap $ 825 $ 1,722 U.S. small cap 386 328 International developed markets 106 86 Total investments measured at NAV $ 1,317 $ 2,136 Other (194 ) 48 Fair value of plan assets, net $ 8,167 $ 7,138 Level 3 holdings and transactions were immaterial to total plan assets at December 31, 2019 and 2018 . The fair value of the postretirement plan assets at December 31, 2019 and 2018 were as follows: 2019 2018 (in millions) Level 1 Level 2 Total Level 1 Level 2 Total U.S. and foreign government securities or their agencies: U.S. government and agencies $ — $ 11 $ 11 $ — $ 13 $ 13 Foreign government and agencies — 5 5 — 3 3 Corporate debt instruments: Above investment grade — 63 63 — 71 71 Below investment grade and no rating — 9 9 — 8 8 Other, net — 7 7 2 2 4 $ — $ 95 $ 95 $ 2 $ 97 $ 99 Investments measured at NAV as a practical expedient for fair value: Collective investment funds: U.S. large cap $ 97 $ 77 International developed markets 24 26 Total investments measured at NAV $ 121 $ 103 Other (3 ) 9 Fair value of plan assets, net $ 213 $ 211 The actual composition of Altria’s plan assets at December 31, 2019 was broadly characterized with the following allocation: Pension Postretirement Equity securities 35 % 56 % Corporate bonds 52 % 34 % U.S. Treasury and foreign government securities 13 % 10 %
Estimated Future Benefit Payments	Estimated future benefit payments at December 31, 2019 were as follows: (in millions) Pension Postretirement 2020 $ 472 $ 126 2021 477 124 2022 479 121 2023 483 117 2024 481 115 2025-2029 2,430 555
Schedule of Amounts Recognized in Other Comprehensive Income (Loss)	The amounts recorded in accumulated other comprehensive losses at December 31, 2019 consisted of the following: (in millions) Pension Post- retirement Post- employment Total Net loss $ (2,565 ) $ (389 ) $ (45 ) $ (2,999 ) Prior service (cost) credit (27 ) 72 (5 ) 40 Deferred income taxes 670 86 11 767 Amounts recorded in accumulated other comprehensive losses $ (1,922 ) $ (231 ) $ (39 ) $ (2,192 ) The amounts recorded in accumulated other comprehensive losses at December 31, 2018 consisted of the following: (in millions) Pension Post- retirement Post- employment Total Net loss $ (2,591 ) $ (327 ) $ (78 ) $ (2,996 ) Prior service (cost) credit (34 ) 108 (6 ) 68 Deferred income taxes 679 61 20 760 Amounts recorded in accumulated other comprehensive losses $ (1,946 ) $ (158 ) $ (64 ) $ (2,168 )
Movements in Other Comprehensive Earnings/Losses	The movements in other comprehensive earnings/losses during the year ended December 31, 2019 were as follows: (in millions) Pension Post- retirement Post- employment Total Amounts reclassified to net earnings as components of net periodic benefit cost: Amortization: Net loss $ 159 $ 5 $ 20 $ 184 Prior service cost/credit 6 (30 ) 1 (23 ) Other expense (income): Net loss 20 — (4 ) 16 Prior service cost/credit 1 (5 ) — (4 ) Deferred income taxes (47 ) 7 (4 ) (44 ) $ 139 $ (23 ) $ 13 $ 129 Other movements during the year: Net loss $ (153 ) $ (67 ) $ 17 $ (203 ) Prior service cost/credit — (1 ) — (1 ) Deferred income taxes 38 18 (5 ) 51 $ (115 ) $ (50 ) $ 12 $ (153 ) Total movements in other comprehensive earnings/losses $ 24 $ (73 ) $ 25 $ (24 ) The movements in other comprehensive earnings/losses during the year ended December 31, 2018 were as follows: (in millions) Pension Post-retirement Post-employment Total Amounts reclassified to net earnings as components of net periodic benefit cost: Amortization: Net loss $ 225 $ 21 $ 17 $ 263 Prior service cost/credit 4 (42 ) — (38 ) Other expense (income): Net loss 13 — — 13 Prior service cost/credit 3 — — 3 Deferred income taxes (61 ) 4 (4 ) (61 ) $ 184 $ (17 ) $ 13 $ 180 Other movements during the year: Adoption of ASU 2018-02 (1) $ (330 ) $ (55 ) $ (12 ) $ (397 ) Net loss (336 ) 264 (2 ) (74 ) Prior service cost/credit (26 ) (45 ) (6 ) (77 ) Deferred income taxes 91 (54 ) 2 39 $ (601 ) $ 110 $ (18 ) $ (509 ) Total movements in other comprehensive earnings/losses $ (417 ) $ 93 $ (5 ) $ (329 ) (1) Reflects the reclassification of the stranded income tax effects of the Tax Reform Act. The movements in other comprehensive earnings/losses during the year ended December 31, 2017 were as follows: (in millions) Pension Post- retirement Post- employment Total Amounts reclassified to net earnings as components of net periodic benefit cost: Amortization: Net loss $ 197 $ 25 $ 17 $ 239 Prior service cost/credit 4 (38 ) — (34 ) Other expense (income): Net loss 86 — — 86 Deferred income taxes (113 ) 6 (6 ) (113 ) $ 174 $ (7 ) $ 11 $ 178 Other movements during the year: Net loss $ 81 $ (56 ) $ (11 ) $ 14 Prior service cost/credit — 38 — 38 Deferred income taxes (32 ) 7 4 (21 ) $ 49 $ (11 ) $ (7 ) $ 31 Total movements in other comprehensive earnings/losses $ 223 $ (18 ) $ 4 $ 209

Additional Information (Tables)

Additional Information (Tables)	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Other Nonoperating Income (Expense)	For the Years Ended December 31, (in millions) 2019 2018 2017 Research and development expense $ 168 $ 252 $ 241 Advertising expense $ 33 $ 37 $ 29 Interest and other debt expense, net: Interest expense $ 1,322 $ 697 $ 736 Interest income (42 ) (32 ) (31 ) $ 1,280 $ 665 $ 705
Schedule of Valuation and Qualifying Accounts	The activity in the allowance for discounts and allowance for returned goods for the years ended December 31, 2019 , 2018 and 2017 was as follows: (in millions) 2019 2018 2017 Discounts Returned Goods Discounts Returned Goods Discounts Returned Goods Balance at beginning of year $ — $ 32 $ — $ 40 $ — $ 49 Charged to costs and expenses 604 127 620 97 626 130 Deductions (1) (604 ) (127 ) (620 ) (105 ) (626 ) (139 ) Balance at end of year $ — $ 32 $ — $ 32 $ — $ 40 (1) Represents the recording of discounts and returns for which allowances were created . The activity in the allowance for losses on finance assets for the years ended December 31, 2019 , 2018 and 2017 was as follows: (in millions) 2019 2018 2017 Balance at beginning of year $ 19 $ 23 $ 32 Decrease to allowance — (4 ) (9 ) Balance at end of year $ 19 $ 19 $ 23

Contingencies (Tables)

Contingencies (Tables)	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Contingencies	The changes in Altria’s accrued liability for tobacco and health litigation items, including related interest costs, for the periods specified below are as follows: (in millions) 2019 2018 2017 Accrued liability for tobacco and health litigation items at beginning of year (1) $ 112 $ 106 $ 47 Pre-tax charges for: Tobacco and health litigation 72 (1)(2) 113 72 Related interest costs 5 18 8 Payments (1) (175 ) (3) (125 ) (21 ) Accrued liability for tobacco and health litigation items at end of period (1) $ 14 $ 112 $ 106 (1) Includes amounts related to the costs of implementing the corrective communications remedy related to the Federal Government’s Lawsuit discussed below. (2) Includes approximately $22 million related to pre-trial resolution of approximately 300 tobacco and health cases. (3) Includes approximately $20 million in payments related to above-mentioned pre-trial resolution of approximately 300 tobacco and health cases (the remaining approximately $2 million was accrued but not paid in 2019). Currently Pending Engle Cases with Accrued Liabilities (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Compensatory Damages (All Defendants) Punitive Damages (PM USA) Appeal Status Accrual (1) Berger ( Cote ) September 2014 PM USA Federal Court - Middle District of Florida $6 million $21 million The Eleventh Circuit Court of Appeals reinstated the punitive and compensatory damages awards and remanded the case to the district court. PM USA’s challenge to the punitive damages award was denied by the district court. PM USA’s appeal to the Eleventh Circuit Court of Appeals is pending. $6 million accrual in the fourth quarter of 2018 (1) Accrual amounts include interest and associated costs, if applicable. For cases with multiple defendants, if any, accrual amounts reflect the portion of compensatory damages PM USA believes it will have to pay if the case is ultimately decided in plaintiff’s favor after taking into account any portion potentially payable by the other defendant(s). Other Currently Pending Engle Cases with Verdicts Against PM USA (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Compensatory Damages (1) Punitive Damages Appeal Status Cuddihee January 2020 PM USA Duval $3 million $0 Trial court entered final judgment. Defendant to file one or more post-trial motions. Rintoul (Caprio) November 2019 PM USA and R.J. Reynolds Broward $9 million ($5 million PM USA) $74 million Defendants’ post-trial motions pending. Gloger November 2019 PM USA and R.J. Reynolds Miami-Dade $15 million ($5 million PM USA) $11 million Appeal by defendants to Third District Court of Appeal pending. McCall March 2019 PM USA Broward <$1 million (<$1 million PM USA) <$1 million New trial ordered on punitive damages. Neff March 2019 PM USA and R.J. Reynolds Broward $4 million $2 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Frogel March 2019 PM USA Palm Beach <$1 million (<$1 million PM USA) $0 Appeals by plaintiff and defendant to Fourth District Court of Appeal pending. Mahfuz February 2019 PM USA and R.J. Reynolds Broward $12 million $10 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Holliman February 2019 PM USA Miami-Dade $3 million $0 Defendant’s appeal to Third District Court of Appeal pending. Chadwell September 2018 PM USA Miami-Dade $2 million $0 Appeals by defendant and plaintiff to Third District Court of Appeal pending. Kaplan July 2018 PM USA and R.J. Reynolds Broward $2 million $2 million Appeals by defendants and plaintiff to Fourth District Court of Appeal pending. Landi June 2018 PM USA and R.J. Reynolds Broward $8 million $5 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Theis May 2018 PM USA and R.J. Reynolds Sarasota $7 million $10 million Second District Court of Appeal affirmed judgment. Defendants’ post-appeal motion pending. Freeman March 2018 PM USA Alachua $4 million $0 First District Court of Appeal reversed judgment against PM USA. Plaintiff petitioned Florida Supreme Court for review. This case is currently stayed . R. Douglas November 2017 PM USA Duval <$1 million $0 Awaiting entry of final judgment by the trial court. Sommers April 2017 PM USA Miami-Dade $1 million $0 Third District Court of Appeal affirmed compensatory damages award and granted new trial on punitive damages. Defendant petitioned Florida Supreme Court for review. Other Currently Pending Engle Cases with Verdicts Against PM USA (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Compensatory Damages (1) Punitive Damages Appeal Status Santoro March 2017 PM USA, R.J. Reynolds and Liggett Group Broward $2 million $0 Trial court set aside punitive damages award; appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Cooper (Blackwood) September 2015 PM USA and R.J. Reynolds Broward $5 million $0 Fourth District Court of Appeal affirmed judgment and granted a new trial on punitive damages. D. Brown January 2015 PM USA Federal Court - Middle District of Florida $8 million $9 million Appeal by defendant to U.S. Court of Appeals for the Eleventh Circuit pending. Kerrivan October 2014 PM USA and R.J. Reynolds Federal Court - Middle District of Florida $16 million $16 million Appeal by defendants to U.S. Court of Appeals for the Eleventh Circuit pending. Harris July 2014 PM USA, Federal Court - Middle District of Florida $2 million (<$ 1 million PM USA) $0 Appeals by plaintiff and defendants to U.S. Court of Appeals for the Eleventh Circuit pending. (1) PM USA’s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies. Engle Cases Concluded Within Past 12 Months (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Accrual Date Payment Amount (if any) Payment Date Alvarez Del Real September 2019 PM USA Miami-Dade Fourth quarter of 2019 <$1 million October 2019 Zingaro May 2019 PM USA and Broward Third quarter of 2019 <$1 million October 2019 Bryant December 2017 PM USA Escambia Second quarter of 2019 <$1 million July 2019 Wallace October 2017 PM USA and Brevard Second quarter of 2019 $26 million May 2019 J. Brown February 2017 PM USA and Pinellas First quarter of 2019 $4 million April 2019 L. Martin May 2017 PM USA Miami-Dade First quarter of 2019 $2 million April 2019 Danielson November 2015 PM USA Escambia First quarter of 2019 $3 million March 2019 S. Martin November 2016 PM USA and Broward First quarter of 2019 $5 million March 2019 Searcy April 2013 PM USA and Federal Court - Middle District of Florida Third quarter of 2018 $2 million March 2019 Boatright November 2014 PM USA and Liggett Group Polk Second quarter of 2018 $42 million March 2019 M. Brown May 2015 PM USA Duval Second quarter of 2018 $8 million March 2019 Jordan (1) August 2015 PM USA Duval Second quarter of 2018 $11 million March 2019 Pardue December 2016 PM USA and Alachua Second and Third quarters of 2018 $11 million March 2019 McKeever February 2015 PM USA Broward Fourth quarter of 2017 $21 million March 2019 Boulter December 2018 PM USA and Lee Fourth quarter of 2018 <$1 million January 2019 (1) The trial court also awarded plaintiff approximately $4 million in fees and costs, which PM USA has appealed. The table below lists the number of certain tobacco-related cases pending in the U.S. against PM USA and, in some instances, Altria as of December 31, 2019, 2018 and 2017: 2019 2018 2017 Individual Smoking and Health Cases (1) 104 100 92 Health Care Cost Recovery Actions (2) 1 1 1 E-vapor Cases (3) 101 — — Other Tobacco-Related Cases (4) 4 4 7 (1) Includes 21 cases filed in Massachusetts and 43 non- Engle cases filed in Florida. Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the Engle case (these Engle progeny cases are discussed below in Smoking and Health Litigation - Engle Class Action ). Also does not include 1,472 cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (“ETS”). The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 ( Broin ). The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages, but prohibited them from seeking punitive damages. In March 2018, 923 of these cases were voluntarily dismissed without prejudice. (2) See Health Care Cost Recovery Litigation - Federal Government’s Lawsuit below. (3) Includes 22 class action lawsuits, 76 individual lawsuits, two state or local government lawsuits and one lawsuit filed by a school district relating to JUUL e-vapor products. JUUL is an additional named defendant in each of these lawsuits. (4) For 2019, includes two inactive smoking and health cases alleging personal injury or seeking court-supervised programs or ongoing medical monitoring and purporting to be brought on behalf of a class of individual plaintiffs, including one case in which the aggregated claims of a number of individual plaintiffs are to be tried in a single proceeding, and two inactive class action lawsuits alleging that use of the terms “Lights” and “Ultra Lights” constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO.

Condensed Consolidating Finan_2

Condensed Consolidating Financial Information (Tables)	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheets (in millions of dollars) ____________________________ at December 31, 2019 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Assets Cash and cash equivalents $ 2,022 $ — $ 95 $ — $ 2,117 Receivables — 30 122 — 152 Inventories: Leaf tobacco — 494 380 — 874 Other raw materials — 120 72 — 192 Work in process — 4 692 — 696 Finished product — 119 412 — 531 — 737 1,556 — 2,293 Due from Altria and subsidiaries 88 4,005 1,359 (5,452 ) — Income taxes 80 47 38 (49 ) 116 Other current assets 53 17 76 — 146 Total current assets 2,243 4,836 3,246 (5,501 ) 4,824 Property, plant and equipment, at cost — 2,956 2,118 — 5,074 Less accumulated depreciation — 2,166 909 — 3,075 — 790 1,209 — 1,999 Goodwill — — 5,177 — 5,177 Other intangible assets, net — 2 12,685 — 12,687 Investments in equity securities 18,071 — 5,510 — 23,581 Investment in consolidated subsidiaries 19,312 2,831 — (22,143 ) — Due from Altria and subsidiaries 4,790 — — (4,790 ) — Other assets 58 951 603 (609 ) 1,003 Total Assets $ 44,474 $ 9,410 $ 28,430 $ (33,043 ) $ 49,271 Condensed Consolidating Balance Sheets (Continued) (in millions of dollars) ____________________________ at December 31, 2019 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Liabilities Current portion of long-term debt $ 1,000 $ — $ — $ — $ 1,000 Accounts payable — 146 179 — 325 Accrued liabilities: Marketing — 320 73 — 393 Settlement charges — 3,340 6 — 3,346 Other 576 482 536 (49 ) 1,545 Dividends payable 1,565 — — — 1,565 Due to Altria and subsidiaries 4,693 514 245 (5,452 ) — Total current liabilities 7,834 4,802 1,039 (5,501 ) 8,174 Long-term debt 27,042 — — — 27,042 Deferred income taxes 3,099 — 2,593 (609 ) 5,083 Accrued pension costs 197 — 276 — 473 Accrued postretirement health care costs — 1,078 719 — 1,797 Due to Altria and subsidiaries — — 4,790 (4,790 ) — Other liabilities 80 87 178 — 345 Total liabilities 38,252 5,967 9,595 (10,900 ) 42,914 Contingencies Redeemable noncontrolling interest — — 38 — 38 Stockholders’ Equity Common stock 935 — 9 (9 ) 935 Additional paid-in capital 5,970 3,310 27,565 (30,875 ) 5,970 Earnings reinvested in the business 36,539 352 (6,997 ) 6,645 36,539 Accumulated other comprehensive losses (2,864 ) (219 ) (1,877 ) 2,096 (2,864 ) Cost of repurchased stock (34,358 ) — — — (34,358 ) Total stockholders’ equity attributable to Altria 6,222 3,443 18,700 (22,143 ) 6,222 Noncontrolling interests — — 97 — 97 Total stockholders’ equity 6,222 3,443 18,797 (22,143 ) 6,319 Total Liabilities and Stockholders’ Equity $ 44,474 $ 9,410 $ 28,430 $ (33,043 ) $ 49,271 Condensed Consolidating Balance Sheets (in millions of dollars) ____________________________ at December 31, 2018 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Assets Cash and cash equivalents $ 1,277 $ — $ 56 $ — $ 1,333 Receivables — 18 124 — 142 Inventories: Leaf tobacco — 561 379 — 940 Other raw materials — 123 63 — 186 Work in process — 2 645 — 647 Finished product — 128 430 — 558 — 814 1,517 — 2,331 Due from Altria and subsidiaries 46 3,828 1,194 (5,068 ) — Income taxes 100 94 — (27 ) 167 Other current assets 41 167 118 — 326 Total current assets 1,464 4,921 3,009 (5,095 ) 4,299 Property, plant and equipment, at cost — 2,928 2,022 — 4,950 Less accumulated depreciation — 2,111 901 — 3,012 — 817 1,121 — 1,938 Goodwill — — 5,196 — 5,196 Other intangible assets, net — 2 12,277 — 12,279 Investments in equity securities 17,696 — 12,800 — 30,496 Investment in consolidated subsidiaries 25,996 2,825 — (28,821 ) — Due from Altria and subsidiaries 4,790 — — (4,790 ) — Other assets 193 955 773 (670 ) 1,251 Total Assets $ 50,139 $ 9,520 $ 35,176 $ (39,376 ) $ 55,459 Condensed Consolidating Balance Sheets (Continued) (in millions of dollars) ____________________________ at December 31, 2018 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Liabilities Short-term borrowings 12,704 — — — 12,704 Current portion of long-term debt $ 1,144 $ — $ — $ — $ 1,144 Accounts payable 1 91 307 — 399 Accrued liabilities: Marketing — 483 103 — 586 Settlement charges — 3,448 6 — 3,454 Other 295 524 611 (27 ) 1,403 Dividends payable 1,503 — — — 1,503 Due to Altria and subsidiaries 4,499 407 162 (5,068 ) — Total current liabilities 20,146 4,953 1,189 (5,095 ) 21,193 Long-term debt 11,898 — — — 11,898 Deferred income taxes 3,010 — 2,653 (670 ) 4,993 Accrued pension costs 187 — 357 — 544 Accrued postretirement health care costs — 1,072 677 — 1,749 Due to Altria and subsidiaries — — 4,790 (4,790 ) — Other liabilities 111 47 96 — 254 Total liabilities 35,352 6,072 9,762 (10,555 ) 40,631 Contingencies Redeemable noncontrolling interest — — 39 — 39 Stockholders’ Equity Common stock 935 — 9 (9 ) 935 Additional paid-in capital 5,961 3,310 25,047 (28,357 ) 5,961 Earnings reinvested in the business 43,962 359 2,201 (2,560 ) 43,962 Accumulated other comprehensive losses (2,547 ) (221 ) (1,884 ) 2,105 (2,547 ) Cost of repurchased stock (33,524 ) — — — (33,524 ) Total stockholders’ equity attributable to Altria 14,787 3,448 25,373 (28,821 ) 14,787 Noncontrolling interests — — 2 — 2 Total stockholders’ equity 14,787 3,448 25,375 (28,821 ) 14,789 Total Liabilities and Stockholders’ Equity $ 50,139 $ 9,520 $ 35,176 $ (39,376 ) $ 55,459
Condensed Consolidating of Earnings and Comprehensive Earnings Income Statement	Condensed Consolidating Statements of Earnings (Losses) and Comprehensive Earnings (Losses) (in millions of dollars) _____________________________ for the year ended December 31, 2019 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Net revenues $ — $ 21,065 $ 4,081 $ (36 ) $ 25,110 Cost of sales — 5,997 1,124 (36 ) 7,085 Excise taxes on products — 5,111 203 — 5,314 Gross profit — 9,957 2,754 — 12,711 Marketing, administration and research costs 182 1,591 453 — 2,226 Asset impairment and exit costs 1 39 119 — 159 Operating (expense) income (183 ) 8,327 2,182 — 10,326 Interest and other debt expense (income), net 1,152 (85 ) 213 — 1,280 Net periodic benefit (income) cost, excluding service cost 5 (34 ) (8 ) — (37 ) Earnings from equity investments (1,229 ) — (496 ) — (1,725 ) Impairment of JUUL equity securities — — 8,600 — 8,600 Loss on Cronos-related financial instruments — — 1,442 — 1,442 Earnings (losses) before income taxes and equity earnings of subsidiaries (111 ) 8,446 (7,569 ) — 766 Provision (benefit) for income taxes (243 ) 2,102 205 — 2,064 Equity earnings (losses) of subsidiaries (1,425 ) 450 — 975 — Net earnings (losses) (1,293 ) 6,794 (7,774 ) 975 (1,298 ) Net (earnings) losses attributable to noncontrolling interests — — 5 — 5 Net earnings (losses) attributable to Altria $ (1,293 ) $ 6,794 $ (7,769 ) $ 975 $ (1,293 ) Net earnings (losses) $ (1,293 ) $ 6,794 $ (7,774 ) $ 975 $ (1,298 ) Other comprehensive earnings (losses), net of deferred income taxes (317 ) 2 7 (9 ) (317 ) Comprehensive earnings (losses) (1,610 ) 6,796 (7,767 ) 966 (1,615 ) Comprehensive (earnings) losses attributable to noncontrolling interests — — 5 — 5 Comprehensive earnings (losses) attributable to Altria $ (1,610 ) $ 6,796 $ (7,762 ) $ 966 $ (1,610 ) Condensed Consolidating Statements of Earnings (Losses) and Comprehensive Earnings (Losses) (in millions of dollars) _____________________________ for the year ended December 31, 2018 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Net revenues $ — $ 21,422 $ 3,980 $ (38 ) $ 25,364 Cost of sales — 6,153 1,258 (38 ) 7,373 Excise taxes on products — 5,517 220 — 5,737 Gross profit — 9,752 2,502 — 12,254 Marketing, administration and research costs 219 1,892 645 — 2,756 Asset impairment and exit costs — 81 302 — 383 Operating (expense) income (219 ) 7,779 1,555 — 9,115 Interest and other debt expense (income), net 511 (61 ) 215 — 665 Net periodic benefit (income) cost, excluding service cost 16 (41 ) (9 ) — (34 ) Earnings from equity investments (890 ) — — — (890 ) (Gain) loss on ABI/SABMiller business combination 33 — — — 33 Earnings (losses) before income taxes and equity earnings of subsidiaries 111 7,881 1,349 — 9,341 Provision (benefit) for income taxes 36 1,980 358 — 2,374 Equity earnings (losses) of subsidiaries 6,888 402 — (7,290 ) — Net earnings (losses) 6,963 6,303 991 (7,290 ) 6,967 Net (earnings) losses attributable to noncontrolling interests — — (4 ) — (4 ) Net earnings (losses) attributable to Altria $ 6,963 $ 6,303 $ 987 $ (7,290 ) $ 6,963 Net earnings (losses) $ 6,963 $ 6,303 $ 991 $ (7,290 ) $ 6,967 Other comprehensive earnings (losses), net of deferred income taxes (242 ) 104 (54 ) (50 ) (242 ) Comprehensive earnings (losses) 6,721 6,407 937 (7,340 ) 6,725 Comprehensive (earnings) losses attributable to noncontrolling interests — — (4 ) — (4 ) Comprehensive earnings (losses) attributable to Altria $ 6,721 $ 6,407 $ 933 $ (7,340 ) $ 6,721 Condensed Consolidating Statements of Earnings (Losses) and Comprehensive Earnings (Losses) (in millions of dollars) _____________________________ for the year ended December 31, 2017 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Net revenues $ — $ 21,826 $ 3,787 $ (37 ) $ 25,576 Cost of sales — 6,394 1,174 (37 ) 7,531 Excise taxes on products — 5,864 218 — 6,082 Gross profit — 9,568 2,395 — 11,963 Marketing, administration and research costs 161 1,713 464 — 2,338 Asset impairment and exit costs — — 32 — 32 Operating (expense) income (161 ) 7,855 1,899 — 9,593 Interest and other debt expense (income), net 510 (20 ) 215 — 705 Net periodic benefit (income) cost, excluding service cost 12 18 7 — 37 Earnings from equity investments (532 ) — — — (532 ) (Gain) loss on ABI/SABMiller business combination (445 ) — — — (445 ) Earnings (losses) before income taxes and equity earnings of subsidiaries 294 7,857 1,677 — 9,828 Provision (benefit) for income taxes (2,624 ) 3,127 (902 ) — (399 ) Equity earnings (losses) of subsidiaries 7,304 558 — (7,862 ) — Net earnings (losses) 10,222 5,288 2,579 (7,862 ) 10,227 Net (earnings) losses attributable to noncontrolling interests — — (5 ) — (5 ) Net earnings (losses) attributable to Altria $ 10,222 $ 5,288 $ 2,574 $ (7,862 ) $ 10,222 Net earnings (losses) $ 10,222 $ 5,288 $ 2,579 $ (7,862 ) $ 10,227 Other comprehensive earnings (losses), net of deferred income taxes 155 3 214 (217 ) 155 Comprehensive earnings (losses) 10,377 5,291 2,793 (8,079 ) 10,382 Comprehensive (earnings) losses attributable to noncontrolling interests — — (5 ) — (5 ) Comprehensive earnings (losses) attributable to Altria $ 10,377 $ 5,291 $ 2,788 $ (8,079 ) $ 10,377
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statements of Cash Flows (in millions of dollars) _____________________________ for the year ended December 31, 2019 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Cash Provided by (Used In) Operating Activities Net cash provided by (used in) operating activities $ 7,769 $ 6,936 $ 1,362 $ (8,230 ) $ 7,837 Cash Provided by (Used in) Investing Activities Capital expenditures — (56 ) (190 ) — (246 ) Investment in Cronos — — (1,899 ) — (1,899 ) Acquisitions of businesses and assets — — (421 ) — (421 ) Investment in JUUL — — (5 ) — (5 ) Investment in consolidated subsidiaries (2,518 ) — — 2,518 — Other, net 41 1 131 — 173 Net cash provided by (used in) investing activities (2,477 ) (55 ) (2,384 ) 2,518 (2,398 ) Cash Provided by (Used in) Financing Activities Repayment of short-term borrowings (12,800 ) — — — (12,800 ) Long-term debt issued 16,265 — — — 16,265 Long-term debt repaid (1,144 ) — — — (1,144 ) Repurchases of common stock (845 ) — — — (845 ) Dividends paid on common stock (6,069 ) — — — (6,069 ) Changes in amounts due to/from Altria and subsidiaries 169 (137 ) 2,486 (2,518 ) — Cash dividends paid to parent — (6,801 ) (1,429 ) 8,230 — Other, net (123 ) — 4 — (119 ) Net cash provided by (used in) financing activities (4,547 ) (6,938 ) 1,061 5,712 (4,712 ) Cash, cash equivalents and restricted cash (1) : Increase (decrease) 745 (57 ) 39 — 727 Balance at beginning of year 1,277 100 56 — 1,433 Balance at end of year $ 2,022 $ 43 $ 95 $ — $ 2,160 (1) Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 19 . Contingencies . Condensed Consolidating Statements of Cash Flows (in millions of dollars) _____________________________ for the year ended December 31, 2018 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Cash Provided by (Used In) Operating Activities Net cash provided by (used in) operating activities $ 6,907 $ 7,580 $ 1,354 $ (7,450 ) $ 8,391 Cash Provided by (Used in) Investing Activities Capital expenditures — (57 ) (181 ) — (238 ) Acquisitions of businesses and assets — — (15 ) — (15 ) Investment in JUUL — — (12,800 ) — (12,800 ) Investment in consolidated subsidiaries (13,003 ) — — 13,003 — Other, net 35 — 30 — 65 Net cash provided by (used in) investing activities (12,968 ) (57 ) (12,966 ) 13,003 (12,988 ) Cash Provided by (Used in) Financing Activities Proceeds from short-term borrowings 12,800 — — — 12,800 Long-term debt repaid (864 ) — — — (864 ) Repurchases of common stock (1,673 ) — — — (1,673 ) Dividends paid on common stock (5,415 ) — — — (5,415 ) Changes in amounts due to/from Altria and subsidiaries 1,415 (1,388 ) 12,976 (13,003 ) — Cash dividends paid to parent — (6,097 ) (1,353 ) 7,450 — Other (128 ) — (4 ) — (132 ) Net cash provided by (used in) financing activities 6,135 (7,485 ) 11,619 (5,553 ) 4,716 Cash, cash equivalents and restricted cash (1) : Increase (decrease) 74 38 7 — 119 Balance at beginning of year 1,203 62 49 — 1,314 Balance at end of year $ 1,277 $ 100 $ 56 $ — $ 1,433 (1) Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 19 . Contingencies . Condensed Consolidating Statements of Cash Flows (in millions of dollars) _____________________________ for the year ended December 31, 2017 Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Cash Provided by (Used In) Operating Activities Net cash provided by (used in) operating activities $ 6,910 $ 4,028 $ 841 $ (6,878 ) $ 4,901 Cash Provided by (Used in) Investing Activities Capital expenditures — (34 ) (165 ) — (199 ) Acquisitions of businesses and assets — — (415 ) — (415 ) Investment in consolidated subsidiaries (460 ) — — 460 — Other, net (5 ) 4 148 — 147 Net cash provided by (used in) investing activities (465 ) (30 ) (432 ) 460 (467 ) Cash Provided by (Used in) Financing Activities Repurchases of common stock (2,917 ) — — — (2,917 ) Dividends paid on common stock (4,807 ) — — — (4,807 ) Changes in amounts due to/from Altria and subsidiaries (1,999 ) 1,410 1,049 (460 ) — Cash dividends paid to parent — (5,429 ) (1,449 ) 6,878 — Other (40 ) — (7 ) — (47 ) Net cash provided by (used in) financing activities (9,763 ) (4,019 ) (407 ) 6,418 (7,771 ) Cash, cash equivalents and restricted cash (1) : Increase (decrease) (3,318 ) (21 ) 2 — (3,337 ) Balance at beginning of year 4,521 83 47 — 4,651 Balance at end of year $ 1,203 $ 62 $ 49 $ — $ 1,314 (1) Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 19 . Contingencies .

Quarterly Financial Data (Una_2

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Data [Abstract]
Schedule of Quarterly Financial Data	2019 Quarters (in millions, except per share data) 1st 2nd 3rd 4th Net revenues $ 5,628 $ 6,619 $ 6,856 $ 6,007 Gross profit $ 2,811 $ 3,319 $ 3,497 $ 3,084 Net earnings (losses) $ 1,121 $ 1,997 $ (2,602 ) $ (1,814 ) Net earnings (losses) attributable to Altria $ 1,120 $ 1,996 $ (2,600 ) $ (1,809 ) Per share data: Basic earnings (losses) per share attributable to Altria $ 0.60 $ 1.07 $ (1.39 ) $ (0.97 ) Diluted earnings (losses) per share attributable to Altria $ 0.60 $ 1.07 $ (1.39 ) $ (1.00 ) 2018 Quarters (in millions, except per share data) 1st 2nd 3rd 4th Net revenues $ 6,108 $ 6,305 $ 6,837 $ 6,114 Gross profit $ 2,936 $ 3,141 $ 3,255 $ 2,922 Net earnings (losses) $ 1,895 $ 1,877 $ 1,944 $ 1,251 Net earnings (losses) attributable to Altria $ 1,894 $ 1,876 $ 1,943 $ 1,250 Per share data: Basic earnings (losses) per share attributable to Altria $ 1.00 $ 0.99 $ 1.03 $ 0.67 Diluted earnings (losses) per share attributable to Altria $ 1.00 $ 0.99 $ 1.03 $ 0.66
Schedule Of Pre-Tax Charges (Gains) Included In Net Earnings	During 2019 and 2018 , the following pre-tax (gains) or charges were included in net earnings attributable to Altria: 2019 Quarters (in millions) 1st 2nd 3rd 4th Impairment of JUUL equity securities $ — $ — $ 4,500 $ 4,100 Tobacco and health litigation items, including accrued interest 17 28 3 29 Asset impairment, exit, implementation and acquisition-related costs 159 45 11 116 ABI-related special items 114 (90 ) (14 ) (364 ) Cronos-related special items 425 119 549 (165 ) $ 715 $ 102 $ 5,049 $ 3,716 2018 Quarters (in millions) 1st 2nd 3rd 4th NPM Adjustment Items $ (68 ) $ (77 ) $ — $ — Tobacco and health litigation items, including accrued interest 28 70 21 12 Asset impairment, exit, implementation and acquisition-related costs 3 6 (3 ) 532 (Gain) loss on ABI/SABMiller business combination 33 — — — ABI-related special items (117 ) (72 ) 35 69 $ (121 ) $ (73 ) $ 53 $ 613 As discussed in Note 15 . Income Taxes , Altria has recognized income tax benefits and charges in the consolidated statements of earnings (losses) during 2019 and 2018 as a result of various tax events, including the impact of the Tax Reform Act in 2018.

Background and Basis of Prese_2

Background and Basis of Presentation (Background Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2019	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2016
ABI [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage (approximately)		10.10%			27.00%
JUUL [Member]
Schedule of Equity Method Investments [Line Items]
Equity securities without readily determinable fair value, ownership percentage		35.00%		35.00%
Cronos [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage (approximately)		45.00%	45.00%
Helix Innovations LLC [Member]
Schedule of Equity Method Investments [Line Items]
Noncontrolling interest, ownership percentage by parent	80.00%	80.00%
Business combination, consideration transferred	$ 353
Noncontrolling interest, ownership percentage by noncontrolling owners		20.00%

Background and Basis of Prese_3

Background and Basis of Presentation (Basis of Presentation Narrative) (Details) - USD ($)	Jan. 01, 2019	Jan. 01, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of new accounting principle in period of adoption		$ (397,000,000)
Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease, liability	$ 179,000,000
Operating lease, right-of-use asset	179,000,000
Cumulative effect of new accounting principle in period of adoption	$ 0

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Revenue, contract duration	1 year
Revenue, performance obligation, description of timing	three days
Maximum [Member]
Property, Plant and Equipment [Line Items]
Definite-lived intangible assets useful life maximum, years	25 years
Maximum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful life of property, plant and equipment	25 years
Maximum [Member] | Building and Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful life of property, plant and equipment	50 years
USSTC [Member]
Property, Plant and Equipment [Line Items]
Revenue, performance obligation, description of timing	one business day
Ste. Michelle [Member]
Property, Plant and Equipment [Line Items]
Revenue, performance obligation, description of timing	45 days

Revenues from Contracts with _2

Revenues from Contracts with Customers (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Allowance for cash discounts	$ 0	$ 0
Contract with customer, liability	$ 362,000,000	288,000,000
Revenue, performance obligation, description of timing	three days
Receivables	$ 152,000,000	$ 142,000,000

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets, net (Schedule of Goodwill and Intangible Assets by Segment) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Goodwill [Line Items]
Goodwill	$ 5,177	$ 5,196	$ 5,307
Other Intangible Assets, net	12,687	12,279	$ 12,400
Smokeable Products [Member]
Goodwill [Line Items]
Goodwill	99	99
Other Intangible Assets, net	3,071	3,037
Smokeless Products [Member]
Goodwill [Line Items]
Goodwill	5,078	5,023
Other Intangible Assets, net	9,196	8,825
Wine [Member]
Goodwill [Line Items]
Goodwill	0	74
Other Intangible Assets, net	238	239
Other [Member]
Goodwill [Line Items]
Goodwill	0	0
Other Intangible Assets, net	$ 182	$ 178

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets, net (Other Intangible Assets Disclosure) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Indefinite-lived intangible assets	$ 11,676	$ 11,846
Definite-lived intangible assets	1,275	654
Total other intangible assets	12,951	12,500
Definite-lived intangible assets, accumulated amortization	$ 264	$ 221

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets, net (Narrative) (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Amortization of intangibles		$ 44,000,000	$ 38,000,000	$ 21,000,000
Indefinite-lived intangible assets reclassified to definite-lived		170,000,000
Estimated future amortization, year 1	$ 70,000,000	70,000,000
Estimated future amortization, year 2	70,000,000	70,000,000
Estimated future amortization, year 3	70,000,000	70,000,000
Estimated future amortization, year 4	70,000,000	70,000,000
Estimated future amortization, year 5	70,000,000	70,000,000
Goodwill impairment		74,000,000	111,000,000
Accumulated goodwill impairment charges	185,000,000	185,000,000	111,000,000
Impairment of intangible assets (excluding goodwill)			44,000,000
Impairment charges				$ 0
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment charges			$ 54,000,000
UST Litigation [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived trademarks	9,000,000,000	9,000,000,000
Middleton [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived trademarks	2,600,000,000	2,600,000,000
Smokeable Products [Member]
Finite-Lived Intangible Assets [Line Items]
Definite-lived intangible assets reclassified from indefinite-lived	$ 170,000,000
Wine [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill impairment		$ 74,000,000
Weighted Average [Member] | Definite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Definite-lived intangible assets amortization period, weighted average, in years		20 years

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets, net (Schedule of Goodwill and Net Carrying Amount of Intangible Assets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Goodwill
Balance at beginning of period	$ 5,196	$ 5,307
Acquisitions	55	0
Asset impairment	(74)	(111)
Balance of end of period	5,177	5,196	$ 5,307
Other Intangible Assets, net
Balance beginning of period	12,279	12,400
Acquisitions	451	15
Asset impairment	0	(98)
Amortization	(43)
Amortization	(44)	(38)	(21)
Balance end of period	$ 12,687	$ 12,279	$ 12,400

Asset Impairment, Exit and Im_3

Asset Impairment, Exit and Implementation Costs (Pre-tax Asset Impairment, Exit and Implementation Costs) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Restructuring Cost and Reserve [Line Items]
Asset Impairment and Exit Costs	$ 159	$ 383	$ 32
Implementation Costs	28	67	45
Total	187	450	77
Plus amounts included in net periodic benefit (income) cost, excluding service cost, asset impairment and exit costs	29	3	1
Plus amounts included in net periodic benefit (income) cost, excluding service cost, implementation costs	0	0	0
Plus amounts included in net periodic benefit (income) cost, excluding service cost, total	29	3	1
Total, Asset Impairment and Exit Costs	188	386	33
Total, Implementation Costs	28	67	45
Total	216	453	78
Operating Segments [Member] | Smokeable Products [Member]
Restructuring Cost and Reserve [Line Items]
Asset Impairment and Exit Costs	59	79	4
Implementation Costs	33	1	17
Total	92	80	21
Operating Segments [Member] | Smokeless Products [Member]
Restructuring Cost and Reserve [Line Items]
Asset Impairment and Exit Costs	9	20	28
Implementation Costs	5	3	28
Total	14	23	56
Operating Segments [Member] | Wine [Member]
Restructuring Cost and Reserve [Line Items]
Asset Impairment and Exit Costs	76	54	0
Implementation Costs	0	0	0
Total	76	54	0
Operating Segments [Member] | All Other [Member]
Restructuring Cost and Reserve [Line Items]
Asset Impairment and Exit Costs	14	227	0
Implementation Costs	(10)	63	0
Total	4	290	0
General Corporate [Member]
Restructuring Cost and Reserve [Line Items]
Asset Impairment and Exit Costs	1	3	0
Implementation Costs	0	0	0
Total	1	3	0
Total, Asset Impairment and Exit Costs	1	$ 0	$ 0
Cost of Sales [Member]
Restructuring Cost and Reserve [Line Items]
Implementation Costs	2
Marketing Administration And Research Costs [Member]
Restructuring Cost and Reserve [Line Items]
Implementation Costs	$ 26

Asset Impairment, Exit and Im_4

Asset Impairment, Exit and Implementation Costs (Restructuring Liabilities) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Restructuring Reserve [Roll Forward]
Balance at beginning of period	$ 155	$ 33
Charges	59	154
Cash spent	(147)	(32)
Balance at end of period	$ 67	$ 155

Asset Impairment, Exit and Im_5

Asset Impairment, Exit and Implementation Costs (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended			39 Months Ended
	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Asset impairment, exit costs and implementation costs		$ 216,000,000	$ 453,000,000	$ 78,000,000
Payments for restructuring		147,000,000	32,000,000
Refocus of Innovative Product Efforts [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment, exit costs and implementation costs		9,000,000	272,000,000
Refocus of Innovative Product Efforts [Member] | Asset Impairment and Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment, exit costs and implementation costs			209,000,000
Refocus of Innovative Product Efforts [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment, exit costs and implementation costs			63,000,000
Cost Reduction Program [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment, exit costs and implementation costs		133,000,000	121,000,000
Restructuring and related cost, cost incurred to date		254,000,000			$ 254,000,000
Payments for restructuring	$ 0	136,000,000
Cost Reduction Program [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, cost incurred to date		52,000,000			52,000,000
Cost Reduction Program [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, cost incurred to date		202,000,000			202,000,000
Facility Consolidation [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment, exit costs and implementation costs			6,000,000	$ 78,000,000
Restructuring and related cost, cost incurred to date	155,000,000		155,000,000
Payments for restructuring		$ 3,000,000			$ 100,000,000
Facility Consolidation [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, cost incurred to date	60,000,000		60,000,000
Facility Consolidation [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, cost incurred to date	40,000,000		40,000,000
Facility Consolidation [Member] | Accelerated Depreciation And Asset Impairment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, cost incurred to date	$ 55,000,000		$ 55,000,000

Inventories (Details)

Inventories (Details) - USD ($) $ in Billions	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventories determined using LIFO method	56.00%	58.00%
Current cost of inventories over LIFO amounts	$ 0.6	$ 0.7

Investments in Equity Securit_3

Investments in Equity Securities (Summary of Investments) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Investments [Line Items]
Investments	$ 23,581	$ 30,496
ABI [Member]
Investments [Line Items]
Equity method investments	18,071	17,696
JUUL [Member]
Investments [Line Items]
Equity securities without readily determinable fair value, amount	4,205	12,800
Cronos [Member]
Investments [Line Items]
Equity method investments	1,305	0
Common Stock [Member] | Cronos [Member]
Investments [Line Items]
Equity method investments	1,002
Net Investment Hedging [Member]
Investments [Line Items]
Fair value of assets	349	41
Not Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Investments In Equity Securities [Member] | Equity Contract, Warrant [Member]
Investments [Line Items]
Fair value of assets	234	0
Not Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Investments In Equity Securities [Member] | Equity Contract, Preemptive Rights [Member]
Investments [Line Items]
Fair value of assets	$ 69	$ 0

Investments in Equity Securit_4

Investments in Equity Securities (Earnings from Equity Investments) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Investments [Line Items]
Earnings from equity investment	$ 1,725	$ 890	$ 532
ABI [Member]
Investments [Line Items]
Earnings from equity investment	1,229	890	532
Cronos [Member]
Investments [Line Items]
Earnings from equity investment	$ 496	$ 0	$ 0

Investments in Equity Securit_5

Investments in Equity Securities (Investment in ABI Narrative) (Details) shares in Millions, $ in Millions	3 Months Ended						12 Months Ended
	Dec. 31, 2019USD ($)shares	Sep. 30, 2019€ / sharesshares	Dec. 31, 2018USD ($)	Sep. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2019€ / shares	Oct. 31, 2016	Sep. 30, 2016
Investments [Line Items]
Equity method investments, recorded gain due to reduction of basis difference in assets							$ 1,725	$ 890	$ 532
Gain (loss) on ABI/SABMiller business combination			$ 0	$ 0	$ 0	$ (33)	$ 0	(33)	445
ABI [Member]
Investments [Line Items]
Equity method investment, ownership percentage (approximately)	10.10%						10.10%					27.00%
Equity method investment, number of shares owned, restricted (in shares) | shares	185						185
Equity method investment, number of shares owned, common (in shares) | shares	12						12
Difference between carrying amount and underlying equity	$ 11,800						$ 11,800
Equity method investments	18,071		17,696				$ 18,071	$ 17,696
Equity method investment, difference between carrying amount and fair value, percentage		(4.00%)					11.00%	26.00%
Gain from equity method investments relating to initial public offering of subsidiary	284
Equity method investments, recorded gain due to reduction of basis difference in assets							$ 1,229	$ 890	532
Derivative instrument, number of shares hedged (in shares) | shares		92.4
Derivative instrument, shares hedged, price per share (in eur per share) | € / shares		€ 87.42								€ 72.71
AB InBev and SABMiller [Member]
Investments [Line Items]
Equity method investment, ownership percentage (approximately)											9.60%
ABI [Member]
Investments [Line Items]
Gain (loss) on ABI/SABMiller business combination								(33)	$ 445
Restricted Stock [Member] | ABI [Member]
Investments [Line Items]
Restricted shares, lock-up period							5 years
Level 1 [Member] | ABI [Member]
Investments [Line Items]
Fair value of investment	$ 16,100		$ 13,100				$ 16,100	$ 13,100

Investments in Equity Securit_6

Investments in Equity Securities (Summary of Financial Data in ABI) (Details) - ABI [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2019	Sep. 30, 2018
Equity Method Investment, Summarized Financial Information, Income Statement [Abstract]
Net revenues	$ 54,187	$ 55,500	$ 56,004
Gross profit	33,735	34,986	34,376
Earnings from continuing operations	10,530	9,020	6,769
Net earnings	10,530	9,020	6,845
Net earnings attributable to ABI	$ 9,189	$ 7,641	$ 5,473
Current assets				$ 27,353	$ 20,289
Long-term assets				199,591	207,921
Current liabilities				36,819	32,019
Long-term liabilities				119,025	130,812
Noncontrolling interests				$ 8,765	$ 7,251

Investments in Equity Securit_7

Investments in Equity Securities (Investment in JUUL Narrative) (Details)	Jan. 28, 2020director	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)casedirector	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)casedirector	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 20, 2018
Investments [Line Items]
Investment in JUUL | $							$ 5,000,000	$ 12,800,000,000	$ 0
Equity securities without readily determinable fair value, upward price adjustment | $			$ 0				0
Equity securities without readily determinable fair value, downward price adjustment, cumulative amount | $			$ 0				$ 0
Number of litigation cases outstanding | case			340				340
Percentage increase of litigation cases outstanding since prior filing			80.00%				80.00%
Impairment of JUUL equity securities | $			$ 4,100,000,000	$ 4,500,000,000	$ 0	$ 0	$ 8,600,000,000	$ 0	$ 0
JUUL [Member]
Investments [Line Items]
Equity Securities Without Readily Determinable Fair Value, Right to Designate Board Members, Percentage										33.33%
Investment in JUUL | $		$ 12,800,000,000
Equity securities without readily determinable fair value, ownership percentage		35.00%	35.00%				35.00%	35.00%
Service agreement term							6 years
Number of board members			7				7
Impairment of JUUL equity securities | $			$ 4,100,000,000	$ 4,500,000,000			$ 8,600,000,000
Investment acquisition costs | $							$ 8,000,000	$ 85,000,000
JUUL [Member] | Subsequent Event [Member]
Investments [Line Items]
Non-compete release trigger period	12 months
Non-compete release trigger percentage of initial investment carrying value	10.00%
No litigation period	1 year
Number of board members upon share conversion	9
Number of independent board members upon share conversion	3
Number of independent board members appointed by investor upon share conversion	1
Number of independent board members appointed by investee stockholders upon share conversion	2
Number of investor nominating committee designees	1
Number of directors designated by investor upon share conversion	2
Number of directors designated by JUUL shareholders other than Altria upon share conversion	3
Number of oversight committee directors designated by investor upon share conversion	2
Number of oversight committee chair directors designated by investor upon share conversion	1

Investments in Equity Securit_8

Investments in Equity Securities (Investment in Cronos Narrative) (Details) - Cronos [Member] $ / shares in Units, shares in Millions, $ in Millions, $ in Billions	Mar. 31, 2019USD ($)	Mar. 31, 2019CAD ($)$ / sharesshares	Mar. 07, 2019CAD ($)	Dec. 31, 2019USD ($)shares	Dec. 31, 2019CAD ($)	Sep. 30, 2019directorboard_member	Dec. 31, 2018USD ($)
Investments [Line Items]
Equity method investment, number of shares owned, common (in shares) | shares		149.8
Equity method investment, ownership percentage (approximately)		45.00%		45.00%
Payments to acquire equity method investments and derivative instruments, investing	$ 1,800	$ 2.4	$ 2.4
Equity method investment, warrant exercised, ownership percentage	55.00%	55.00%
Payments to acquire equity method investments	$ 400
Payments for deferred tax liability	300
Number of directors nominated | director						4
Number of independent directors nominated | director						1
Number of members on the board of directors | board_member						7
Difference between carrying amount and underlying equity				$ 200
Equity method investments				$ 1,305			$ 0
Equity Contract, Preemptive Rights [Member]
Investments [Line Items]
Equity method investment, price per share if exercised | $ / shares		$ 16.25
Equity method investment, number of shares eligible for purchase | shares				37
Equity method investment, total exercise price				$ 500	$ 0.6
Payments for derivative instrument, investing activities	500
Equity Contract, Warrant [Member]
Investments [Line Items]
Equity method investment, price per share if exercised | $ / shares		$ 19
Equity method investment, number of shares eligible for purchase | shares				78
Equity method investment, percentage of shares eligible for purchase		10.00%
Equity method investment, total exercise price				$ 1,100	$ 1.5
Payments for derivative instrument, investing activities	$ 1,200
Common Stock [Member]
Investments [Line Items]
Equity method investments				1,002
Level 1 [Member]
Investments [Line Items]
Fair value of investment				$ 1,200

Investments in Equity Securit_9

Investments in Equity Securities (Summary of Financial Data in Cronos) (Details) - Cronos Group Inc. [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019
Schedule of Equity Method Investments [Line Items]
Net revenues	$ 21
Gross profit	10
Net earnings	$ 1,117
Current assets		$ 1,575
Long-term assets		511
Current liabilities		457
Long-term liabilities		7
Noncontrolling interests		$ 0

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details) $ in Billions	Mar. 31, 2019USD ($)	Mar. 31, 2019CAD ($)	Mar. 07, 2019CAD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Mar. 07, 2019USD ($)	Mar. 07, 2019CAD ($)
Derivative [Line Items]
Long-term debt					$ 28,042,000,000	$ 13,042,000,000
Unrealized gain (loss) on derivatives					(1,411,000,000)
Derivative, gain (loss) on derivative, net					(1,442,000,000)	0	$ 0
Equity Contract, Preemptive Rights [Member]
Derivative [Line Items]
Unrealized gain (loss) on derivatives					(434,000,000)
Equity Contract, Warrant [Member]
Derivative [Line Items]
Unrealized gain (loss) on derivatives					(977,000,000)
Net Investment Hedging [Member] | Foreign Exchange Contract [Member]
Derivative [Line Items]
Derivative, notional amount					2,246,000,000	1,226,000,000
Foreign Currency Denominated Debt [Member]
Derivative [Line Items]
Debt instrument, fair value disclosure					5,057,000,000
Long-term debt					4,741,000,000	0
Cronos [Member]
Derivative [Line Items]
Payments to acquire equity method investments and derivative instruments, investing	$ 1,800,000,000	$ 2.4	$ 2.4
Not Designated as Hedging Instrument [Member] | Forward Contracts [Member]
Derivative [Line Items]
Derivative asset, notional amount								$ 1,800,000,000	$ 2.4
Derivative, gain (loss) on derivative, net				$ (31,000,000)
Estimate of Fair Value Measurement [Member] | Level 2 [Member]
Derivative [Line Items]
Long-term debt, fair value					30,700,000,000	12,500,000,000
Reported Value Measurement [Member]
Derivative [Line Items]
Long-term debt, fair value					$ 28,000,000,000	$ 13,000,000,000

Financial Instruments (Fair Val

Financial Instruments (Fair Value using Black-Scholes Option-Pricing Model) (Details)	Dec. 31, 2019year	Mar. 08, 2019year
Expected Life [Member] | Fixed Price Preemptive Rights [Member]
Derivative [Line Items]
Derivative asset, measurement input	1.67	2.32
Expected Life [Member] | Warrant [Member]
Derivative [Line Items]
Derivative asset, measurement input	3.18	4
Expected Volatility [Member] | Fixed Price Preemptive Rights [Member]
Derivative [Line Items]
Derivative asset, measurement input	0.8161	0.9302
Expected Volatility [Member] | Warrant [Member]
Derivative [Line Items]
Derivative asset, measurement input	0.8161	0.9302
Risk Free Interest Rate [Member] | Fixed Price Preemptive Rights [Member]
Derivative [Line Items]
Derivative asset, measurement input	0.0171	0.0161
Risk Free Interest Rate [Member] | Warrant [Member]
Derivative [Line Items]
Derivative asset, measurement input	0.0169	0.0167
Expected Dividend Rate [Member] | Fixed Price Preemptive Rights [Member]
Derivative [Line Items]
Derivative asset, measurement input	0	0
Expected Dividend Rate [Member] | Warrant [Member]
Derivative [Line Items]
Derivative asset, measurement input	0	0
Weighted Average Expected Term [Member] | Fixed Price Preemptive Rights [Member] | Minimum [Member]
Derivative [Line Items]
Derivative asset, measurement input	0.25
Weighted Average Expected Term [Member] | Fixed Price Preemptive Rights [Member] | Maximum [Member]
Derivative [Line Items]
Derivative asset, measurement input	7

Financial Instruments (Beginnin

Financial Instruments (Beginning and Ending Balance of Fixed-price Preemptive Rights and Warrants) (Details) - Level 3 [Member] - Equity Contract [Member] $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Balance at beginning of period	$ 0
Initial investment in Fixed-price Preemptive Rights and warrant	1,736
Exercise of Fixed-price Preemptive Rights	(22)
Pre-tax earnings (losses) recognized in net earnings	(1,411)
Balance at end of period	$ 303

Financial Instruments (Fair V_2

Financial Instruments (Fair Value Derivative Financial Instruments) (Details) - Net Investment Hedging [Member] - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Derivatives, Fair Value [Line Items]
Fair Value of Assets	$ 349	$ 41
Fair Value of Liabilities	28	4
Foreign Currency Contract [Member] | Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	46	41
Fair Value of Liabilities	28	4
Foreign Currency Contract [Member] | Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	46	37
Foreign Currency Contract [Member] | Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	0	4
Foreign Currency Contract [Member] | Designated as Hedging Instrument [Member] | Other Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Liabilities	7	0
Foreign Currency Contract [Member] | Designated as Hedging Instrument [Member] | Other Liabilities [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Liabilities	21	4
Equity Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	303	0
Equity Contract, Warrant [Member] | Not Designated as Hedging Instrument [Member] | Investments In Equity Securities [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	234	0
Fixed Price Preemptive Rights [Member] | Not Designated as Hedging Instrument [Member] | Investments In Equity Securities [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	$ 69	$ 0

Financial Instruments (Effects

Financial Instruments (Effects of Net Investment Hedges on Accumulated Other Comprehensive Losses) (Details) - Net Investment Hedging [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in Accumulated Other Comprehensive Losses	$ 58	$ 69
Gain (Loss) Recognized in Net Earnings (Losses)	36	35
Foreign Currency Contract [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in Accumulated Other Comprehensive Losses	23	69
Gain (Loss) Recognized in Net Earnings (Losses)	36	35
Foreign Currency Denominated Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in Accumulated Other Comprehensive Losses	35	0
Gain (Loss) Recognized in Net Earnings (Losses)	$ 0	$ 0

Short-Term Borrowings and Bor_2

Short-Term Borrowings and Borrowing Arrangements (Narrative) (Details)	Aug. 01, 2018USD ($)Extension	Feb. 28, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Short-term Debt [Line Items]
Short-term borrowings			$ 0	$ 12,704,000,000
Debt issuance costs (approximately)				95,000,000
Repayment of short-term borrowings			$ 12,800,000,000	0	$ 0
Accrued interest				15,000,000
Debt instrument, covenant, consolidated EBITDA to interest expense ratio, minimum			4
Debt instrument, consolidated EBITDA to interest expense ratio			8.2
Term Loan Agreement, JUUL and Cronos [Member]
Short-term Debt [Line Items]
Repayment of short-term borrowings		$ 12,800,000,000
Payments of debt issuance costs (approximately)			$ 95,000,000
Line of Credit [Member] | Revolving Credit Facility Due August 2023 [Member] | Revolving Credit Facility [Member]
Short-term Debt [Line Items]
Term of debt			5 years
Debt instrument, face amount	$ 3,000,000,000
Debt instrument, number of extensions | Extension	2
Debt instrument, extension term	1 year
Short term and long term borrowings			$ 0
Line of Credit [Member] | Revolving Credit Facility Due August 2023 [Member] | Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Short-term Debt [Line Items]
Interest rate for borrowing			1.00%
Credit line available under the credit agreement			$ 3,000,000,000
Notes Payable, Other Payables [Member] | Term Loan Agreement [Member]
Short-term Debt [Line Items]
Short-term borrowings				$ 12,800,000,000
Debt instrument, average interest rate during period (approximately)				3.50%

Long-Term Debt (Components of L

Long-Term Debt (Components of Long-Term Debt) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Long-term debt	$ 28,042	$ 13,042
Less current portion of long-term debt	1,000	1,144
Long-term debt excluding current portion	27,042	11,898
Notes 2.625% To 10.20%, interest payable semi-annually, due through 2059 [Member] | Notes [Member]
Debt Instrument [Line Items]
Long-term debt	$ 23,259	$ 13,000
Notes 2.625% To 10.20%, interest payable semi-annually, due through 2059 [Member] | Notes [Member] | Minimum [Member]
Debt Instrument [Line Items]
Stated interest rate	2.625%
Notes 2.625% To 10.20%, interest payable semi-annually, due through 2059 [Member] | Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Stated interest rate	10.20%
Notes 2.625% To 10.20%, interest payable semi-annually, due through 2059 [Member] | Notes [Member] | Weighted Average [Member]
Debt Instrument [Line Items]
Weighted average interest rate	4.60%	4.60%
Debenture, 7.75% interest payable semi-annually, due 2027 [Member] | Debenture [Member]
Debt Instrument [Line Items]
Long-term debt	$ 42	$ 42
Stated interest rate	7.75%
Euro notes, 1.000% to 3.125%, interest payable annually, due through 2031 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Long-term debt	$ 4,741	$ 0
Euro notes, 1.000% to 3.125%, interest payable annually, due through 2031 [Member] | Notes Payable, Other Payables [Member] | Minimum [Member]
Debt Instrument [Line Items]
Stated interest rate	1.00%
Euro notes, 1.000% to 3.125%, interest payable annually, due through 2031 [Member] | Notes Payable, Other Payables [Member] | Maximum [Member]
Debt Instrument [Line Items]
Stated interest rate	3.125%
Euro notes, 1.000% to 3.125%, interest payable annually, due through 2031 [Member] | Notes Payable, Other Payables [Member] | Weighted Average [Member]
Debt Instrument [Line Items]
Weighted average interest rate	2.00%

Long-Term Debt (Aggregate Matur

Long-Term Debt (Aggregate Maturities of Long-Term Debt) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
2020	$ 1,000
2021	1,500
2022	2,900
2023	1,752
2024	2,400
Thereafter	18,723
Long-term debt before debt issuance costs and debt discount	28,275
Less:	154
Less: debt discounts	79
Long-term debt	$ 28,042	$ 13,042

Long-Term Debt (Narrative) (Det

Long-Term Debt (Narrative) (Details)	1 Months Ended	12 Months Ended
	Feb. 28, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Feb. 28, 2019EUR (€)
Debt Instrument [Line Items]
Interest payable		$ 470,000,000	$ 207,000,000
Long-term debt issued		16,265,000,000	0	$ 0
Repayment of short-term borrowings		12,800,000,000	$ 0	$ 0
Senior Notes [Member]
Debt Instrument [Line Items]
Repayments of debt		$ 1,144,000,000
Senior Notes [Member] | Change of Control and Loss of Investment Grade Rating [Member]
Debt Instrument [Line Items]
Required purchase price as percentage of aggregate principal amount		101.00%
USD Denominated Notes [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 11,500,000,000
Euro Denominated Notes [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount | €					€ 4,250,000,000
Long-term debt issued	4,800,000,000
Term Loan Agreement, JUUL and Cronos [Member]
Debt Instrument [Line Items]
Repayment of short-term borrowings	12,800,000,000
US Denominated Notes Due 2022 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,000,000,000
Stated interest rate	3.49%				3.49%
US Denominated Notes Due 2024 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,000,000,000
Stated interest rate	3.80%				3.80%
US Denominated Notes Due 2026 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,500,000,000
Stated interest rate	4.40%				4.40%
US Denominated Notes Due 2029 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 3,000,000,000
Stated interest rate	4.80%				4.80%
US Denominated Notes Due 2039 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 2,000,000,000
Stated interest rate	5.80%				5.80%
US Denominated Notes Due 2049 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 2,500,000,000
Stated interest rate	5.95%				5.95%
US Denominated Notes Due 2059 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 500,000,000
Stated interest rate	6.20%				6.20%
Euro Denominated Notes Due 2023 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount | €					€ 1,250,000,000
Stated interest rate	1.00%				1.00%
Euro Denominated Notes Due 2025 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount | €					€ 750,000,000
Stated interest rate	1.70%				1.70%
Euro Denominated Notes Due 2027 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount | €					€ 1,000,000,000
Stated interest rate	2.20%				2.20%
Euro Denominated Notes Due 2031 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount | €					€ 1,250,000,000
Stated interest rate	3.125%				3.125%

Capital Stock (Narrative) (Deta

Capital Stock (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended	12 Months Ended			18 Months Ended	31 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2019	Jan. 31, 2018	Jul. 31, 2019	May 31, 2018	Jul. 31, 2017	Oct. 31, 2016	Jul. 31, 2015
Class of Stock [Line Items]
Common stock, shares authorized (in shares)				12,000,000,000
Increase in quarterly dividend rate	5.00%
Cash dividends declared (USD per share)	$ 0.84	$ 0.80		$ 3.28	$ 3	$ 2.54
Common stock, dividends, per share, annualized (USD per share)			$ 3.36
Repurchase of common stock (in shares)				16,503,317	27,878,324	41,604,141
Average price of repurchased shares (USD per share)				$ 51.24	$ 60	$ 70.10
July 2015 Share Repurchase Program [Member]
Class of Stock [Line Items]
Stock repurchase program, authorized amount											$ 4,000,000,000	$ 3,000,000,000	$ 1,000,000,000
Repurchase of common stock (in shares)					300,000	41,600,000		58,700,000
Average price of repurchased shares (USD per share)					$ 71.68	$ 70.10		$ 68.15
January 2018 Share Repurchase Program [Member]
Class of Stock [Line Items]
Stock repurchase program, authorized amount								$ 1,000,000,000		$ 2,000,000,000
Repurchase of common stock (in shares)				6,400,000	27,600,000		34,000,000
Average price of repurchased shares (USD per share)				$ 54.36	$ 59.89		$ 58.86
July 2019 Share Repurchase Program [Member]
Class of Stock [Line Items]
Stock repurchase program, authorized amount									$ 1,000,000,000
Repurchase of common stock (in shares)				10,100,000
Average price of repurchased shares (USD per share)				$ 49.29
Amount remaining in the share repurchased program				$ 500,000,000
Serial Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized (in shares)				10,000,000
Preferred stock, par value (USD per share)				$ 1
Preferred stock, shares issued (in shares)				0
Share-based Payment Arrangement [Member]
Class of Stock [Line Items]
Shares of common stock reserved for stock-based awards (in shares)				39,288,323

Capital Stock (Schedule of Issu

Capital Stock (Schedule of Issued Repurchased and Outstanding Shares) (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Common Stock, Shares Outstanding [Roll Forward]
Beginning balance, Shares Issued (in shares)	2,805,961,317	2,805,961,317	2,805,961,317
Beginning balance, Shares Repurchased (in shares)	(931,903,722)	(904,702,125)	(862,689,093)
Beginning balance, Shares Outstanding (in shares)	1,874,057,595	1,901,259,192	1,943,272,224
Stock award activity (in shares)	427,276	676,727	(408,891)
Repurchases of common stock (in shares)	(16,503,317)	(27,878,324)	(41,604,141)
Ending balance, Shares Issued (in shares)	2,805,961,317	2,805,961,317	2,805,961,317
Ending balance, Shares Repurchased (in shares)	(947,979,763)	(931,903,722)	(904,702,125)
Ending balance, Shares Outstanding (in shares)	1,857,981,554	1,874,057,595	1,901,259,192

Capital Stock (Schedule of Shar

Capital Stock (Schedule of Shares Repurchased) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended			18 Months Ended	31 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2019	Jan. 31, 2018
Class of Stock [Line Items]
Total number of shares repurchased (in shares)	16,503,317	27,878,324	41,604,141
Aggregate cost of shares repurchased	$ 845	$ 1,673	$ 2,917
Average price per share of shares repurchased (USD per share)	$ 51.24	$ 60	$ 70.10
July 2019 Share Repurchase Program [Member]
Class of Stock [Line Items]
Total number of shares repurchased (in shares)	10,100,000
Aggregate cost of shares repurchased	$ 500
Average price per share of shares repurchased (USD per share)	$ 49.29
January 2018 Share Repurchase Program [Member]
Class of Stock [Line Items]
Total number of shares repurchased (in shares)	6,400,000	27,600,000		34,000,000
Aggregate cost of shares repurchased	$ 345	$ 1,655
Average price per share of shares repurchased (USD per share)	$ 54.36	$ 59.89		$ 58.86
July 2015 Share Repurchase Program [Member]
Class of Stock [Line Items]
Total number of shares repurchased (in shares)		300,000	41,600,000		58,700,000
Aggregate cost of shares repurchased		$ 18	$ 2,917
Average price per share of shares repurchased (USD per share)		$ 71.68	$ 70.10		$ 68.15

Stock Plans (Narrative) (Detail

Stock Plans (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Restricted Stock And Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, in years	3 years
Pre-tax compensation expense	$ 28	$ 39	$ 49
Deferred tax benefit	7	9	18
Unamortized compensation expense	$ 50
Weighted-average period of recognition, in years	2 years
Weighted-average grant date fair value	$ 37	$ 60	$ 46
Weighted-average grant date fair value, per share (in USD per share)	$ 52.03	$ 67.17	$ 71.05
Total fair value vested	$ 30	$ 65	$ 95
Granted, number of shares (in shares)	719,677
Number of shares remaining (in shares)	1,909,642	2,129,626
Grant date fair value (in USD per share)	$ 61.46	$ 64.94
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, outstanding (in shares)			0
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, in years	3 years
Pre-tax compensation expense	$ 4	$ 7	$ 6
Unamortized compensation expense	$ 10	$ 10
Granted, number of shares (in shares)	181,409	177,338	187,886
Number of shares remaining (in shares)	360,685
Grant date fair value (in USD per share)	$ 58.41
Common Stock [Member] | 2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares issuable under the stock compensation plan (in shares)	40,000,000
Shares available to be granted (in shares)	36,078,232
Common Stock [Member] | 2015 Directors Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares issuable under the stock compensation plan (in shares)	1,000,000,000,000
Shares available to be granted (in shares)	831,560

Stock Plans (Schedule of Restri

Stock Plans (Schedule of Restricted and Restricted Stock Units Activity) (Details) - Restricted Stock And Restricted Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Number of Shares
Balance at beginning of year (in shares)	2,129,626
Granted (in shares)	719,677
Vested (in shares)	(611,657)
Forfeited (in shares)	(328,004)
Balance at end of year, (in shares)	1,909,642	2,129,626
Weighted-Average Grant Date Fair Value Per Share
Balance at beginning of year (USD per share)	$ 64.94
Granted (USD per share)	52.03	$ 67.17	$ 71.05
Vested (USD per share)	59.78
Forfeited (USD per share)	66.52
Balance at end of year (USD per share)	$ 61.46	$ 64.94

Earnings (Losses) per Share (De

Earnings (Losses) per Share (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Net earnings (losses) attributable to Altria	$ (1,809)	$ (2,600)	$ 1,996	$ 1,120	$ 1,250	$ 1,943	$ 1,876	$ 1,894	$ (1,293)	$ 6,963	$ 10,222
Less: Distributed and undistributed earnings attributable to share-based awards									(7)	(8)	(14)
Earnings (losses) for basic and diluted EPS									$ (1,300)	$ 6,955	$ 10,208
Weighted-average shares for basic EPS (in shares)									1,869	1,887	1,921
Plus: contingently issuable PSUs (in shares)									0	1	0
Weighted-average shares for diluted EPS (in shares)									1,869	1,888	1,921

Other Comprehensive Earnings__3

Other Comprehensive Earnings/Losses (Changes in Each Component of Accumulated Other Comprehensive Losses) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2018
Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	$ 14,789	$ 15,380	$ 12,773
Adoption of ASU No. 2018-02				$ (397)
Other comprehensive earnings (losses), net of deferred income taxes	(317)	(242)	155
Ending balances	6,319	14,789	15,380
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	(2,547)	(1,897)	(2,052)
Adoption of ASU No. 2018-02				(408)
Other comprehensive earnings (losses) before reclassifications	(545)	(475)	(39)
Deferred income taxes	126	103	11
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes	(419)	(372)	(28)
Amounts reclassified to net earnings (losses)	139	177	299
Deferred income taxes	(37)	(47)	(116)
Amounts reclassified to net earnings (losses), net of deferred income taxes	102	130	183
Other comprehensive earnings (losses), net of deferred income taxes	(317)	(242)	155
Ending balances	(2,864)	(2,547)	(1,897)
Benefit Plans [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	(2,168)	(1,839)	(2,048)
Other comprehensive earnings (losses) before reclassifications	(204)	(151)	52
Deferred income taxes	51	39	(21)
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes	(153)	(112)	31
Amounts reclassified to net earnings (losses)	173	241	291
Deferred income taxes	(44)	(61)	(113)
Amounts reclassified to net earnings (losses), net of deferred income taxes	129	180	178
Other comprehensive earnings (losses), net of deferred income taxes	(24)	68	209
Ending balances	(2,192)	(2,168)	(1,839)
Accumulated Equity Method Investments Attributable To Parent [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	(374)	(54)	0
Other comprehensive earnings (losses) before reclassifications	(367)	(323)	(91)
Deferred income taxes	75	64	32
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes	(292)	(259)	(59)
Amounts reclassified to net earnings (losses)	(34)	(64)	8
Deferred income taxes	7	14	(3)
Amounts reclassified to net earnings (losses), net of deferred income taxes	(27)	(50)	5
Other comprehensive earnings (losses), net of deferred income taxes	(319)	(309)	(54)
Ending balances	(693)	(374)	(54)
Currency Translation Adjustments and Other [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	(5)	(4)	(4)
Other comprehensive earnings (losses) before reclassifications	26	(1)	0
Deferred income taxes	0	0	0
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes	26	(1)	0
Amounts reclassified to net earnings (losses)	0	0	0
Deferred income taxes	0	0	0
Amounts reclassified to net earnings (losses), net of deferred income taxes	0	0	0
Other comprehensive earnings (losses), net of deferred income taxes	26	(1)	0
Ending balances	$ 21	$ (5)	$ (4)
Accounting Standards Update 2018-02 [Member] | Benefit Plans [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Adoption of ASU No. 2018-02				(397)
Accounting Standards Update 2018-02 [Member] | Accumulated Equity Method Investments Attributable To Parent [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Adoption of ASU No. 2018-02				(11)
Accounting Standards Update 2018-02 [Member] | Currency Translation Adjustments and Other [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Adoption of ASU No. 2018-02				$ 0

Other Comprehensive Earnings__4

Other Comprehensive Earnings/Losses (Reclassifications) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net periodic benefit (income) cost, excluding service cost									$ (37)	$ (34)	$ 37
Earnings from equity investment in ABI									(1,725)	(890)	(532)
Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses)	$ 1,814	$ 2,602	$ (1,997)	$ (1,121)	$ (1,251)	$ (1,944)	$ (1,877)	$ (1,895)	1,298	(6,967)	(10,227)
Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Earnings from equity investment in ABI									(34)	(64)	8
Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses)									139	177	299
Reclassification out of Accumulated Other Comprehensive Income [Member] | Net loss [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net periodic benefit (income) cost, excluding service cost									200	276	325
Reclassification out of Accumulated Other Comprehensive Income [Member] | Prior service costs/credit [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net periodic benefit (income) cost, excluding service cost									(27)	(35)	(34)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Benefit Plans [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net periodic benefit (income) cost, excluding service cost									$ 173	$ 241	$ 291

Income Taxes (Schedule of Earni

Income Taxes (Schedule of Earnings Before Income Taxes and Provision for Income Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
United States	$ 266	$ 9,441	$ 9,809
Outside United States	500	(100)	19
Earnings (losses) before income taxes	766	9,341	9,828
Current:
Federal	1,686	1,911	2,346
State and local	470	519	366
Outside United States	3	1	15
Total current provision for income taxes	2,159	2,431	2,727
Deferred:
Federal	(78)	(18)	(3,213)
State and local	(19)	(42)	86
Outside United States	2	3	1
Total deferred provision for income taxes	(95)	(57)	(3,126)
Total provision (benefit) for income taxes	$ 2,064	$ 2,374	$ (399)

Income Taxes (Reconciliation of

Income Taxes (Reconciliation of Beginning and Ending Unrecognized Tax Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of Unrecognized Tax Benefits
Balance at beginning of year	$ 85	$ 66	$ 169
Additions based on tax positions related to the current year	0	0	0
Additions for tax positions of prior years	32	22	129
Reductions for tax positions due to lapse of statutes of limitations	0	0	(4)
Reductions for tax positions of prior years	(16)	(1)	(208)
Tax settlements	(37)	(2)	(20)
Balance at end of year	$ 64	$ 85	$ 66

Income Taxes (Schedule of Unrec

Income Taxes (Schedule of Unrecognized Tax Benefits and Consolidated Liability for Tax Contingencies) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Unrecognized tax benefits	$ 64	$ 85	$ 66	$ 169
Accrued interest and penalties	11	13
Tax credits and other indirect benefits	(1)	(1)
Liability for tax contingencies	$ 74	$ 97

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Line Items]
Unrecognized tax benefits if recognized would impact effective tax rate		$ 40	$ 59
Unrecognized tax benefits if recognized would affect deferred taxes		24	26
Interest (income) expense associated with uncertain tax position		6	5	$ (13)
Potential decrease in liability for uncertain tax positions		28
Effective income tax rate reconciliation, Tax Cuts and Jobs Act, transition tax on accumulated foreign earnings, amount	$ 413	84	14
Effective income tax rate reconciliation, Tax Cuts and Jobs Act, tax credit, foreign		38	34
Tax Cuts and Jobs Act of 2017, incomplete accounting, change in tax rate, provisional income tax expense (benefit)	(3,367)		188
Effective income tax rate reconciliation, Tax Cuts and Jobs Act, transition tax on accumulated foreign earnings, amount			$ 140
Effective income tax rate reconciliation, change in enacted tax rate, amount	3,017
Tax Cuts and Jobs Act of 2017, measurement period adjustment, income tax benefit	$ 763			763
Tax (benefit) provision recorded				232
Tax Year 2010 Through Tax Year 2013 [Member]
Income Taxes [Line Items]
Tax (benefit) provision recorded				152
Audit Adjustments Prior Year Tax Audits [Member]
Income Taxes [Line Items]
Tax (benefit) provision recorded		105
Accruals no longer required [Member]
Income Taxes [Line Items]
Tax (benefit) provision recorded		100		$ (114)
Equity Method Investments [Member]
Income Taxes [Line Items]
Tax (benefit) provision recorded		79
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Net operating losses carry forward		655
JUUL [Member]
Income Taxes [Line Items]
Effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount		$ 2,024

Income Taxes (Reconciliation _2

Income Taxes (Reconciliation of Effective Tax Rate and U.S. Federal Statutory Rate) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
$
U.S. federal statutory rate	$ 161	$ 1,962	$ 3,440
State and local income taxes, net of federal tax benefit	356	377	345
Re-measurement of net deferred tax liabilities	0	0	(3,063)
Tax basis in foreign investments	84	140	(763)
Deemed repatriation tax	0	14	413
Uncertain tax positions	(40)	8	(89)
Domestic manufacturing deduction	0	0	(181)
Other	(29)	(38)	79
Total provision (benefit) for income taxes	$ 2,064	$ 2,374	$ (399)
%
U.S. federal statutory rate	21.00%	21.00%	35.00%
State and local income taxes, net of federal tax benefit	46.50%	4.00%	3.50%
Re-measurement of net deferred tax liabilities	0.00%	0.00%	(31.20%)
Tax basis in foreign investments	11.00%	1.50%	(7.80%)
Deemed repatriation tax	0.00%	0.10%	4.20%
Uncertain tax positions	(5.20%)	0.10%	(0.90%)
Domestic manufacturing deduction	0.00%	0.00%	(1.80%)
Other	(3.80%)	(0.40%)	0.80%
Effective tax rate	269.50%	25.40%	(4.10%)
Effective Income Tax Rate Reconciliation, Deferred Profit Sharing Dividends	$ 21
JUUL [Member]
$
Investment	$ 1,808	$ 15	$ 0
%
Investment	236.00%	0.20%	0.00%
AB InBev [Member]
$
Investment in ABI	$ (210)	$ (104)	$ (580)
%
Investment in ABI	(27.40%)	(1.10%)	(5.90%)
Cronos [Member]
$
Investment	$ (66)	$ 0	$ 0
%
Investment	(8.60%)	0.00%	0.00%

Income Taxes (Schedule of Defer

Income Taxes (Schedule of Deferred Income Tax Assets and Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Deferred income tax assets:
Accrued postretirement and postemployment benefits	$ 491	$ 500
Settlement charges	833	864
Accrued pension costs	131	155
Investment in JUUL	2,047	0
Investment in Cronos	197	0
Net operating losses and tax credit carryforwards	92	57
Total deferred income tax assets	3,791	1,576
Deferred income tax liabilities:
Property, plant and equipment	(255)	(251)
Intangible assets	(2,758)	(2,689)
Investment in ABI	(3,115)	(3,038)
Finance assets, net	(204)	(313)
Other	(158)	(115)
Total deferred income tax liabilities	(6,490)	(6,406)
Valuation allowances	(2,324)	(71)	$ 0	$ (240)
Net deferred income tax liabilities	$ (5,023)	$ (4,901)

Income Taxes (Summary of Valuat

Income Taxes (Summary of Valuation Allowance) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Deferred Tax Assets, Valuation Allowance [Roll Forward]
Balance at beginning of year	$ 71	$ 0	$ 240
Additions to valuation allowance related to Altria’s initial investment in Cronos	352	0	0
Additions to valuation allowance charged to income tax expense	2,063	71	0
Reductions to valuation allowance credited to income tax benefit	(159)	0	(240)
Foreign currency translation	(3)	0	0
Balance at end of year	$ 2,324	$ 71	$ 0

Segment Reporting (Segment Data

Segment Reporting (Segment Data Schedule) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Net revenues	$ 6,007	$ 6,856	$ 6,619	$ 5,628	$ 6,114	$ 6,837	$ 6,305	$ 6,108	$ 25,110	$ 25,364	$ 25,576
Operating income									10,326	9,115	9,593
Amortization of intangibles									(44)	(38)	(21)
Corporate asset impairment and exit costs									(188)	(386)	(33)
Interest and other debt expense, net									(1,280)	(665)	(705)
Net periodic benefit income (cost), excluding service cost									37	34	(37)
Earnings from equity investments									1,725	890	532
Impairment of JUUL equity securities	$ (4,100)	$ (4,500)	$ 0	$ 0					(8,600)	0	0
Loss on Cronos-related financial instruments									(1,442)	0	0
Gain (loss) on ABI/SABMiller business combination					$ 0	$ 0	$ 0	$ (33)	0	(33)	445
Earnings (losses) before income taxes									766	9,341	9,828
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
General corporate expenses									(199)	(315)	(213)
Corporate asset impairment and exit costs									(1)	0	0
Smokeable Products [Member]
Segment Reporting Information [Line Items]
Net revenues									21,996	22,297	22,636
Smokeable Products [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income									9,009	8,408	8,426
Smokeless Products [Member]
Segment Reporting Information [Line Items]
Net revenues									2,367	2,262	2,155
Smokeless Products [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income									1,580	1,431	1,306
Wine [Member]
Segment Reporting Information [Line Items]
Net revenues									689	691	698
Wine [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income									(3)	50	146
All Other [Member]
Segment Reporting Information [Line Items]
Net revenues									58	114	87
All Other [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income									$ (16)	$ (421)	$ (51)

Segment Reporting (Narrative) (

Segment Reporting (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Net revenues	$ 6,007	$ 6,856	$ 6,619	$ 5,628	$ 6,114	$ 6,837	$ 6,305	$ 6,108	$ 25,110	$ 25,364	$ 25,576
Revenue Benchmark [Member] | Credit Concentration Risk [Member] | McLane Company Inc [Member]
Segment Reporting Information [Line Items]
Contribution of net revenues by major customer percentage									25.00%	27.00%	26.00%
Revenue Benchmark [Member] | Credit Concentration Risk [Member] | Core-Mark Holding Company, Inc. [Member]
Segment Reporting Information [Line Items]
Contribution of net revenues by major customer percentage									15.00%	14.00%	14.00%
Smokeable Products [Member]
Segment Reporting Information [Line Items]
Net revenues									$ 21,996	$ 22,297	$ 22,636
Smokeable Products [Member] | Cigarettes [Member]
Segment Reporting Information [Line Items]
Net revenues									21,158	21,506	21,900
Smokeable Products [Member] | Cigars [Member]
Segment Reporting Information [Line Items]
Net revenues									838	791	736
Wine [Member]
Segment Reporting Information [Line Items]
Net revenues									$ 689	$ 691	$ 698
Wine [Member] | Revenue Benchmark [Member] | Credit Concentration Risk [Member] | Two Distributors [Member]
Segment Reporting Information [Line Items]
Contribution of net revenues by major customer percentage									67.00%	64.00%
Wine [Member] | Revenue Benchmark [Member] | Credit Concentration Risk [Member] | Three Distributors [Member]
Segment Reporting Information [Line Items]
Contribution of net revenues by major customer percentage											67.00%
Smokeless Products [Member]
Segment Reporting Information [Line Items]
Net revenues									$ 2,367	$ 2,262	$ 2,155
Operating Segments [Member] | Smokeless Products [Member]
Segment Reporting Information [Line Items]
Inventory recall expense											$ 60

Segment Reporting (Schedule of

Segment Reporting (Schedule of Depreciation Expense and Capital Expenditures of Segments) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Depreciation expense	$ 182	$ 189	$ 188
Capital expenditures	246	238	199
Operating Segments [Member] | Smokeable Products [Member]
Segment Reporting Information [Line Items]
Depreciation expense	88	90	93
Capital expenditures	61	81	39
Operating Segments [Member] | Smokeless Products [Member]
Segment Reporting Information [Line Items]
Depreciation expense	27	28	29
Capital expenditures	44	73	61
Operating Segments [Member] | Wine [Member]
Segment Reporting Information [Line Items]
Depreciation expense	41	40	40
Capital expenditures	63	40	53
General Corporate and Other [Member]
Segment Reporting Information [Line Items]
Depreciation expense	26	31	26
Capital expenditures	$ 78	$ 44	$ 46

Segment Reporting (Schedule o_2

Segment Reporting (Schedule of NPM Adjustment Items) (Details) - USD ($) $ in Millions	3 Months Ended				12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
NPM Adjustment Items [Line Items]
NPM Adjustment Items	$ 0	$ 0	$ (77)	$ (68)
Non-Participating Manufacturer Arbitration Panel Decision [Member]
NPM Adjustment Items [Line Items]
NPM Adjustment Items					$ (145)	$ 4
Operating Income (Loss) [Member] | Smokeable Products [Member] | PM USA [Member] | NPM Adjustment to Cost Of Sales [Member] | Non-Participating Manufacturer Arbitration Panel Decision [Member]
NPM Adjustment Items [Line Items]
NPM Adjustment Items					(145)	(5)
Interest And Other Debt Expense, Net [Member] | PM USA [Member] | Non-Participating Manufacturer Arbitration Panel Decision [Member]
NPM Adjustment Items [Line Items]
Interest and other debt expense, net					$ 0	$ 9

Segment Reporting (Schedule o_3

Segment Reporting (Schedule of Pre-tax Tobacco and Health Litigation Charges) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]
Provision related to litigation recorded	$ 29	$ 3	$ 28	$ 17	$ 12	$ 21	$ 70	$ 28
Tobacco and Health Litigation Cases [Member]
Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]
Provision related to litigation recorded									$ 77	$ 131	$ 80
Tobacco and Health Litigation Cases [Member] | Operating Income (Loss) [Member] | Operating Segments [Member] | Smokeless Products [Member]
Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]
Provision related to litigation recorded									0	10	0
Tobacco and Health Litigation Cases [Member] | Interest And Other Debt Expense, Net [Member] | Segment Reconciling Items [Member]
Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]
Provision related to litigation recorded									5	18	8
PM USA [Member] | Tobacco and Health Litigation Cases [Member] | Operating Income (Loss) [Member] | Operating Segments [Member] | Smokeable Products [Member]
Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]
Provision related to litigation recorded									$ 72	$ 103	$ 72

Benefit Plans (Narrative) (Deta

Benefit Plans (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2019
Defined Benefit Plan Disclosure [Line Items]
Lump sum payment	$ 277,000,000
One-time settlement charge relating to lump sum distributions					$ 81,000,000
Amounts charged to expense for defined contribution plans			$ 78,000,000	$ 85,000,000	83,000,000
Pension [Member]
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation			8,400,000,000	7,400,000,000
Projected benefit obligation			8,522,000,000
Accumulated benefit obligation			357,000,000	7,239,000,000
Fair value of plan assets			134,000,000	7,012,000,000
Defined benefit plan, plan assets, amount	8,015,000,000		$ 8,167,000,000	$ 7,138,000,000	$ 8,015,000,000
Defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets			7.80%	7.80%	8.00%
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets				$ 8,023,000,000
Pension [Member] | Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected future employer contributions			$ 30,000,000
Pension [Member] | Emerging Markets [Member]
Defined Benefit Plan Disclosure [Line Items]
Composition of plan assets			1.00%
Pension [Member] | Below grade investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Composition of plan assets			5.00%
Pension [Member] | Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets, target allocation percentage			30.00%			55.00%
Pension [Member] | Equity Securities [Member] | Emerging Markets [Member]
Defined Benefit Plan Disclosure [Line Items]
Composition of plan assets			1.00%
Pension [Member] | Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets, target allocation percentage			70.00%			45.00%
Pension [Member] | Fixed Income Securities [Member] | Below grade investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Composition of plan assets			8.00%
Postretirement Benefit Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, plan assets, amount	$ 270,000,000		$ 213,000,000	$ 211,000,000	$ 270,000,000
Defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets			7.80%	7.80%	0.00%
Postretirement Benefit Plan [Member] | Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected future employer contributions			$ 60,000,000
Postretirement Benefit Plan [Member] | Emerging Markets [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, plan assets, amount			$ 0
Postretirement Benefit Plan [Member] | Below grade investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Composition of plan assets			4.00%
Postretirement Benefit Plan [Member] | Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets, target allocation percentage						55.00%
Postretirement Benefit Plan [Member] | Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets, target allocation percentage						45.00%
Postretirement Benefit Plan [Member] | Fixed Income Securities [Member] | Below grade investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Composition of plan assets			8.00%
Level 3 [Member] | Postretirement Benefit Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, plan assets, amount			$ 0	$ 0
Forecast [Member] | Pension [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets		6.60%
Forecast [Member] | Postretirement Benefit Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets		7.70%

Benefit Plans (Projected Benefi

Benefit Plans (Projected Benefit Obligations, Plan Assets and Funded Status of Pension Plans) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Change in plan assets:
Accrued pension costs	$ (473)	$ (544)
Accrued postretirement health care costs	(1,797)	(1,749)
Pension [Member]
Change in benefit obligation:
Benefit obligation at beginning of year	7,726	8,510
Service cost	70	81	$ 75
Interest cost	306	276	288
Benefits paid	(493)	(488)
Actuarial (gains) losses	1,025	(660)
Settlement and curtailment	25	(18)
Other	0	25
Benefit obligation at end of year	8,659	7,726	8,510
Change in plan assets:
Fair value of plan assets at beginning of year	7,138	8,015
Actual return on plan assets	1,466	(430)
Employer contributions	56	41
Benefits paid	(493)	(488)
Fair value of plan assets at end of year	8,167	7,138	8,015
Funded status at December 31	(492)	(588)
Other accrued liabilities	(26)	(44)
Accrued pension costs	(473)	(544)
Other assets	7	0
Accrued postretirement health care costs	0	0
Defined benefit plan, amounts for asset (liability) recognized in statement of financial position	(492)	(588)
Postretirement Benefit Plan [Member]
Change in benefit obligation:
Benefit obligation at beginning of year	2,040	2,335
Service cost	16	18	16
Interest cost	76	70	76
Benefits paid	(126)	(130)
Actuarial (gains) losses	78	(298)
Settlement and curtailment	7	0
Other	0	45
Benefit obligation at end of year	2,091	2,040	2,335
Change in plan assets:
Fair value of plan assets at beginning of year	211	270
Actual return on plan assets	45	(14)
Employer contributions	0	0
Benefits paid	(43)	(45)
Fair value of plan assets at end of year	213	211	$ 270
Funded status at December 31	(1,878)	(1,829)
Other accrued liabilities	(81)	(80)
Accrued pension costs	0	0
Other assets	0	0
Accrued postretirement health care costs	(1,797)	(1,749)
Defined benefit plan, amounts for asset (liability) recognized in statement of financial position	$ (1,878)	$ (1,829)

Benefit Plans (Assumptions to D

Benefit Plans (Assumptions to Determine Postretirement Benefit Obligations) (Details)	Dec. 31, 2019	Dec. 31, 2018
Pension [Member]
Defined Benefit Plan Disclosure [Line Items]
Discount rate	3.40%	4.40%
Rate of compensation increase	4.00%	4.00%
Postretirement Benefit Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Discount rate	3.40%	4.40%
Rate of compensation increase	0.00%	0.00%
Health care cost trend rate assumed for next year	6.50%	6.50%
Ultimate trend rate	5.00%	5.00%

Benefit Plans (Schedule of Comp

Benefit Plans (Schedule of Components of Net Periodic Pension Cost) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Pension [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 70	$ 81	$ 75
Interest cost	306	276	288
Expected return on plan assets	(576)	(585)	(601)
Amortization of net loss	159	225	197
Amortization of prior service cost (credit)	6	4	4
Settlement and curtailment	27	16	86
Net periodic benefit cost (income)	(8)	17	49
Postretirement Benefit Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	16	18	16
Interest cost	76	70	76
Expected return on plan assets	(15)	(19)	0
Amortization of net loss	5	21	25
Amortization of prior service cost (credit)	(30)	(42)	(38)
Settlement and curtailment	5	0	0
Net periodic benefit cost (income)	$ 57	$ 48	$ 79

Benefit Plans (Termination, Set

Benefit Plans (Termination, Settlement and Curtailment Costs) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Pension [Member]
Defined Benefit Plan Disclosure [Line Items]
Benefit obligation	$ 6	$ 0	$ 0
Net loss	20	13	86
Prior service cost (credit)	1	3	0
Termination, settlement, and curtailment costs	27	16	86
Postretirement Benefit Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Benefit obligation	10
Net loss	0
Prior service cost (credit)	(5)
Termination, settlement, and curtailment costs	$ 5	$ 0	$ 0

Benefit Plans (Assumptions used

Benefit Plans (Assumptions used to Determine Net Periodic Benefit Cost) (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Pension [Member]
Defined Benefit Plan Disclosure [Line Items]
Discount rate: Service cost	4.60%	3.80%	4.30%
Discount rate: Interest cost	4.00%	3.30%	3.50%
Expected rate of return on plan assets	7.80%	7.80%	8.00%
Rate of compensation increase	4.00%	4.00%	4.00%
Postretirement Benefit Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Discount rate: Service cost	4.50%	3.80%	4.30%
Discount rate: Interest cost	4.00%	3.30%	3.50%
Expected rate of return on plan assets	7.80%	7.80%	0.00%
Health care cost trend rate	6.50%	7.00%	7.00%

Benefit Plans (Asset Allocation

Benefit Plans (Asset Allocations) (Details)	Dec. 31, 2019
Equity Securities [Member] | Pension [Member]
Defined Benefit Plan Disclosure [Line Items]
Composition of plan assets	35.00%
Equity Securities [Member] | Postretirement Benefit Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Composition of plan assets	56.00%
Corporate Bonds [Member] | Pension [Member]
Defined Benefit Plan Disclosure [Line Items]
Composition of plan assets	52.00%
Corporate Bonds [Member] | Postretirement Benefit Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Composition of plan assets	34.00%
US Treasury And Foreign Government Securities [Member] | Pension [Member]
Defined Benefit Plan Disclosure [Line Items]
Composition of plan assets	13.00%
US Treasury And Foreign Government Securities [Member] | Postretirement Benefit Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Composition of plan assets	10.00%

Benefit Plans (Fair Values of P

Benefit Plans (Fair Values of Pension and Postretirement Plan Assets) (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Pension [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	$ 8,167,000,000	$ 7,138,000,000	$ 8,015,000,000
Pension [Member] | Fair Value, Recurring [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	8,167,000,000	7,138,000,000
Pension [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	(194,000,000)	48,000,000
Pension [Member] | Fair Value, Recurring [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	1,555,000,000	1,355,000,000
Pension [Member] | Fair Value, Recurring [Member] | Level 1 [Member] | US Treasury and Government [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	0	0
Pension [Member] | Fair Value, Recurring [Member] | Level 1 [Member] | Municipal Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	0	0
Pension [Member] | Fair Value, Recurring [Member] | Level 1 [Member] | Debt Security, Government, Non-US [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	0	0
Pension [Member] | Fair Value, Recurring [Member] | Level 1 [Member] | Corporate Debt Security, Above Investment Grade [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	0	0
Pension [Member] | Fair Value, Recurring [Member] | Level 1 [Member] | Corporate Debt Security, Below Investment Grade [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	0	0
Pension [Member] | Fair Value, Recurring [Member] | Level 1 [Member] | Common stock: International equities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	296,000,000	237,000,000
Pension [Member] | Fair Value, Recurring [Member] | Level 1 [Member] | Common stock: U.S. equities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	1,263,000,000	1,082,000,000
Pension [Member] | Fair Value, Recurring [Member] | Level 1 [Member] | Other, Net [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	(4,000,000)	36,000,000
Pension [Member] | Fair Value, Recurring [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	5,489,000,000	3,599,000,000
Pension [Member] | Fair Value, Recurring [Member] | Level 2 [Member] | US Treasury and Government [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	811,000,000	868,000,000
Pension [Member] | Fair Value, Recurring [Member] | Level 2 [Member] | Municipal Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	57,000,000	73,000,000
Pension [Member] | Fair Value, Recurring [Member] | Level 2 [Member] | Debt Security, Government, Non-US [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	98,000,000	115,000,000
Pension [Member] | Fair Value, Recurring [Member] | Level 2 [Member] | Corporate Debt Security, Above Investment Grade [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	3,523,000,000	1,726,000,000
Pension [Member] | Fair Value, Recurring [Member] | Level 2 [Member] | Corporate Debt Security, Below Investment Grade [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	521,000,000	478,000,000
Pension [Member] | Fair Value, Recurring [Member] | Level 2 [Member] | Common stock: International equities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	0	0
Pension [Member] | Fair Value, Recurring [Member] | Level 2 [Member] | Common stock: U.S. equities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	0	0
Pension [Member] | Fair Value, Recurring [Member] | Level 2 [Member] | Other, Net [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	479,000,000	339,000,000
Pension [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1, 2 and 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	7,044,000,000	4,954,000,000
Pension [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1, 2 and 3 [Member] | US Treasury and Government [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	811,000,000	868,000,000
Pension [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1, 2 and 3 [Member] | Municipal Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	57,000,000	73,000,000
Pension [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1, 2 and 3 [Member] | Debt Security, Government, Non-US [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	98,000,000	115,000,000
Pension [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1, 2 and 3 [Member] | Corporate Debt Security, Above Investment Grade [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	3,523,000,000	1,726,000,000
Pension [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1, 2 and 3 [Member] | Corporate Debt Security, Below Investment Grade [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	521,000,000	478,000,000
Pension [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1, 2 and 3 [Member] | Common stock: International equities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	296,000,000	237,000,000
Pension [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1, 2 and 3 [Member] | Common stock: U.S. equities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	1,263,000,000	1,082,000,000
Pension [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1, 2 and 3 [Member] | Other, Net [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	475,000,000	375,000,000
Pension [Member] | Fair Value, Recurring [Member] | NAV [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	1,317,000,000	2,136,000,000
Pension [Member] | Fair Value, Recurring [Member] | NAV [Member] | U S Large Cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	825,000,000	1,722,000,000
Pension [Member] | Fair Value, Recurring [Member] | NAV [Member] | U S Small Cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	386,000,000	328,000,000
Pension [Member] | Fair Value, Recurring [Member] | NAV [Member] | International Developed Markets [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	106,000,000	86,000,000
Postretirement Benefit Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	213,000,000	211,000,000	$ 270,000,000
Postretirement Benefit Plan [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	0	0
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	213,000,000	211,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	(3,000,000)	9,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	0	2,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Level 1 [Member] | US Treasury and Government [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	0	0
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Level 1 [Member] | Debt Security, Government, Non-US [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	0	0
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Level 1 [Member] | Corporate Debt Security, Above Investment Grade [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	0	0
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Level 1 [Member] | Corporate Debt Security, Below Investment Grade [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	0	0
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Level 1 [Member] | Other, Net [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	0	2,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	95,000,000	97,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Level 2 [Member] | US Treasury and Government [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	11,000,000	13,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Level 2 [Member] | Debt Security, Government, Non-US [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	5,000,000	3,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Level 2 [Member] | Corporate Debt Security, Above Investment Grade [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	63,000,000	71,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Level 2 [Member] | Corporate Debt Security, Below Investment Grade [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	9,000,000	8,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Level 2 [Member] | Other, Net [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	7,000,000	2,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1, 2 and 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	95,000,000	99,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1, 2 and 3 [Member] | US Treasury and Government [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	11,000,000	13,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1, 2 and 3 [Member] | Debt Security, Government, Non-US [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	5,000,000	3,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1, 2 and 3 [Member] | Corporate Debt Security, Above Investment Grade [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	63,000,000	71,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1, 2 and 3 [Member] | Corporate Debt Security, Below Investment Grade [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	9,000,000	8,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1, 2 and 3 [Member] | Other, Net [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	7,000,000	4,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | NAV [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	121,000,000	103,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | NAV [Member] | U S Large Cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	97,000,000	77,000,000
Postretirement Benefit Plan [Member] | Fair Value, Recurring [Member] | NAV [Member] | International Developed Markets [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, net	$ 24,000,000	$ 26,000,000

Benefit Plans (Estimated Future

Benefit Plans (Estimated Future Benefit Payments) (Details) $ in Millions	Dec. 31, 2019USD ($)
Pension [Member]
Defined Benefit Plan Disclosure [Line Items]
2020	$ 472
2021	477
2022	479
2023	483
2024	481
2025-2029	2,430
Postretirement Benefit Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
2020	126
2021	124
2022	121
2023	117
2024	115
2025-2029	$ 555

Benefit Plans (Amounts Recorded

Benefit Plans (Amounts Recorded in Accumulated Other Comprehensive Losses) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net loss	$ (2,999)	$ (2,996)
Prior service (cost) credit	40	68
Deferred income taxes	767	760
Amounts recorded in accumulated other comprehensive losses	(2,192)	(2,168)
Pension [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net loss	(2,565)	(2,591)
Prior service (cost) credit	(27)	(34)
Deferred income taxes	670	679
Amounts recorded in accumulated other comprehensive losses	(1,922)	(1,946)
Postretirement Benefit Plan [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net loss	(389)	(327)
Prior service (cost) credit	72	108
Deferred income taxes	86	61
Amounts recorded in accumulated other comprehensive losses	(231)	(158)
Postemployment Retirement Benefits [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net loss	(45)	(78)
Prior service (cost) credit	(5)	(6)
Deferred income taxes	11	20
Amounts recorded in accumulated other comprehensive losses	$ (39)	$ (64)

Benefit Plans (Movements in Oth

Benefit Plans (Movements in Other Comprehensive Earnings/Losses) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2018
Amortization:
Net loss	$ 184	$ 263	$ 239
Prior service cost/credit	(23)	(38)	(34)
Other expense (income):
Net loss	16	13	86
Prior service cost/credit	(4)	3
Deferred income taxes	(44)	(61)	(113)
Amounts reclassified to net earnings as components of net periodic benefit cost	129	180	178
Other movements during the year:
Adoption of ASU No. 2018-02				$ (397)
Net loss	(203)	(74)	14
Prior service cost/credit	(1)	(77)	38
Deferred income taxes	51	39	(21)
Other movements	(153)		31
Other movements		(509)
Total movements in other comprehensive earnings/losses	(24)
Total movements in other comprehensive earnings/losses		(329)
Total movements in other comprehensive earnings/losses	(24)	68	209
Pension [Member]
Amortization:
Net loss	159	225	197
Prior service cost/credit	6	4	4
Other expense (income):
Net loss	20	13	86
Prior service cost/credit	1	3
Deferred income taxes	(47)	(61)	(113)
Amounts reclassified to net earnings as components of net periodic benefit cost	139	184	174
Other movements during the year:
Adoption of ASU No. 2018-02				(330)
Net loss	(153)	(336)	81
Prior service cost/credit	0	(26)	0
Deferred income taxes	38	91	(32)
Other movements	(115)		49
Other movements		(601)
Total movements in other comprehensive earnings/losses	24
Total movements in other comprehensive earnings/losses		(417)
Total movements in other comprehensive earnings/losses			223
Postretirement Benefit Plan [Member]
Amortization:
Net loss	5	21	25
Prior service cost/credit	(30)	(42)	(38)
Other expense (income):
Net loss	0	0	0
Prior service cost/credit	(5)	0
Deferred income taxes	7	4	6
Amounts reclassified to net earnings as components of net periodic benefit cost	(23)	(17)	(7)
Other movements during the year:
Adoption of ASU No. 2018-02				(55)
Net loss	(67)	264	(56)
Prior service cost/credit	(1)	(45)	38
Deferred income taxes	18	(54)	7
Other movements	(50)		(11)
Other movements		110
Total movements in other comprehensive earnings/losses	(73)
Total movements in other comprehensive earnings/losses		93
Total movements in other comprehensive earnings/losses			(18)
Postemployment Retirement Benefits [Member]
Amortization:
Net loss	20	17	17
Prior service cost/credit	1	0	0
Other expense (income):
Net loss	(4)	0	0
Prior service cost/credit	0	0
Deferred income taxes	(4)	(4)	(6)
Amounts reclassified to net earnings as components of net periodic benefit cost	13	13	11
Other movements during the year:
Adoption of ASU No. 2018-02				$ (12)
Net loss	17	(2)	(11)
Prior service cost/credit	0	(6)	0
Deferred income taxes	(5)	2	4
Other movements	12		(7)
Other movements		(18)
Total movements in other comprehensive earnings/losses	$ 25
Total movements in other comprehensive earnings/losses		$ (5)
Total movements in other comprehensive earnings/losses			$ 4

Additional Information (Schedul

Additional Information (Schedule of Additional Information) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Research and development expense	$ 168	$ 252	$ 241
Advertising expense	33	37	29
Interest expense	1,322	697	736
Interest income	(42)	(32)	(31)
Interest and other debt expense, net	$ 1,280	$ 665	$ 705

Additional Information (Sched_2

Additional Information (Schedule of Valuation and Qualifying Accounts) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Discounts [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of year	$ 0	$ 0	$ 0
Charged to costs and expenses	604	620	626
Deductions	(604)	(620)	(626)
Balance at end of year	0	0	0
Returned Goods [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of year	32	40	49
Charged to costs and expenses	127	97	130
Deductions	(127)	(105)	(139)
Balance at end of year	32	32	40
Allowance for Losses on Finance Assets [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of year	19	23	32
Decrease to allowance	0	(4)	(9)
Balance at end of year	$ 19	$ 19	$ 23

Contingencies (General Informat

Contingencies (General Information) (Details)	Dec. 31, 2019state
Commitments and Contingencies Disclosure [Abstract]
Number of states that cap bond or require no bond	47

Contingencies (Schedule of Pend

Contingencies (Schedule of Pending Cases) (Details)	1 Months Ended	12 Months Ended
	Mar. 31, 2018case	Dec. 31, 2019caseclaimlawsuit	Dec. 31, 2018case	Dec. 31, 2017case
Individual Smoking and Health Cases [Member]
Loss Contingencies [Line Items]
Number of cases pending		104	100	92
Individual Smoking and Health Cases [Member] | Pending Litigation [Member] | Massachusetts [Member]
Loss Contingencies [Line Items]
Number of cases pending		21
Individual Smoking and Health Cases [Member] | Pending Litigation [Member] | Florida [Member]
Loss Contingencies [Line Items]
Number of cases pending		43
ETS Smoking and Health Case, Flight Attendants [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of cases		1,472
Number of claims dismissed	923
Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending		1	1	1
E-vapor Cases [Member]
Loss Contingencies [Line Items]
Number of cases pending		101	0	0
Number of class action lawsuits | lawsuit		22
E-vapor Cases [Member] | Pending Individual Lawsuits [Member]
Loss Contingencies [Line Items]
Number of cases pending | claim		76
E-vapor Cases [Member] | Pending Lawsuits Filed By State Or Local Governments [Member]
Loss Contingencies [Line Items]
Number of cases pending | claim		2
E-vapor Cases [Member] | Pending Lawsuit Filed By School District [Member]
Loss Contingencies [Line Items]
Number of cases pending | claim		1
Other Tabacco-Related Cases [Member]
Loss Contingencies [Line Items]
Number of cases pending		4	4	7
Number of inactive cases		2
Number of cases tried in a single proceeding		1
Number of cases alleging unfair practices		2

Contingencies (Overview of Altr

Contingencies (Overview of Altria and/or PM USA Tobacco-Related Litigation Narrative) (Details) - case	Jan. 27, 2020	Jan. 27, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending			1	1	1
Individual Smoking and Health Cases [Member]
Loss Contingencies [Line Items]
Number of cases pending			104	100	92
Subsequent Event [Member] | PM USA [Member] | Health Care Cost Recovery Actions [Member] | Canada [Member]
Loss Contingencies [Line Items]
Number of cases pending	10	10
Subsequent Event [Member] | PM USA [Member] | Engle Progeny Cases [Member]
Loss Contingencies [Line Items]
Number of cases set for trial	4	4
Number of verdicts returned	134
Number of favorable verdicts	47
Number of unfavorable verdicts	77
Subsequent Event [Member] | PM USA [Member] | Individual Smoking and Health Cases [Member]
Loss Contingencies [Line Items]
Number of cases set for trial	1	1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member]
Loss Contingencies [Line Items]
Number of verdicts returned		68
Number of favorable verdicts		44
Number of unfavorable verdicts		24
Number of claims resolved		20
Verdicts reversed, number		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Alaska [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | California [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		7
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Connecticut [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Florida [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		10
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Louisiana [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Massachusetts [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		4
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Mississippi [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Missouri [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		4
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | New Hampshire [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | New Jersey [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | New York [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		5
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Ohio [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		2
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Pennsylvania [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Rhode Island [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Tennessee [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		2
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | West Virginia [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		2
Subsequent Event [Member] | Philip Morris USA and Altria Group [Member] | Health Care Cost Recovery Actions [Member] | Canada [Member]
Loss Contingencies [Line Items]
Number of cases pending	8	8
Subsequent Event [Member] | Philip Morris USA and Altria Group [Member] | Smoking and Health Class Actions and Aggregated Claims Litigation [Member] | Canada [Member]
Loss Contingencies [Line Items]
Number of cases pending	7	7

Contingencies (Judgments Paid a

Contingencies (Judgments Paid and Provisions for Tobacco and Health Litigation) (Details) $ in Millions	3 Months Ended								12 Months Ended			183 Months Ended
	Dec. 31, 2019USD ($)case	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Sep. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2019USD ($)case	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2019USD ($)case
Loss Contingency Accrual [Roll Forward]
Accrued liability for tobacco and health litigation items at beginning of period				$ 112				$ 106	$ 112	$ 106	$ 47
Provision related to litigation recorded	$ 29	$ 3	$ 28	$ 17	$ 12	$ 21	$ 70	$ 28
Payments									(175)	(125)	(21)
Accrued liability for tobacco and health litigation items at end of period	14				$ 112				14	112	106	$ 14
Interest Expense Related to Litigation [Member]
Loss Contingency Accrual [Roll Forward]
Provision related to litigation recorded									5	18	8
Pre-Trial Resolution [Member]
Loss Contingency Accrual [Roll Forward]
Payments									(20)
Accrued liability for tobacco and health litigation items at end of period	$ 2								2			2
Tobacco and Health Judgment [Member]
Loss Contingencies [Line Items]
Judgments paid (approximately)												724
Interest and other debt expense, net												$ 214
Tobacco and Health Judgment [Member] | Litigation Cases Results [Member]
Loss Contingency Accrual [Roll Forward]
Provision related to litigation recorded									72	$ 113	$ 72
Tobacco and Health Judgment [Member] | Pre-Trial Resolution [Member]
Loss Contingency Accrual [Roll Forward]
Provision related to litigation recorded									$ 22
Number of pre-trial resolution cases | case	300								300			300
Engle Progeny Cases [Member]
Loss Contingencies [Line Items]
Judgments paid (approximately)												$ 312
Interest and other debt expense, net												52
Assets [Member] | Pending Litigation [Member] | PM USA [Member]
Loss Contingency Accrual [Roll Forward]
Security posted for appeal of judgments	$ 43								$ 43			$ 43

Contingencies (Non-Engle Progen

Contingencies (Non-Engle Progeny Litigation) (Details) - USD ($)	1 Months Ended	3 Months Ended
	Apr. 30, 2019	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Aug. 31, 2019	Oct. 31, 2017
Loss Contingencies [Line Items]
Provision related to litigation recorded		$ 29,000,000	$ 3,000,000	$ 28,000,000	$ 17,000,000	$ 12,000,000	$ 21,000,000	$ 70,000,000	$ 28,000,000
Non-Engle Progeny Smoking and Health Case, Greene [Member]
Loss Contingencies [Line Items]
Compensatory damages awarded			$ 10,000,000
Non-Engle Progeny Smoking and Health Case, Laramie [Member]
Loss Contingencies [Line Items]
Compensatory damages awarded										$ 11,000,000
Punitive damages awarded										$ 10,000,000
Non-Engle Progeny Smoking and Health Case, Capone [Member]
Loss Contingencies [Line Items]
Compensatory damages awarded						$ 225,000
Provision related to litigation recorded	$ 325,000
Non-Engle Progeny Smoking and Health Case, Gentile [Member]
Loss Contingencies [Line Items]
Compensatory damages awarded											$ 7,100,000
Non-Engle Progeny Smoking and Health Case, Gentile [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Compensatory damages awarded											$ 5,300,000
Compensatory damages award, allocation percentage											75.00%

Contingencies (Engle Class Acti

Contingencies (Engle Class Action And Engle Progeny Trial Results) (Details)	Jan. 27, 2020USD ($)caseplantiff	Jul. 31, 2006	Dec. 31, 2015case	Jan. 31, 2008case	Jul. 31, 2000USD ($)
Engle Progeny Cases [Member]
Loss Contingencies [Line Items]
Punitive damages awarded | $					$ 145,000,000,000
Engle Progeny Cases [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Punitive damages awarded | $					$ 74,000,000,000
Period for decertified class members could file individual actions		1 year
Engle Progeny Cases, State [Member]
Loss Contingencies [Line Items]
Number of cases pending				9,300
Engle Progeny Cases, Federal [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of claims resolved			415
Subsequent Event [Member] | Engle Progeny Cases [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of verdicts returned	134
Number of unfavorable verdicts	77
Number of claims with unfavorable verdicts pending/reversed	6
Number of favorable verdicts	47
Subsequent Event [Member] | Engle Progeny Cases, State [Member]
Loss Contingencies [Line Items]
Number of cases pending	1,700
Number of plaintiffs | plantiff	2,100
Subsequent Event [Member] | Engle Progeny Cases, State [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts	42
Subsequent Event [Member] | Engle Progeny Cases, Federal [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of cases pending	4
Subsequent Event [Member] | Engle Progeny Cases, D Cohen, Collar, Chacon [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Verdicts reversed, number	4
Subsequent Event [Member] | Engle Progeny Cases, Reider and Banks [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Zero damages verdicts	2
Damages awarded, value | $	$ 0
Subsequent Event [Member] | Engle Progeny Cases, Weingart and Hancock [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Zero damages verdict modified	2
Damages awarded, value | $	$ 0
Subsequent Event [Member] | Engle Progeny Cases, Pollari [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts	1
Subsequent Event [Member] | Engle Progeny Cases, Gloger And Rintoul [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts	2

Contingencies (Engle Progeny Ca

Contingencies (Engle Progeny Cases Trial Results - Pending and Concluded) (Details) - USD ($) $ in Millions

3 Months Ended

6 Months Ended

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2017

Sep. 30, 2018

Jan. 31, 2020

Nov. 30, 2019

Feb. 28, 2019

Jul. 31, 2018

May 31, 2018

Nov. 30, 2017

Apr. 30, 2017

Mar. 31, 2017

Sep. 30, 2015

Jan. 31, 2015

Oct. 31, 2014

Sep. 30, 2014

Jul. 31, 2014

Loss Contingencies [Line Items]

Provision related to litigation recorded

$ 29

$ 3

$ 28

$ 17

$ 12

$ 21

$ 70

$ 28

Engle Progeny Cases, Berger [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 6

Provision related to litigation recorded

6

Engle Progeny Cases, Berger [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 21

Engle Progeny Cases, Rintoul [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 9

Engle Progeny Cases, Rintoul [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

5

Punitive damages awarded

74

Engle Progeny Cases, Gloger [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

15

Engle Progeny Cases, Gloger [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

5

Punitive damages awarded

$ 11

Engle Progeny Cases, McCall [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Engle Progeny Cases, McCall [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Punitive damages awarded

1

Engle Progeny Cases, Neff [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

4

Engle Progeny Cases, Neff [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

2

Engle Progeny Cases, Frogel [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Engle Progeny Cases, Frogel [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Punitive damages awarded

0

Engle Progeny Cases, Mahfuz [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 12

Engle Progeny Cases, Mahfuz [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

10

Engle Progeny Cases, Holliman [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

3

Engle Progeny Cases, Holliman [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 0

Engle Progeny Cases, Chadwell [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

2

$ 2

Engle Progeny Cases, Chadwell [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

0

0

Engle Progeny Cases, Kaplan [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 2

Engle Progeny Cases, Kaplan [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 2

Engle Progeny Cases, Landi [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

8

Engle Progeny Cases, Landi [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

5

Engle Progeny Cases, Theis [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 7

Engle Progeny Cases, Theis [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 10

Engle Progeny Cases, Freeman [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

4

Engle Progeny Cases, Freeman [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 0

Engle Progeny Cases, R. Douglas [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 1

Punitive damages awarded

$ 0

Engle Progeny Cases, Sommers [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 1

Engle Progeny Cases, Sommers [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 0

Engle Progeny Cases, Santoro [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 2

Engle Progeny Cases, Santoro [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 0

Engle Progeny Cases, Cooper [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 5

Engle Progeny Cases, Cooper [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Punitive damages awarded

$ 0

Engle Progeny Cases, D. Brown [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 8

Engle Progeny Cases, D. Brown [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 9

Engle Progeny Cases, Kerrivan [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 16

Engle Progeny Cases, Kerrivan [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 16

Engle Progeny Cases, Harris [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 2

Engle Progeny Cases, Harris [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Punitive damages awarded

$ 0

Engle Progeny Cases, Alvarez del Real [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 1

Engle Progeny Cases, Zingaro [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 1

Engle Progeny Cases, Bryant [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

1

Engle Progeny Cases, Wallace [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 26

Engle Progeny Cases, J. Brown [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

4

Engle Progeny Cases, L. Martin [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

2

Engle Progeny Cases, Danielson [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

3

Engle Progeny Cases, S. Martin [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 5

Engle Progeny Cases, Searcy [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 2

Engle Progeny Cases, Boatright [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

42

Engle Progeny Cases, M. Brown [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

8

Engle Progeny Cases, Jordan [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

4

Engle Progeny Cases, Jordan [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 11

Engle Progeny Cases, Pardue [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 11

Engle Progeny Cases, McKeever [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 21

Engle Progeny Cases, Boulter [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 1

Subsequent Event [Member] | Engle Progeny Cases, Cuddihee [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 3

Subsequent Event [Member] | Engle Progeny Cases, Cuddihee [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 0

Contingencies (Florida Bond Sta

Contingencies (Florida Bond Statute) (Details) $ in Millions	Jun. 30, 2009USD ($)
Florida [Member] | Engle Progeny Cases, State [Member]
Loss Contingencies [Line Items]
Maximum bond for all defendants	$ 200

Contingencies (Other Smoking an

Contingencies (Other Smoking and Health Class Actions) (Details) - Smoking and Health Class Actions and Aggregated Claims Litigation [Member] $ in Billions	1 Months Ended	284 Months Ended
	Mar. 31, 2019CAD ($)rulingmanufacture	Dec. 31, 2019case	Jan. 27, 2020case
PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		61
Arkansas [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
California [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Delaware [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
District of Columbia [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		2
Florida [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		2
Illinois [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		3
Iowa [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Kansas [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Louisiana [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Maryland [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Michigan [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Minnesota [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Nevada [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		29
New Jersey [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		6
New York [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		2
Ohio [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Oklahoma [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Oregon [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Pennsylvania [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Puerto Rico [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
South Carolina [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Texas [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Wisconsin [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Canada [Member] | Canadian Tobacco Manufacturers [Member]
Loss Contingencies [Line Items]
Number of manufacturers | manufacture	3
Number of verdicts upheld | ruling	2
Amount awarded to other party | $	$ 13
Subsequent Event [Member] | Canada [Member] | Philip Morris USA and Altria Group [Member]
Loss Contingencies [Line Items]
Number of cases pending			7
Subsequent Event [Member] | British Columbia and Saskatchewan [Member] | Philip Morris USA and Altria Group [Member]
Loss Contingencies [Line Items]
Number of cases pending			2

Contingencies (Health Care Cost

Contingencies (Health Care Cost Recovery Litigation) (Details) - Health Care Cost Recovery Actions [Member] $ in Millions	1 Months Ended	12 Months Ended
	Nov. 30, 1998USD ($)state	Dec. 31, 2019USD ($)case	Dec. 31, 2018USD ($)case	Dec. 31, 2017USD ($)case
Loss Contingencies [Line Items]
Number of cases pending | case		1	1	1
Number of states with settled litigation | state	46
State settlement agreements annual payments	$ 9,400
State settlement agreements attorney fees annual cap	$ 500
Litigation settlement		$ 4,200	$ 4,200	$ 4,500
Threatened Litigation [Member] | Canada [Member]
Loss Contingencies [Line Items]
Number of cases pending | case		10

Contingencies (NPM Adjustment D

Contingencies (NPM Adjustment Disputes - Settlement with 36 States and Territories and Settlement with New York) (Details) $ in Millions	1 Months Ended					3 Months Ended		9 Months Ended	12 Months Ended
	Apr. 30, 2019USD ($)	Apr. 30, 2018USD ($)	Oct. 31, 2017USD ($)state	Sep. 30, 2013USD ($)state	Nov. 30, 1998state	Mar. 31, 2019USD ($)	Mar. 31, 2018state	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)stateclaim	Dec. 31, 2018USD ($)settlement_development	Dec. 31, 2017USD ($)
Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Number of states with settled litigation | state					46
PM USA [Member] | Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Loss contingency, reduction to cost of sales						$ 52				$ 209	$ 39
PM USA [Member] | Health Care Cost Recovery Actions [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of states with settled litigation including New York, subsequent expansion | state									36
Settlement agreements, number | claim									2
Number of states with settled litigation | state									37
PM USA [Member] | Health Care Cost Recovery Actions, 2003-2015 NPM Adjustments [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of states with settled litigation including New York, subsequent expansion | state			26
​Proceeds from legal settlements			$ 740
Loss contingency, number of settlement developments | settlement_development										2
PM USA [Member] | Health Care Cost Recovery Actions, 2004-2017 [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of additional states added | state							10
Payments received from litigation settlement	$ 121	$ 68						$ 248
PM USA [Member] | Health Care Cost Recovery Actions, 2003 NPM Adjustment [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Number of states with settled litigation | state				2
PM USA [Member] | Health Care Cost Recovery Actions, 2003 NPM Adjustment [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of states | state				15
Number of states without defense | state				6
Loss contingency, number of disputes outstanding | state				2
PM USA [Member] | Health Care Cost Recovery Actions, 2003 NPM Adjustment [Member] | Pending Litigation [Member] | Cost of Sales [Member]
Loss Contingencies [Line Items]
Loss contingency, reduction to cost of sales				$ 74
PM USA [Member] | Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain									$ 388
PM USA [Member] | Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain									181
PM USA [Member] | Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain									154
PM USA [Member] | Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain									185
PM USA [Member] | Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain									250
PM USA [Member] | Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain									211
PM USA [Member] | Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain									218
PM USA [Member] | Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain									166
PM USA [Member] | Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain									214
PM USA [Member] | Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain									224
PM USA [Member] | Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain									258
PM USA [Member] | Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member]
Loss Contingencies [Line Items]
Estimate of possible gain									299
PM USA [Member] | Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member]
Loss Contingencies [Line Items]
Estimate of possible gain									292
PM USA [Member] | Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member]
Loss Contingencies [Line Items]
Estimate of possible gain									285
PM USA [Member] | Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member]
Loss Contingencies [Line Items]
Estimate of possible gain									332
New York [Member] | PM USA [Member] | Health Care Cost Recovery Actions, Transition Years 2004-2017 [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
​Proceeds from legal settlements									$ 265
Maryland, Missouri, New Mexico and Pennsylvania [Member] | PM USA [Member] | Health Care Cost Recovery Actions, 2003 NPM Adjustment [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of states remaining | state				4

Contingencies (Other Disputes U

Contingencies (Other Disputes Under the State Settlement Agreements) (Details) $ in Millions	1 Months Ended
	Aug. 31, 2018USD ($)
PM USA [Member] | Other Disputes Under the State Settlement Agreements [Member]
Loss Contingencies [Line Items]
Amount ordered to be paid from other party	$ 9.8

Contingencies (Federal Governme

Contingencies (Federal Government's Lawsuit) (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended								12 Months Ended
	Aug. 31, 2006	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2014
Loss Contingencies [Line Items]
Provision related to litigation recorded		$ 29	$ 3	$ 28	$ 17	$ 12	$ 21	$ 70	$ 28
Federal Governments Lawsuit [Member]
Loss Contingencies [Line Items]
Disclosure period	10 years
Implementation of Corrective Communications [Member] | Federal Governments Lawsuit [Member]
Loss Contingencies [Line Items]
Provision related to litigation recorded		$ 5								$ 31

Contingencies (E-vapor Litigati

Contingencies (E-vapor Litigation) (Details) - E-vapor Litigation [Member]	Jan. 27, 2020claim	Dec. 31, 2019caseclaim	Dec. 31, 2018case	Dec. 31, 2017case
Loss Contingencies [Line Items]
Number of cases pending | case		101	0	0
Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of cases set for trial	0
Pending Class Action Lawsuits [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of cases pending	21
Pending Individual Lawsuits [Member]
Loss Contingencies [Line Items]
Number of cases pending		76
Pending Individual Lawsuits [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of cases pending	76
Pending Lawsuits Filed By State Or Local Governments [Member]
Loss Contingencies [Line Items]
Number of cases pending		2
Pending Lawsuits Filed By State Or Local Governments [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of cases pending	2
Pending Lawsuit Filed By School District [Member]
Loss Contingencies [Line Items]
Number of cases pending		1
Pending Lawsuit Filed By School District [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of cases pending	1

Contingencies (Lights_Ultra Lig

Contingencies (Lights/Ultra Lights Cases) (Details) - Subsequent Event [Member]	Jan. 27, 2020casecourt
Lights [Member]
Loss Contingencies [Line Items]
Claims not certified, number | case	23
Number of cases pending | court	2
Lights [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of state courts | court	21
Lights Ultra Lights Class Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending | case	2

Contingencies (UST Litigations

Contingencies (UST Litigations Narrative) (Details)	Jan. 27, 2020claim
Pending Individual Lawsuits [Member] | Subsequent Event [Member] | UST Litigation [Member]
Loss Contingencies [Line Items]
Claims filed, number	1

Contingencies (Guarantees and O

Contingencies (Guarantees and Other Similar Matters Narrative) (Details)	3 Months Ended	12 Months Ended
	Dec. 31, 2019USD ($)shareholder	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Loss Contingencies [Line Items]
Loss contingency, number of shareholders filing class action lawsuits | shareholder	2
Contingent liability related to performance surety bonds	$ 26,000,000	$ 26,000,000
Redeemable noncontrolling interest	38,000,000	38,000,000	$ 39,000,000
Letter of Credit [Member]
Loss Contingencies [Line Items]
Credit line available under the agreement	51,000,000	51,000,000
Revolving Credit Facility [Member] | Credit Agreement [Member]
Loss Contingencies [Line Items]
Credit line available under the agreement	$ 3,000,000,000	$ 3,000,000,000
Debt instrument, term		5 years

Condensed Consolidating Finan_3

Condensed Consolidating Financial Information (Condensed Consolidating Balance Sheets) (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Condensed Financial Statements, Captions [Line Items]
Cash and cash equivalents	$ 2,117,000,000	$ 1,333,000,000	$ 1,253,000,000
Receivables	152,000,000	142,000,000
Inventories:
Leaf tobacco	874,000,000	940,000,000
Other raw materials	192,000,000	186,000,000
Work in process	696,000,000	647,000,000
Finished product	531,000,000	558,000,000
Inventory, net	2,293,000,000	2,331,000,000
Due from Altria and subsidiaries	0	0
Income taxes	116,000,000	167,000,000
Other current assets	146,000,000	326,000,000
Total current assets	4,824,000,000	4,299,000,000
Property, plant and equipment, at cost	5,074,000,000	4,950,000,000
Less accumulated depreciation	3,075,000,000	3,012,000,000
Property, plant and equipment, net	1,999,000,000	1,938,000,000
Goodwill	5,177,000,000	5,196,000,000	5,307,000,000
Other intangible assets, net	12,687,000,000	12,279,000,000	12,400,000,000
Investments in equity securities	23,581,000,000	30,496,000,000
Investment in consolidated subsidiaries	0	0
Due from Altria and subsidiaries	0	0
Other assets	1,003,000,000	1,251,000,000
Total Assets	49,271,000,000	55,459,000,000
Liabilities
Short-term borrowings	0	12,704,000,000
Current portion of long-term debt	1,000,000,000	1,144,000,000
Accounts payable	325,000,000	399,000,000
Accrued liabilities:
Marketing	393,000,000	586,000,000
Settlement charges	3,346,000,000	3,454,000,000
Other	1,545,000,000	1,403,000,000
Dividends payable	1,565,000,000	1,503,000,000
Due to Altria and subsidiaries	0	0
Total current liabilities	8,174,000,000	21,193,000,000
Long-term debt	27,042,000,000	11,898,000,000
Deferred income taxes	5,083,000,000	4,993,000,000
Accrued pension costs	473,000,000	544,000,000
Accrued postretirement health care costs	1,797,000,000	1,749,000,000
Due to Altria and subsidiaries	0	0
Other liabilities	345,000,000	254,000,000
Total liabilities	42,914,000,000	40,631,000,000
Contingencies
Redeemable noncontrolling interest	38,000,000	39,000,000
Stockholders' Equity
Common stock	935,000,000	935,000,000
Additional paid-in capital	5,970,000,000	5,961,000,000
Earnings reinvested in the business	36,539,000,000	43,962,000,000
Accumulated other comprehensive losses	(2,864,000,000)	(2,547,000,000)
Cost of repurchased stock	(34,358,000,000)	(33,524,000,000)
Total stockholders’ equity attributable to Altria	6,222,000,000	14,787,000,000
Noncontrolling interests	97,000,000	2,000,000
Total stockholders’ equity	6,319,000,000	14,789,000,000	$ 15,380,000,000	$ 12,773,000,000
Total Liabilities and Stockholders’ Equity	49,271,000,000	55,459,000,000
Reportable Legal Entities [Member] | Altria Group, Inc. [Member]
Condensed Financial Statements, Captions [Line Items]
Cash and cash equivalents	2,022,000,000	1,277,000,000
Receivables	0	0
Inventories:
Leaf tobacco	0	0
Other raw materials	0	0
Work in process	0	0
Finished product	0	0
Inventory, net	0	0
Due from Altria and subsidiaries	88,000,000	46,000,000
Income taxes	80,000,000	100,000,000
Other current assets	53,000,000	41,000,000
Total current assets	2,243,000,000	1,464,000,000
Property, plant and equipment, at cost	0	0
Less accumulated depreciation	0	0
Property, plant and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Investments in equity securities	18,071,000,000	17,696,000,000
Investment in consolidated subsidiaries	19,312,000,000	25,996,000,000
Due from Altria and subsidiaries	4,790,000,000	4,790,000,000
Other assets	58,000,000	193,000,000
Total Assets	44,474,000,000	50,139,000,000
Liabilities
Short-term borrowings		12,704,000,000
Current portion of long-term debt	1,000,000,000	1,144,000,000
Accounts payable	0	1,000,000
Accrued liabilities:
Marketing	0	0
Settlement charges	0	0
Other	576,000,000	295,000,000
Dividends payable	1,565,000,000	1,503,000,000
Due to Altria and subsidiaries	4,693,000,000	4,499,000,000
Total current liabilities	7,834,000,000	20,146,000,000
Long-term debt	27,042,000,000	11,898,000,000
Deferred income taxes	3,099,000,000	3,010,000,000
Accrued pension costs	197,000,000	187,000,000
Accrued postretirement health care costs	0	0
Due to Altria and subsidiaries	0	0
Other liabilities	80,000,000	111,000,000
Total liabilities	38,252,000,000	35,352,000,000
Contingencies
Redeemable noncontrolling interest	0	0
Stockholders' Equity
Common stock	935,000,000	935,000,000
Additional paid-in capital	5,970,000,000	5,961,000,000
Earnings reinvested in the business	36,539,000,000	43,962,000,000
Accumulated other comprehensive losses	(2,864,000,000)	(2,547,000,000)
Cost of repurchased stock	(34,358,000,000)	(33,524,000,000)
Total stockholders’ equity attributable to Altria	6,222,000,000	14,787,000,000
Noncontrolling interests	0	0
Total stockholders’ equity	6,222,000,000	14,787,000,000
Total Liabilities and Stockholders’ Equity	44,474,000,000	50,139,000,000
Reportable Legal Entities [Member] | PM USA [Member]
Condensed Financial Statements, Captions [Line Items]
Cash and cash equivalents	0	0
Receivables	30,000,000	18,000,000
Inventories:
Leaf tobacco	494,000,000	561,000,000
Other raw materials	120,000,000	123,000,000
Work in process	4,000,000	2,000,000
Finished product	119,000,000	128,000,000
Inventory, net	737,000,000	814,000,000
Due from Altria and subsidiaries	4,005,000,000	3,828,000,000
Income taxes	47,000,000	94,000,000
Other current assets	17,000,000	167,000,000
Total current assets	4,836,000,000	4,921,000,000
Property, plant and equipment, at cost	2,956,000,000	2,928,000,000
Less accumulated depreciation	2,166,000,000	2,111,000,000
Property, plant and equipment, net	790,000,000	817,000,000
Goodwill	0	0
Other intangible assets, net	2,000,000	2,000,000
Investments in equity securities	0	0
Investment in consolidated subsidiaries	2,831,000,000	2,825,000,000
Due from Altria and subsidiaries	0	0
Other assets	951,000,000	955,000,000
Total Assets	9,410,000,000	9,520,000,000
Liabilities
Short-term borrowings		0
Current portion of long-term debt	0	0
Accounts payable	146,000,000	91,000,000
Accrued liabilities:
Marketing	320,000,000	483,000,000
Settlement charges	3,340,000,000	3,448,000,000
Other	482,000,000	524,000,000
Dividends payable	0	0
Due to Altria and subsidiaries	514,000,000	407,000,000
Total current liabilities	4,802,000,000	4,953,000,000
Long-term debt	0	0
Deferred income taxes	0	0
Accrued pension costs	0	0
Accrued postretirement health care costs	1,078,000,000	1,072,000,000
Due to Altria and subsidiaries	0	0
Other liabilities	87,000,000	47,000,000
Total liabilities	5,967,000,000	6,072,000,000
Contingencies
Redeemable noncontrolling interest	0	0
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	3,310,000,000	3,310,000,000
Earnings reinvested in the business	352,000,000	359,000,000
Accumulated other comprehensive losses	(219,000,000)	(221,000,000)
Cost of repurchased stock	0	0
Total stockholders’ equity attributable to Altria	3,443,000,000	3,448,000,000
Noncontrolling interests	0	0
Total stockholders’ equity	3,443,000,000	3,448,000,000
Total Liabilities and Stockholders’ Equity	9,410,000,000	9,520,000,000
Reportable Legal Entities [Member] | Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Cash and cash equivalents	95,000,000	56,000,000
Receivables	122,000,000	124,000,000
Inventories:
Leaf tobacco	380,000,000	379,000,000
Other raw materials	72,000,000	63,000,000
Work in process	692,000,000	645,000,000
Finished product	412,000,000	430,000,000
Inventory, net	1,556,000,000	1,517,000,000
Due from Altria and subsidiaries	1,359,000,000	1,194,000,000
Income taxes	38,000,000	0
Other current assets	76,000,000	118,000,000
Total current assets	3,246,000,000	3,009,000,000
Property, plant and equipment, at cost	2,118,000,000	2,022,000,000
Less accumulated depreciation	909,000,000	901,000,000
Property, plant and equipment, net	1,209,000,000	1,121,000,000
Goodwill	5,177,000,000	5,196,000,000
Other intangible assets, net	12,685,000,000	12,277,000,000
Investments in equity securities	5,510,000,000	12,800,000,000
Investment in consolidated subsidiaries	0	0
Due from Altria and subsidiaries	0	0
Other assets	603,000,000	773,000,000
Total Assets	28,430,000,000	35,176,000,000
Liabilities
Short-term borrowings		0
Current portion of long-term debt	0	0
Accounts payable	179,000,000	307,000,000
Accrued liabilities:
Marketing	73,000,000	103,000,000
Settlement charges	6,000,000	6,000,000
Other	536,000,000	611,000,000
Dividends payable	0	0
Due to Altria and subsidiaries	245,000,000	162,000,000
Total current liabilities	1,039,000,000	1,189,000,000
Long-term debt	0	0
Deferred income taxes	2,593,000,000	2,653,000,000
Accrued pension costs	276,000,000	357,000,000
Accrued postretirement health care costs	719,000,000	677,000,000
Due to Altria and subsidiaries	4,790,000,000	4,790,000,000
Other liabilities	178,000,000	96,000,000
Total liabilities	9,595,000,000	9,762,000,000
Contingencies
Redeemable noncontrolling interest	38,000,000	39,000,000
Stockholders' Equity
Common stock	9,000,000	9,000,000
Additional paid-in capital	27,565,000,000	25,047,000,000
Earnings reinvested in the business	(6,997,000,000)	2,201,000,000
Accumulated other comprehensive losses	(1,877,000,000)	(1,884,000,000)
Cost of repurchased stock	0	0
Total stockholders’ equity attributable to Altria	18,700,000,000	25,373,000,000
Noncontrolling interests	97,000,000	2,000,000
Total stockholders’ equity	18,797,000,000	25,375,000,000
Total Liabilities and Stockholders’ Equity	28,430,000,000	35,176,000,000
Total Consolidating Adjustments [Member]
Condensed Financial Statements, Captions [Line Items]
Cash and cash equivalents	0	0
Receivables	0	0
Inventories:
Leaf tobacco	0	0
Other raw materials	0	0
Work in process	0	0
Finished product	0	0
Inventory, net	0	0
Due from Altria and subsidiaries	(5,452,000,000)	(5,068,000,000)
Income taxes	(49,000,000)	(27,000,000)
Other current assets	0	0
Total current assets	(5,501,000,000)	(5,095,000,000)
Property, plant and equipment, at cost	0	0
Less accumulated depreciation	0	0
Property, plant and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Investments in equity securities	0	0
Investment in consolidated subsidiaries	(22,143,000,000)	(28,821,000,000)
Due from Altria and subsidiaries	(4,790,000,000)	(4,790,000,000)
Other assets	(609,000,000)	(670,000,000)
Total Assets	(33,043,000,000)	(39,376,000,000)
Liabilities
Short-term borrowings		0
Current portion of long-term debt	0	0
Accounts payable	0	0
Accrued liabilities:
Marketing	0	0
Settlement charges	0	0
Other	(49,000,000)	(27,000,000)
Dividends payable	0	0
Due to Altria and subsidiaries	(5,452,000,000)	(5,068,000,000)
Total current liabilities	(5,501,000,000)	(5,095,000,000)
Long-term debt	0	0
Deferred income taxes	(609,000,000)	(670,000,000)
Accrued pension costs	0	0
Accrued postretirement health care costs	0	0
Due to Altria and subsidiaries	(4,790,000,000)	(4,790,000,000)
Other liabilities	0	0
Total liabilities	(10,900,000,000)	(10,555,000,000)
Contingencies
Redeemable noncontrolling interest	0	0
Stockholders' Equity
Common stock	(9,000,000)	(9,000,000)
Additional paid-in capital	(30,875,000,000)	(28,357,000,000)
Earnings reinvested in the business	6,645,000,000	(2,560,000,000)
Accumulated other comprehensive losses	2,096,000,000	2,105,000,000
Cost of repurchased stock	0	0
Total stockholders’ equity attributable to Altria	(22,143,000,000)	(28,821,000,000)
Noncontrolling interests	0	0
Total stockholders’ equity	(22,143,000,000)	(28,821,000,000)
Total Liabilities and Stockholders’ Equity	$ (33,043,000,000)	$ (39,376,000,000)

Condensed Consolidating Finan_4

Condensed Consolidating Financial Information (Condensed Consolidating Statements of Earnings (Losses) and Comprehensive Earnings (Losses)) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Condensed Financial Statements, Captions [Line Items]
Net revenues	$ 6,007	$ 6,856	$ 6,619	$ 5,628	$ 6,114	$ 6,837	$ 6,305	$ 6,108	$ 25,110	$ 25,364	$ 25,576
Cost of sales									7,085	7,373	7,531
Excise taxes on products									5,314	5,737	6,082
Gross profit	3,084	3,497	3,319	2,811	2,922	3,255	3,141	2,936	12,711	12,254	11,963
Marketing, administration and research costs									2,226	2,756	2,338
Asset Impairment and Exit Costs									159	383	32
Operating (expense) income									10,326	9,115	9,593
Interest and other debt expense, net									1,280	665	705
Net periodic benefit (income) cost, excluding service cost									(37)	(34)	37
Earnings from equity investments									(1,725)	(890)	(532)
Impairment of JUUL equity securities	4,100	4,500	0	0					8,600	0	0
Loss on Cronos-related financial instruments									1,442	0	0
(Gain) loss on ABI/SABMiller business combination					0	0	0	33	0	33	(445)
Earnings (losses) before income taxes									766	9,341	9,828
Provision (benefit) for income taxes									2,064	2,374	(399)
Equity earnings (losses) of subsidiaries									0	0	0
Net earnings (losses)	(1,814)	(2,602)	1,997	1,121	1,251	1,944	1,877	1,895	(1,298)	6,967	10,227
Net (earnings) losses attributable to noncontrolling interests									5	(4)	(5)
Net earnings (losses) attributable to Altria	$ (1,809)	$ (2,600)	$ 1,996	$ 1,120	$ 1,250	$ 1,943	$ 1,876	$ 1,894	(1,293)	6,963	10,222
Other comprehensive earnings (losses), net of deferred income taxes									(317)	(242)	155
Comprehensive earnings (losses)									(1,615)	6,725	10,382
Comprehensive (earnings) losses attributable to noncontrolling interests									5	(4)	(5)
Comprehensive earnings (losses) attributable to Altria									(1,610)	6,721	10,377
Reportable Legal Entities [Member] | Altria Group, Inc. [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenues									0	0	0
Cost of sales									0	0	0
Excise taxes on products									0	0	0
Gross profit									0	0	0
Marketing, administration and research costs									182	219	161
Asset Impairment and Exit Costs									1	0	0
Operating (expense) income									(183)	(219)	(161)
Interest and other debt expense, net									1,152	511	510
Net periodic benefit (income) cost, excluding service cost									5	16	12
Earnings from equity investments									(1,229)	(890)	(532)
Impairment of JUUL equity securities									0
Loss on Cronos-related financial instruments									0
(Gain) loss on ABI/SABMiller business combination										33	(445)
Earnings (losses) before income taxes									(111)	111	294
Provision (benefit) for income taxes									(243)	36	(2,624)
Equity earnings (losses) of subsidiaries									(1,425)	6,888	7,304
Net earnings (losses)									(1,293)	6,963	10,222
Net (earnings) losses attributable to noncontrolling interests									0	0	0
Net earnings (losses) attributable to Altria									(1,293)	6,963	10,222
Other comprehensive earnings (losses), net of deferred income taxes									(317)	(242)	155
Comprehensive earnings (losses)									(1,610)	6,721	10,377
Comprehensive (earnings) losses attributable to noncontrolling interests									0	0	0
Comprehensive earnings (losses) attributable to Altria									(1,610)	6,721	10,377
Reportable Legal Entities [Member] | PM USA [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenues									21,065	21,422	21,826
Cost of sales									5,997	6,153	6,394
Excise taxes on products									5,111	5,517	5,864
Gross profit									9,957	9,752	9,568
Marketing, administration and research costs									1,591	1,892	1,713
Asset Impairment and Exit Costs									39	81	0
Operating (expense) income									8,327	7,779	7,855
Interest and other debt expense, net									(85)	(61)	(20)
Net periodic benefit (income) cost, excluding service cost									(34)	(41)	18
Earnings from equity investments									0	0	0
Impairment of JUUL equity securities									0
Loss on Cronos-related financial instruments									0
(Gain) loss on ABI/SABMiller business combination										0	0
Earnings (losses) before income taxes									8,446	7,881	7,857
Provision (benefit) for income taxes									2,102	1,980	3,127
Equity earnings (losses) of subsidiaries									450	402	558
Net earnings (losses)									6,794	6,303	5,288
Net (earnings) losses attributable to noncontrolling interests									0	0	0
Net earnings (losses) attributable to Altria									6,794	6,303	5,288
Other comprehensive earnings (losses), net of deferred income taxes									2	104	3
Comprehensive earnings (losses)									6,796	6,407	5,291
Comprehensive (earnings) losses attributable to noncontrolling interests									0	0	0
Comprehensive earnings (losses) attributable to Altria									6,796	6,407	5,291
Reportable Legal Entities [Member] | Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenues									4,081	3,980	3,787
Cost of sales									1,124	1,258	1,174
Excise taxes on products									203	220	218
Gross profit									2,754	2,502	2,395
Marketing, administration and research costs									453	645	464
Asset Impairment and Exit Costs									119	302	32
Operating (expense) income									2,182	1,555	1,899
Interest and other debt expense, net									213	215	215
Net periodic benefit (income) cost, excluding service cost									(8)	(9)	7
Earnings from equity investments									(496)	0	0
Impairment of JUUL equity securities									8,600
Loss on Cronos-related financial instruments									1,442
(Gain) loss on ABI/SABMiller business combination										0	0
Earnings (losses) before income taxes									(7,569)	1,349	1,677
Provision (benefit) for income taxes									205	358	(902)
Equity earnings (losses) of subsidiaries									0	0	0
Net earnings (losses)									(7,774)	991	2,579
Net (earnings) losses attributable to noncontrolling interests									5	(4)	(5)
Net earnings (losses) attributable to Altria									(7,769)	987	2,574
Other comprehensive earnings (losses), net of deferred income taxes									7	(54)	214
Comprehensive earnings (losses)									(7,767)	937	2,793
Comprehensive (earnings) losses attributable to noncontrolling interests									5	(4)	(5)
Comprehensive earnings (losses) attributable to Altria									(7,762)	933	2,788
Total Consolidating Adjustments [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenues									(36)	(38)	(37)
Cost of sales									(36)	(38)	(37)
Excise taxes on products									0	0	0
Gross profit									0	0	0
Marketing, administration and research costs									0	0	0
Asset Impairment and Exit Costs									0	0	0
Operating (expense) income									0	0	0
Interest and other debt expense, net									0	0	0
Net periodic benefit (income) cost, excluding service cost									0	0	0
Earnings from equity investments									0	0	0
Impairment of JUUL equity securities									0
Loss on Cronos-related financial instruments									0
(Gain) loss on ABI/SABMiller business combination										0	0
Earnings (losses) before income taxes									0	0	0
Provision (benefit) for income taxes									0	0	0
Equity earnings (losses) of subsidiaries									975	(7,290)	(7,862)
Net earnings (losses)									975	(7,290)	(7,862)
Net (earnings) losses attributable to noncontrolling interests									0	0	0
Net earnings (losses) attributable to Altria									975	(7,290)	(7,862)
Other comprehensive earnings (losses), net of deferred income taxes									(9)	(50)	(217)
Comprehensive earnings (losses)									966	(7,340)	(8,079)
Comprehensive (earnings) losses attributable to noncontrolling interests									0	0	0
Comprehensive earnings (losses) attributable to Altria									$ 966	$ (7,340)	$ (8,079)

Condensed Consolidating Finan_5

Condensed Consolidating Financial Information (Condensed Consolidating Statements of Cash Flows) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	$ 7,837	$ 8,391	$ 4,901
Cash Provided by (Used in) Investing Activities
Capital expenditures	(246)	(238)	(199)
Investment in Cronos	(1,899)	0	0
Acquisitions of businesses and assets	(421)	(15)	(415)
Investment in JUUL	(5)	(12,800)
Investment in consolidated subsidiaries	0	0	0
Other, net	173	65	147
Net cash (used in) provided by investing activities	(2,398)	(12,988)	(467)
Cash Provided by (Used in) Financing Activities
Repayment of short-term borrowings	(12,800)	0	0
Proceeds from short-term borrowings	0	12,800	0
Long-term debt issued	16,265	0	0
Long-term debt repaid	(1,144)	(864)	0
Repurchases of common stock	(845)	(1,673)	(2,917)
Dividends paid on common stock	(6,069)	(5,415)	(4,807)
Changes in amounts due to/from Altria and subsidiaries	0	0	0
Cash dividends paid to parent	0	0	0
Other	(119)	(132)	(47)
Net cash used in financing activities	(4,712)	4,716	(7,771)
Increase (decrease)	727	119	(3,337)
Balance at beginning of year	1,433	1,314	4,651
Balance at end of year	2,160	1,433	1,314
Reportable Legal Entities [Member]
Cash Provided by (Used in) Financing Activities
Cash dividends paid to parent			0
Reportable Legal Entities [Member] | Altria Group, Inc. [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	7,769	6,907	6,910
Cash Provided by (Used in) Investing Activities
Capital expenditures	0	0	0
Investment in Cronos	0
Acquisitions of businesses and assets	0	0	0
Investment in JUUL	0	0
Investment in consolidated subsidiaries	(2,518)	(13,003)	(460)
Other, net	41	35	(5)
Net cash (used in) provided by investing activities	(2,477)	(12,968)	(465)
Cash Provided by (Used in) Financing Activities
Repayment of short-term borrowings	(12,800)
Proceeds from short-term borrowings		12,800
Long-term debt issued	16,265
Long-term debt repaid	(1,144)	(864)
Repurchases of common stock	(845)	(1,673)	(2,917)
Dividends paid on common stock	(6,069)	(5,415)	(4,807)
Changes in amounts due to/from Altria and subsidiaries	169	1,415	(1,999)
Cash dividends paid to parent	0	0
Other	(123)	(128)	(40)
Net cash used in financing activities	(4,547)	6,135	(9,763)
Increase (decrease)	745	74	(3,318)
Balance at beginning of year	1,277	1,203	4,521
Balance at end of year	2,022	1,277	1,203
Reportable Legal Entities [Member] | PM USA [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	6,936	7,580	4,028
Cash Provided by (Used in) Investing Activities
Capital expenditures	(56)	(57)	(34)
Investment in Cronos	0
Acquisitions of businesses and assets	0	0	0
Investment in JUUL	0	0
Investment in consolidated subsidiaries	0	0	0
Other, net	1	0	4
Net cash (used in) provided by investing activities	(55)	(57)	(30)
Cash Provided by (Used in) Financing Activities
Repayment of short-term borrowings	0
Proceeds from short-term borrowings		0
Long-term debt issued	0
Long-term debt repaid	0	0
Repurchases of common stock	0	0	0
Dividends paid on common stock	0	0	0
Changes in amounts due to/from Altria and subsidiaries	(137)	(1,388)	1,410
Cash dividends paid to parent	(6,801)	(6,097)	(5,429)
Other	0	0	0
Net cash used in financing activities	(6,938)	(7,485)	(4,019)
Increase (decrease)	(57)	38	(21)
Balance at beginning of year	100	62	83
Balance at end of year	43	100	62
Reportable Legal Entities [Member] | Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	1,362	1,354	841
Cash Provided by (Used in) Investing Activities
Capital expenditures	(190)	(181)	(165)
Investment in Cronos	(1,899)
Acquisitions of businesses and assets	(421)	(15)	(415)
Investment in JUUL	(5)	(12,800)
Investment in consolidated subsidiaries	0	0	0
Other, net	131	30	148
Net cash (used in) provided by investing activities	(2,384)	(12,966)	(432)
Cash Provided by (Used in) Financing Activities
Repayment of short-term borrowings	0
Proceeds from short-term borrowings		0
Long-term debt issued	0
Long-term debt repaid	0	0
Repurchases of common stock	0	0	0
Dividends paid on common stock	0	0	0
Changes in amounts due to/from Altria and subsidiaries	2,486	12,976	1,049
Cash dividends paid to parent	(1,429)	(1,353)	(1,449)
Other	4	(4)	(7)
Net cash used in financing activities	1,061	11,619	(407)
Increase (decrease)	39	7	2
Balance at beginning of year	56	49	47
Balance at end of year	95	56	49
Total Consolidating Adjustments [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	(8,230)	(7,450)	(6,878)
Cash Provided by (Used in) Investing Activities
Capital expenditures	0	0	0
Investment in Cronos	0
Acquisitions of businesses and assets	0	0	0
Investment in JUUL	0	0
Investment in consolidated subsidiaries	2,518	13,003	460
Other, net	0	0	0
Net cash (used in) provided by investing activities	2,518	13,003	460
Cash Provided by (Used in) Financing Activities
Repayment of short-term borrowings	0
Proceeds from short-term borrowings		0
Long-term debt issued	0
Long-term debt repaid	0	0
Repurchases of common stock	0	0	0
Dividends paid on common stock	0	0	0
Changes in amounts due to/from Altria and subsidiaries	(2,518)	(13,003)	(460)
Cash dividends paid to parent	8,230	7,450	6,878
Other	0	0	0
Net cash used in financing activities	5,712	(5,553)	6,418
Increase (decrease)	0	0	0
Balance at beginning of year	0	0	0
Balance at end of year	$ 0	$ 0	$ 0

Quarterly Financial Data (Una_3

Quarterly Financial Data (Unaudited) (EPS attributable to Altria Group, Inc.) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Quarterly Financial Data [Abstract]
Net revenues	$ 6,007	$ 6,856	$ 6,619	$ 5,628	$ 6,114	$ 6,837	$ 6,305	$ 6,108	$ 25,110	$ 25,364	$ 25,576
Gross profit	3,084	3,497	3,319	2,811	2,922	3,255	3,141	2,936	12,711	12,254	11,963
Net earnings (losses)	(1,814)	(2,602)	1,997	1,121	1,251	1,944	1,877	1,895	(1,298)	6,967	10,227
Net earnings (losses) attributable to Altria	$ (1,809)	$ (2,600)	$ 1,996	$ 1,120	$ 1,250	$ 1,943	$ 1,876	$ 1,894	$ (1,293)	$ 6,963	$ 10,222
Basic earnings (losses) per share attributable to Altria (in usd per share)	$ (0.97)	$ (1.39)	$ 1.07	$ 0.60	$ 0.67	$ 1.03	$ 0.99	$ 1	$ (0.70)	$ 3.69	$ 5.31
Diluted earnings (losses) per share attributable to Altria (in usd per share)	$ (1)	$ (1.39)	$ 1.07	$ 0.60	$ 0.66	$ 1.03	$ 0.99	$ 1	$ (0.70)	$ 3.68	$ 5.31

Quarterly Financial Data (Una_4

Quarterly Financial Data (Unaudited) (Schedule of Pre-tax Charges or (Gains) Included in Net Earnings Attributable to Altria Group, Inc.) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Investments [Line Items]
Impairment of JUUL equity securities	$ 4,100	$ 4,500	$ 0	$ 0					$ 8,600	$ 0	$ 0
NPM Adjustment Items					$ 0	$ 0	$ (77)	$ (68)
Tobacco and health litigation items, including accrued interest	29	3	28	17	12	21	70	28
Asset impairment, exit, implementation and acquisition-related costs	116	11	45	159	532	(3)	6	3
(Gain) loss on ABI/SABMiller business combination					0	0	0	33	$ 0	$ 33	$ (445)
Pre-tax charges (gains) included in net earnings	3,716	5,049	102	715	613	53	(73)	(121)
ABI [Member]
Investments [Line Items]
Investment special items	(364)	(14)	(90)	114	$ 69	$ 35	$ (72)	$ (117)
Cronos [Member]
Investments [Line Items]
Investment special items	$ (165)	$ 549	$ 119	$ 425

Uncategorized Items - a2019form

Label	Element	Value	[1]
Restricted Cash, Noncurrent	us-gaap_RestrictedCashNoncurrent	$ 36,000,000
Restricted Cash, Noncurrent	us-gaap_RestrictedCashNoncurrent	43,000,000
Restricted Cash, Noncurrent	us-gaap_RestrictedCashNoncurrent	43,000,000
Restricted Cash, Current	us-gaap_RestrictedCashCurrent	25,000,000
Restricted Cash, Current	us-gaap_RestrictedCashCurrent	0
Restricted Cash, Current	us-gaap_RestrictedCashCurrent	$ 57,000,000
[1]	Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 19 . Contingencies .